Page last updated: 2024-12-05

suramin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5361
CHEMBL ID265502
CHEBI ID45906
SCHEMBL ID3161
MeSH IDM0020853

Synonyms (98)

Synonym
8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-1,3,5-naphthalenetrisulfonic acid
gtpl1728
DIVK1C_006758
SGCTO-001 ,
metaret
1,5-naphthalenetrisulfonic acid, 8,8'-[ureylenebis[m-phenylenecarbonylimino(4-methyl-m-phenylene)carbonylimino]]di-, hexasodium salt
wln: l66j bswq dswq gswq jmvr d1 cmvr cmvmr cvmr b1 evm-jl66j bswq dswq gswq &-na-6
naganol 6 na
bayer 205
sodium suramin
1,5-naphthylenetrisulfonic acid, 8,8'-[ureylenebis[m-phenylenecarbonylimino(4-methyl-m-phenylene)carbonylimino]]di-, hexasodium salt
1-(3-benzamido-4-methylbenzamido)naphthalene-4,8-trisulfonic acid sym-3''-urea sodium salt
1,5-naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-, hexasodium salt
nsc-34936
8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-1,3,5-naphthalenetrisulfon ic acid
einecs 205-658-4
1,3,5-naphthylenetrisulfonic acid, 8,8'-(ureylenebis(m-phenylenecarbonylimino(4-methyl-m-phenylene)carbonylimino))di-
8,8'-(carbonylbis(imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino))bisnaphthalene-1,3,5-trisulphonic acid
brn 3230873
1,3,5-naphthalenetrisulfonic acid, 8,8'-(carbonylbis(imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino))bis-
SPECTRUM_001877
LOPAC0_001182
BSPBIO_002248
8-[[4-methyl-3-[[3-[[3-[[2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl]carbamoyl]phenyl]carbamoylamino]benzoyl]amino]benzoyl]amino]naphthalene-1,3,5-trisulfonic acid
naganol
germanin
naganil
nsc34936
8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonyl-imino]]bis-1,3,5-naphthalenetrisulfonic acid
sym-bis(m-aminobenzoyl-m-amino-p-methylbenzoyl-1-napthylamino-4,6,8-trisulfonate) carbamide
belganyl
1,3,5-naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-
1,3,5-naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis- (9ci)
fourneau
8,8'-[ureylenebis[m-phenylenecarbonylimino(4-methyl-m-phenylene)carbonylimino]]di-1,3,5-naphthalenetrisulfonic acid
8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonyl-imino]]bis-1,3,5-napthalenetrisulfonic acid
suramine
farma
carbanilide, 3,3'-bis((5-((4,6,8-trisulfo-1-naphthyl)carbamoyl)-o-tolyl)carbamoyl)-
farma 939
1,3,5-naphthalenetrisulfonic acid, 8,8'-[ureylenebis[m-phenylenecarbonylimino(4-methyl-m-phenylene)carbonylimino]]di- (8ci)
m,m'-ureylen-bis-(8-(m-(benzamido)-p-toluamido)naphthalin-1,3,5-trisulfonsaeure)
harnstoff, symmetischer der 3-aminobenzoyl-3-amino-4-methylbenzoyl-1-naphthylamin-4,6,8-trisulfonsaeure
8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bisnaphthalene-1,3,5-trisulphonic acid
C07974
suramin
145-63-1
SVR ,
CHEBI:45906 ,
DB04786
NCGC00163318-01
KBIO2_002397
KBIO2_004965
KBIOGR_001774
KBIO3_001468
KBIOSS_002402
KBIO1_001702
KBIO2_007533
SPECTRUM4_001247
SPECTRUM3_000724
SPECPLUS_000662
farma-939
CHEMBL265502 ,
L000585
8-[[4-methyl-3-[[3-[[3-[[2-methyl-5-[(4,6,8-trisulfonaphthalen-1-yl)carbamoyl]phenyl]carbamoyl]phenyl]carbamoylamino]benzoyl]amino]benzoyl]amino]naphthalene-1,3,5-trisulfonic acid
NCGC00163318-03
NCGC00163318-02
us8835659, suramin
bdbm50336799
8,8''-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-1,3,5-naphthalenetrisulfonic acid
8,8''-(carbonylbis(imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino))bisnaphthalene-1,3,5-trisulphonic acid
8-[(4-methyl-3-{[3-({[3-({2-methyl-5-[(4,6,8-trisulfonaphthalen-1-yl)carbamoyl]phenyl}carbamoyl)phenyl]carbamoyl}amino)benzene]amido}benzene)amido]naphthalene-1,3,5-trisulfonic acid
8,8''-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonyl-imino]]bis-1,3,5-naphthalenetrisulfonic acid(suramin)
dtxsid1046344 ,
cas-145-63-1
dtxcid9026344
tox21_112045
CCG-36173
6032d45bem ,
3-14-00-02267 (beilstein handbook reference)
unii-6032d45bem
8,8'-(ureylenebis(m-phenylenecarbonylimino(4-methyl-m-phenylene)carbonylimino))di-1,3,5-naphthalenetrisulfonic acid
8,8'-(carbonylbis(imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino))bis-1,3,5-naphthalenetrisulfonic acid
suramin [who-dd]
BRD-K70327167-348-01-9
SCHEMBL3161
tox21_112045_1
NCGC00025177-08
CS-4444
HY-B0879
8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-1,3,5-naphthalenetrisulphonic acid
mmv637953
8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-1,3,5-naphthalenetrisulfon
8-[(4-methyl-3-{[3-({[3-({2-methyl-5-[(4,6,8-trisulfonaphthalen-1-yl)carbamoyl]phenyl}carbamoyl)phenyl]carbamoyl}amino)benzoyl]amino}benzoyl)amino]naphthalene-1,3,5-trisulfonic acid
8,8-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bisnaphthalene-1,3,5-trisulphonic acid
Q425946
BRD-K70327167-348-09-2
SR-01000075238-10

Research Excerpts

Overview

Suramin is a novel hepsin inhibitor that reduces its protumorigenic and prothrombotic effects in colorectal cancer cells. Suramin is an activator of ryanodine receptors and competitively binds to the calmodulin-binding site.

ExcerptReferenceRelevance
"Suramin is an anti-parasitic drug that has potent anti-purinergic properties."( Suramin ameliorates osteoarthritis by acting on the Nrf2/HO-1 and NF-κB signaling pathways in chondrocytes and promoting M2 polarization in macrophages.
Chou, SH; Huang, SH; Liu, ZM; Lu, CC; Shen, PC; Tien, YC, 2023
)
3.07
"Suramin is a multifunctional molecule with a wide range of potential applications, including parasitic and viral diseases, as well as cancer."( Phase I, Single-Dose Study to Assess the Pharmacokinetics and Safety of Suramin in Healthy Chinese Volunteers.
Gu, L; Hong, N; Kai, J; Lv, D; Shentu, J; Wu, G; Wu, L; Xu, N; Yu, S; Zheng, R; Zhou, H, 2023
)
2.59
"Suramin is a novel hepsin inhibitor that reduces its protumorigenic and prothrombotic effects in colorectal cancer cells. "( Suramin, a drug for the treatment of trypanosomiasis, reduces the prothrombotic and metastatic phenotypes of colorectal cancer cells by inhibiting hepsin.
Carmona-Bayonas, A; Espín, S; García-Molina, F; Lozano, ML; Martínez-Martínez, I; Mulero, V; Nieto, A; Pardo-Sánchez, I; Peña-García, J; Peñas-Martínez, J; Pérez-Sánchez, H; Ricote, G; Rodenas, MC; Vicente, V; Zaragoza-Huesca, D, 2023
)
3.8
"Suramin is a polysulfonated naphthylurea with antiparasitic and potential antineoplastic activity. "( Suramin inhibits PDGF-stimulated receptor phosphorylation, proteoglycan synthesis and glycosaminoglycan hyperelongation in human vascular smooth muscle cells.
Ballinger, ML; Getachew, R; Guidone, D; Kamato, D; Little, PJ; Osman, N; Piva, TJ; Rostam, MA; Zheng, W, 2013
)
3.28
"Suramin is a commercially available compound, commonly used as a positive control for in vitro angiogenic inhibition assays."( Amphiphilic suramin dissolves Matrigel, causing an 'inhibition' artefact within in vitro angiogenesis assays.
Cosford, ND; Heisel, AJ; Price, JH; Prigozhina, NL; Seldeen, JR, 2013
)
1.49
"Suramin is an activator of ryanodine receptors and competitively binds to the calmodulin-binding site. "( Suramin is a novel activator of PP5 and biphasically modulates S100-activated PP5 activity.
Kobayashi, R; Shimamoto, S; Tokuda, M; Tokumitsu, H; Yamaguchi, F; Yamamura, S, 2014
)
3.29
"Suramin is a polysulfonated napthylurea, which at noncytotoxic concentrations in vitro, increases tumor sensitivity to chemotherapy, including doxorubicin."( Postoperative adjuvant combination therapy with doxorubicin and noncytotoxic suramin in dogs with appendicular osteosarcoma.
Alvarez, FJ; Au, JL; Couto, G; Couto, J; Hosoya, K; Kisseberth, W; Kosarek, C; Lara-Garcia, A; Murahari, S; Wientjes, MG,
)
1.08
"Suramin is a clinically prescribed drug for treatment of human African trypanosomiasis, cancer and infection. "( Suppression of cell membrane permeability by suramin: involvement of its inhibitory actions on connexin 43 hemichannels.
Chi, Y; Gao, K; Takeda, M; Yao, J; Zhang, H, 2014
)
2.1
"Suramin is a polysulphonated naphthylurea and is used as an antiprotozoal drug for African Trypanosomiasis."( Suramin inhibits Hsp104 ATPase and disaggregase activity.
Castellano, LM; Shorter, J; Torrente, MP, 2014
)
2.57
"Suramin is a symmetric polyanionic naphthylurea that is widely used in the clinical treatment of parasite infections."( Suramin Inhibits Chikungunya Virus Entry and Transmission.
Ho, YJ; Kuo, SC; Lin, CC; Lin, LI; Lu, JW; Wang, YM; Wu, TY, 2015
)
2.58
"Suramin is an antiparasiticdrug and a potent inhibitor of FGF-induced angiogenesis."( Suramin blocks interaction between human FGF1 and FGFR2 D2 domain and reduces downstream signaling activity.
Chou, RH; Fu, B; Liu, CF; Wu, ZS; Yu, C, 2016
)
2.6
"Suramin, which is an IGF-1 receptor non-specific blocker, had the opposite effect on K562 cells, also in a dose- and time-dependent manner."( [Inhibitory Effect of High Concentration Insulin on the Proliferation of Human Leukemia Cell Strain K562].
Huang, MJ; Pan, JX; Zhuang, WH, 2016
)
1.16
"Suramin is a polysulfonated naphthylurea originally designed as a treatment for trypanosomiasis; but that has also been used to treat rodent models of fulminant hepatic failure and focal brain ischemia. "( Suramin promotes recovery from renal ischemia/reperfusion injury in mice.
Chavin, KD; Daubert, RA; Lu, B; Schnellmann, RG; Wang, L; Zhuang, S, 2009
)
3.24
"Suramin is a polysulfonated polyaromatic symmetrical urea. "( Suramin: clinical uses and structure-activity relationships.
Bennett, AJ; Cosgrove, KL; McGeary, RP; Ross, BP; Tran, QB, 2008
)
3.23
"Suramin is a polysulphonated napthylurea antiprotozoal and anthelminitic drug, which also presents inhibitory activity against a broad range of enzymes. "( Suramin inhibits macrophage activation by human group IIA phospholipase A2, but does not affect bactericidal activity of the enzyme.
Aragão, EA; Chioato, L; de Medeiros, AI; Faccioli, LH; Ferreira, TL; Secatto, A; Ward, RJ, 2009
)
3.24
"Suramin is a polysulphonated napthylurea used as an antiprotozoal/anthelminitic drug, which also inhibits a broad range of enzymes. "( Mapping of suramin binding sites on the group IIA human secreted phospholipase A2.
Aragão, EA; Lourenzoni, MR; Vieira, DS; Ward, RJ, 2009
)
2.19
"Suramin is a symmetric polysulfonated naphthylamine-benzamide urea derivative approved for the treatment of trypanosomiasis and onchocerciasis and a known P2 (ATP/UTP purine receptor) antagonist. "( Suramin inhibits the CD40-CD154 costimulatory interaction: a possible mechanism for immunosuppressive effects.
Berggren, PO; Buchwald, P; Ganesan, L; Jacques-Silva, MC; Kenyon, NS; Margolles-Clark, E; Ricordi, C; Umland, O, 2009
)
3.24
"Suramin is a hexasulfonated naphthylurea which has been recently characterized as a non-competitive inhibitor of human alpha-thrombin activity over fibrinogen, although its binding site and mode of interaction with the enzyme remain elusive. "( Structural and thermodynamic analysis of thrombin:suramin interaction in solution and crystal phases.
Becker, CF; Cargnelutti, MT; de Oliveira Neto, M; Giesel, GM; Lima, LM; Marques, AF; Monteiro, RQ; Polikarpov, I; Verli, H, 2009
)
2.05
"Suramin is a polysulfonated naphthylurea, which was originally synthesized and designed as a treatment for trypanosomiasis and selected malignancies and metastatic diseases. "( Tissue protective and anti-fibrotic actions of suramin: new uses of an old drug.
Liu, N; Zhuang, S, 2011
)
2.07
"Suramin is a compound that inhibits the interaction of several cytokines and growth factors with their receptors, but whether suramin inhibits the progression of renal fibrosis is unknown."( Suramin inhibits renal fibrosis in chronic kidney disease.
Liu, N; Pang, M; Ponnusamy, M; Tolbert, E; Yan, H; Zhuang, S, 2011
)
2.53
"Suramin is a polysulphonated naphthylurea with inhibitory activity against the human secreted group IIA phospholipase A(2) (hsPLA2GIIA), and we have investigated suramin binding to recombinant hsPLA2GIIA using site-directed mutagenesis and molecular dynamics (MD) simulations. "( Characterization of suramin binding sites on the human group IIA secreted phospholipase A2 by site-directed mutagenesis and molecular dynamics simulation.
Aragão, EA; Chioato, L; Ferreira, TL; Lourenzoni, MR; Silva, SR; Vieira, DS; Ward, RJ, 2012
)
2.15
"Suramin, which is an antagonist of wild type receptors, behaved as an agonist at AM546-treated K69C receptors."( Covalent modification of mutant rat P2X2 receptors with a thiol-reactive fluorophore allows channel activation by zinc or acidic pH without ATP.
Dellal, SS; Hume, RI, 2012
)
1.1
"Suramin is a polysulfonated naphthylurea that inhibits proliferation and DNA synthesis of transitional cell carcinoma cell lines. "( A phase I study of intravesical suramin for the treatment of superficial transitional cell carcinoma of the bladder.
Figg, WD; Linehan, WM; Uchio, EM; Walther, MM, 2003
)
2.05
"Suramin is a well known antitrypanosomal drug and a novel experimental agent for the treatment of several cancers, yet the molecular mechanisms through which suramin exerts its effects on cell functions are not completely clear. "( Stimulation of extracellular signal-regulated kinase pathway by suramin with concomitant activation of DNA synthesis in cultured cells.
Nakata, H, 2004
)
2
"Suramin is a polysulfonated naphthylurea that inhibits the function of growth factors and growth factor receptors implicated in glioma progression, angiogenesis, and radioresistance. "( Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study.
Carson, KA; Gilbert, MR; Grossman, SA; Hochberg, FH; Laterra, JJ; Lesser, GJ, 2004
)
3.21
"Suramin is a polysulfonated derivative of urea and has been widely used both to treat infections and as a chemotherapeutic drug. "( Suramin inhibits death receptor-induced apoptosis in vitro and fulminant apoptotic liver damage in mice.
Bilzer, M; Eichhorst, ST; Fas, SC; Gerbes, AL; Golks, A; Gruetzner, U; Krammer, PH; Krueger, A; Müerköster, S; Opelz, C; Schubert, L, 2004
)
3.21
"Suramin is a hexasulfonated naphthylurea commonly used as antitrypanosomial drug and more recently for the treatment of malignant tumors. "( Suramin interaction with human alpha-thrombin: inhibitory effects and binding studies.
Bianconi, ML; Campana, PT; Melo, PA; Monteiro, RQ, 2004
)
3.21
"Suramin is a large naphthyl-polysulfonate compound that inhibits an array of receptors and enzymes, and it has also been reported to block currents mediated by glutamate receptors. "( Divergent effects of the purinoceptor antagonists suramin and pyridoxal-5'-phosphate-6-(2'-naphthylazo-6'-nitro-4',8'-disulfonate) (PPNDS) on alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors.
Arai, AC; Kessler, M; Montgomery, K; Suzuki, E, 2004
)
2.02
"Suramin is a highly charged polysulfonated napthylurea that interferes in a number of physiologically relevant processes such as myotoxicity, blood coagulation and several kinds of cancers. "( Crystallization and preliminary X-ray diffraction analysis of suramin, a highly charged polysulfonated napthylurea, complexed with a myotoxic PLA2 from Bothrops asper venom.
Arni, RK; Arruda, EZ; Gava, LM; Gutierrez, JM; Melo, PA; Murakami, MT; Zela, SP, 2004
)
2.01
"Suramin is a naphthalene trisulfonic acid derivative that inhibits osteoclast differentiation and bone resorption in vitro and in vivo; however, the mechanisms underlying this activity have not been studied. "( Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation.
Chandrashekhar, S; Fuson, T; Galvin, RJ; Kays, J; Moxham, C; Regmi, A; Yang, X; Zartler, E, 2005
)
3.21
"Suramin is an antitrypanosomal agent with antineoplastic activity, but with serious systemic side effects. "( Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma.
Banks, RE; Cranston, D; Crew, J; Harris, AL; Joel, SP; Jones, A; Le Monnier, K; Ord, JJ; Roberts, IS; Rogers, MA; Streeter, E, 2005
)
2.06
"Suramin is a competitive inhibitor of heparin binding to many proteins, including viral envelope proteins, protein tyrosine phosphatases, and fibroblast growth factors (FGFs). "( Structural basis for antagonism by suramin of heparin binding to vaccinia complement protein.
Ganesh, VK; Kotwal, GJ; Murthy, KH; Muthuvel, SK; Smith, SA, 2005
)
2.05
"Suramin is a very potent competitive inhibitor of both human Ap(3)Aase and Fhit protein with K(i) values in the range 20-30 nM."( Biochemical and immunochemical characterisation of human diadenosine triphosphatase provides evidence for its identification with the tumour suppressor Fhit protein.
Asensio, AC; Oaknin, S; Rodríguez-Ferrer, CR; Rotllán, P, 2006
)
1.06
"Suramin is a symmetrical polysulfonated naphthylamine derivative of urea. "( Suramin prevents fulminant hepatic failure resulting in reduction of lethality through the suppression of NF-kappaB activity.
Endo, A; Goto, T; Kataoka, E; Mikami, K; Miura, K; Ohshima, S; Sato, M; Sato, W; Segawa, D; Shibuya, T; Takeuchi, S; Watanabe, D; Watanabe, S; Yoneyama, K; Yoshino, R, 2006
)
3.22
"Suramin is a hexasulfonated naphthylurea derivative that was recently characterized as a thrombin inhibitor (Monteiro et al., 2004."( Suramin counteracts the haemostatic disturbances produced by Bothrops jararaca snake venom.
Arruda, EZ; Assafim, M; Fernandes, RS; Melo, PA; Monteiro, RQ; Zingali, RB, 2007
)
2.5
"Suramin is a well-known antitrypanosomal drug and a novel experimental agent for the treatment of several cancers. "( Mitogen-activated protein kinase signaling is involved in suramin-induced neurite outgrowth in a neuronal cell line.
Nakata, H, 2007
)
2.03
"Suramin is a symmetric polyanionic naphthylurea originally used for the treatment of trypanosomiasis and onchocerciasis. "( Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins).
Hongwiset, D; Jung, M; Kassack, MU; Meier, R; Sippl, W; Trapp, J, 2007
)
2.07
"Suramin, which is a noncompetitive antagonist at wild-type P2X2 receptors, had a pronounced agonist action at both P2X2[T339S] and P2X2[K69A/T339S] receptors but not at P2X2[K308A/T339S]."( Thr339-to-serine substitution in rat P2X2 receptor second transmembrane domain causes constitutive opening and indicates a gating role for Lys308.
Broomhead, HE; Cao, L; Fountain, SJ; North, RA; Young, MT, 2007
)
1.06
"Suramin is a drug used in the therapy of Rhodesian trypanosomiasis and onchocerciasis, and it inhibits the reverse transcriptase of a number of retroviruses including HTLV-III."( Protection of T cells against infectivity and cytopathic effect of HTLV-III in vitro.
Broder, S; Matsushita, S; Mitsuya, H; Yarchoan, R, 1984
)
0.99
"Suramin is a drug used in the therapy of Rhodesian trypanosomiasis and onchocerciasis, and it is known to inhibit the reverse transcriptase of a number of retroviruses."( Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III.
Broder, S; Gallo, RC; Matsushita, S; Mitsuya, H; Popovic, M; Yarchoan, R, 1984
)
2.43
"Suramin, in vitro is a weak inhibitor of glucocerebrosidase, galactocerebrosidase, alpha-galactosidase and arylsulfatase A (less than 50% inhibition at 10(-3M) concentration of the drug)."( Effect of suramin on the activities of degradative enzymes of sphingolipids in rats.
Barranger, JA; Brady, RO; Constantopoulos, G; Cragg, BG; Rees, S, 1981
)
1.39
"Suramin is an antitrypanosomal compound with confirmed efficacy against several human malignancies. "( Stimulation of tumor growth in vitro and in vivo by suramin on the VX2 model.
Bonnay, M; Gouyette, A; Juliéron, M; Koscielny, S; Munck, JN; Ramirez, LH; Zhao, Z, 1995
)
1.98
"Suramin is an experimental chemotherapeutic agent which produces a severe dose-related neuropathy. "( Mechanism of suramin toxicity in stable myelinating dorsal root ganglion cultures.
Gill, JS; Hobday, KL; Windebank, AJ, 1995
)
2.1
"Suramin is a promising agent for the treatment of hormone-refractory metastatic prostate cancer. "( Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
Janish, L; Kobayashi, K; Ratain, MJ; Soliven, B; Vogelzang, NJ; Vokes, EE, 1995
)
2.07
"Suramin is a polyanionic compound with potent antineoplastic properties. "( Suppression of polymorphonuclear leukocyte bactericidal activity by suramin.
Freifeld, A; Paschalides, P; Pizzo, PA; Roilides, E, 1993
)
1.96
"Suramin is a novel anticancer agent that blocks the binding of growth factors, including basic fibroblast growth factor (bFGF), to their receptors. "( Suramin inhibits glioma cell proliferation in vitro and in the brain.
Brem, S; Engelhard, H; Gately, S; Takano, S; Tsanaclis, AM, 1994
)
3.17
"Suramin is a polyanionic agent which has been found to be an effective antineoplastic agent against various human tumors including adrenal, renal and prostatic cancer, and osteosarcoma. "( Suramin suppresses hypercalcemia and osteoclastic bone resorption in nude mice bearing a human squamous cancer.
Boyce, BF; Dunstan, C; Mundy, GR; Rhine, C; Williams, P; Yoneda, T, 1995
)
3.18
"Suramin is an experimental anti-neoplastic agent which has shown promising activity against prostatic carcinoma and lymphoma in clinical trials. "( Suramin sodium: pronounced effects on methotrexate transport and anti-folate activity in cultured tumor cells.
Bustamante, A; Henderson, GB; Patel, R; Rideout, DC, 1995
)
3.18
"Suramin is a polysulfonated naphthylurea that binds to several cellular growth factors and has in vitro activity against human colorectal cancer cells."( Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study.
Brunetti, I; Cianci, C; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Pfanner, E, 1995
)
2.46
"Suramin acts as a scavenger neutralizing exogenous growth factors; thus it can interrupt autocrine loops and paracrine stimulation of human meningioma cell growth."( Inhibition of proliferation of human cerebral meningioma cells by suramin: effects on cell growth, cell cycle phases, extracellular growth factors, and PDGF-BB autocrine growth loop.
Adams, EF; Bickel, A; Fahlbusch, R; Gauer, S; Hren, J; Kiesewetter, F; Schrell, UM, 1995
)
1.25
"Suramin was shown to be a competitive antagonist with a Ki value of 7.3 +/- 2.2 microM."( Novel competitive antagonists for P2 purinoceptors.
Beukers, MW; IJzerman, AP; Nickel, P; Soudijn, W; van der Heijden, MP; van Rhee, AM, 1994
)
1.01
"Suramin is a competitive antagonist for the nucleotide receptor; reactive blue and DIDS are more selective antagonists for the P2Y receptor."( Different signal transduction pathways are coupled to the nucleotide receptor and the P2Y receptor in C6 glioma cells.
Chuang, DM; Lin, WW, 1994
)
1.01
"Suramin is an antiparasitic agent that is currently being evaluated for antineoplastic activity. "( Postoperative complications in patients receiving suramin therapy.
Cole, DJ; Cooper, MR; Danforth, DN; Ettinghausen, SE; Linehan, MW; Myers, CW; Pass, HI; Sindelar, WF, 1994
)
1.98
"Suramin is an effective antitumor agent in hormone-refractory prostate cancer, but its mechanism(s) of action is not well understood."( Inhibition of fibroblast hyaluronic acid production by suramin.
August, EM; Cysyk, RL; Duncan, KL; Malinowski, NM, 1993
)
1.25
"Suramin is an antiparasitic drug being evaluated as an antitumor compound. "( Suramin-induced weakness from hypophosphatemia and mitochondrial myopathy. Association of suramin with mitochondrial toxicity in humans.
Miles, JM; Rago, RP; Spriggs, DR; Sufit, RL; Wilding, G, 1994
)
3.17
"Suramin is a polysulfonated naphthylurea developed originally to treat trypanosomiasis. "( Dual effect of suramin on calcium fluxes across sarcoplasmic reticulum vesicle membranes.
Besch, HR; Besch, KT; Bidasee, KR; Emmick, JT; Kwon, S, 1994
)
2.08
"Suramin is a prototype of a new class of anticancer drugs. "( Suramin inhibits the phosphorylation and catalytic activity of DNA topoisomerase II in human lung cancer cells.
Funayama, Y; Hasegawa, S; Kubota, N; Nishio, K; Ogasawara, H; Ohira, T; Ohmori, T; Ohta, S; Saijo, N; Takeda, Y,
)
3.02
"Suramin is a polysulphonated compound which can selectively bind to, and inhibit the activity of, a wide range of growth factors. "( Modulation of CD4 by suramin.
Allen, PD; Johnston, DH; Macey, MG; Newland, AC; Williams, NS, 1993
)
2.05
"Suramin is an anthelmintic drug that recently has been shown to have clinical efficacy in the treatment of patients with some advanced malignancies, including prostate carcinoma. "( Effect of suramin on the mitogenic response of the human prostate carcinoma cell line PC-3.
Ewing, MW; Gnarra, JR; Linehan, WM; Liu, SC; Meyers, CE; Walther, MM, 1993
)
2.13
"Suramin is an important anti-tumor and anti-viral chemotherapeutic agent. "( Precision in capillary electrophoresis with respect to quantitative analysis of suramin.
Cheung, AP; Hettiarachchi, K, 1995
)
1.96
"Suramin is a newer agent employed in the management of prostate cancer. "( Suramin as adjuvant therapy with radical prostatectomy.
Chou, P; Guinan, P; Ray, V; Rubenstein, M; Saffrin, R; Shaw, M, 1996
)
3.18
"Suramin is a polysulfonated compound currently under investigation for the treatment of various types of cancer. "( Co-localization of suramin and serum albumin in lysosomes of suramin-treated human colon cancer cells.
Baghdiguian, S; Boudier, JA; Boudier, JL; Fantini, J, 1996
)
2.07
"Suramin is a polysulfonated naphthylurea with demonstrated antineoplastic activity. "( Suramin induces phosphorylation of the high-affinity nerve growth factor receptor in PC12 cells and dorsal root ganglion neurons.
Connolly, DC; Gill, JS; Maihle, NJ; McManus, MJ; Windebank, AJ, 1996
)
3.18
"Suramin is a polysulphonated naphthylurea currently investigated for the treatment of advanced malignancy. "( Intracellular localisation of suramin, an anticancer drug, in human colon adenocarcinoma cells: a study by quantitative autoradiography.
Baghdiguian, S; Boudier, JA; Boudier, JL; Fantini, J, 1996
)
2.03
"Suramin is a more potent (IC50, 0.9 microM) inhibitor of FPGS partially purified from CCRF-CEM human leukemia cells than is bromosulfophthalein (IC50, 17 microM), the first reported nonsubstrate-analog inhibitor of FPGS (J."( Potent inhibition of human folylpolyglutamate synthetase by suramin.
Haile, WH; McGuire, JJ, 1996
)
1.26
"Suramin is a synthetic polysulfonated naphthylurea which has been used for the treatment of African trypanosomiasis and onchocerciasis, but since the mid-1980s has received attention as a possible antiretroviral and antineoplastic agent."( A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.
Bitton, RJ; Bowden, CJ; Cooper, MR; Dawson, NA; Figg, WD; Headlee, D; Myers, CE; Reed, E; Sartor, O; Weinberger, MS, 1996
)
2
"Suramin is an investigational drug that has shown therapeutic activity in hormone-refractory metastatic prostate cancer in Phase I/II trials. "( A prospective study of suramin-induced peripheral neuropathy.
Chaudhry, V; Cornblath, DR; Eisenberger, MA; Griffin, JW; Sheikh, K; Sinibaldi, VJ, 1996
)
2.05
"Suramin is an experimental chemotherapeutic agent and a neurotoxin which causes a dose-dependent peripheral neuropathy in vivo and inhibits dorsal root ganglion (DRG) neurite outgrowth in vitro. "( Calcium in suramin-induced rat sensory neuron toxicity in vitro.
Sun, X; Windebank, AJ, 1996
)
2.13
"Suramin is a multi-targeted antiproliferative drug developed for the treatment of African trypanosomiasis but with potential efficacy for the treatment of human cancer. "( Suramin is synergistic with vinblastine in human colonic tumor cell lines: effect of cell density and timing of drug delivery.
Frommel, TO,
)
3.02
"Suramin is a polysulphonated compound that inhibits binding of capacitated mouse spermatozoa to the zona pellucida in vitro with an IC50 of 12.4 microM."( Inhibition of sperm-zona binding by suramin, a potential 'lead' compound for design of new anti-fertility agents.
Jones, R; Lo Leggio, L; Nickel, P; Parry, R, 1996
)
1.29
"Suramin is a novel cytostatic/cytotoxic agent that is currently undergoing clinical trials in the treatment of hormone- and chemo-refractory tumors. "( Apoptosis and clonogenic cell death in PC3 human prostate cancer cells after treatment with gamma radiation and suramin.
Bump, EA; Coleman, CN; Palayoor, ST; Teicher, BA, 1997
)
1.95
"Suramin is a lead compound for treatment of cancer, HIV, and trypanosomiasis. "( Conformation of the trypanocidal pharmaceutical suramin in its free and bound forms: transferred nuclear overhauser studies.
Iwashita, T; McDermott, AE; Palmer, AG; Polenova, T, 1997
)
2
"Suramin is a synthetic anticancer agent that works, in part, by blocking the binding of growth factors to their receptors."( Inhibition of growth factor mitogenicity and growth of tumor cell xenografts by a sulfonated distamycin A derivative.
Calabresi, P; Chen, TM; Chu, MY; Epstein, MH; Finch, PW; Friedman, S; Lipsky, MH; Maciag, T; Yee, LK, 1997
)
1.02
"Suramin is a polysulfated drug used in the treatment of cancer and AIDS. "( Pharmacological concentrations of suramin inhibit the binding of alpha2-macroglobulin to its cell-surface receptor.
Vassiliou, G, 1997
)
2.02
"Suramin is an experimental antineoplastic agent which is currently being tested in clinical trials for its utility in treating breast and prostate cancer. "( Role of ceramide in suramin-induced cancer cell death.
Gill, JS; Windebank, AJ, 1997
)
2.06
"Suramin is a reversible and competitive PTPase inhibitor with Kis values in the low microM range, whereas the Kis for the dual specificity phosphatase VHR is at least 10-fold higher."( Suramin is an active site-directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatases.
Keng, YF; Wu, L; Zhang, YL; Zhang, ZY; Zhao, Y, 1998
)
2.46
"Suramin is a drug of choice in the treatment of sleeping sickness, but its mechanism of action is not known."( Reactivation of triosephosphate isomerase from three trypanosomatids and human: effect of suramin.
Cabrera, N; De Gómez-Puyou, MT; Gao, XG; Garza-Ramos, G; Gómez-Puyou, A; Perez-Montfort, R; Saavedra-Lira, E, 1998
)
1.24
"Suramin is a symmetrical planar polyanionic molecule which is being used as a novel experimental anti-neoplastic agent."( Direct activation of the high-affinity nerve growth factor receptor by a non-peptide symmetrical polyanion.
Gill, JS; Windebank, AJ, 1998
)
1.02
"Suramin is an antineoplastic agent which has a cytostatic effect on both normal and tumor-derived cells. "( Suramin increases p53 protein levels but does not activate the p53-dependent G1 checkpoint.
Coleman, CN; Howard, SP; Hughes-Davies, L; Park, SJ; Price, BD, 1996
)
3.18
"Suramin is a polyanionic chemotherapeutic agent which causes severe peripheral neuropathy. "( Activation of the high affinity nerve growth factor receptor by two polyanionic chemotherapeutic agents: role in drug induced neurotoxicity.
Gill, JS; Windebank, AJ, 1998
)
1.74
"Suramin is an experimental antineoplastic agent that is currently being tested in clinical trials for a number of human cancers. "( Suramin induced ceramide accumulation leads to apoptotic cell death in dorsal root ganglion neurons.
Gill, JS; Windebank, AJ, 1998
)
3.19
"Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC). "( Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone.
Chen, L; Eisenberger, M; Lenehan, PF; Marshall, ME; Meyer, M; Meyers, FJ; Natale, RB; Reyno, LM; Slichenmyer, WJ; Small, EJ, 2000
)
3.19
"Suramin is a rather rigid molecule."( Angiostatic effects of suramin analogs in vitro.
Allolio, B; Firsching-Hauck, A; Kulik, R; Nehls, V; Nickel, P; Simon, N; Wandt, C; Yahya, C; Zink, M, 2000
)
1.34
"Suramin is a polysulfonated naphthylurea with multiple potential mechanisms of action against tumors, including the ability to bind growth factors known to promote tumor angiogenesis. "( A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients.
Benson, AB; Bouck, N; Cisneros, A; French, S; Gradishar, WJ; Liu, J; Rademaker, A; Soff, G, 2000
)
2.09
"Suramin is a polysulfonated naphthylurea that inhibits tumor cell proliferation and angiogenesis, but the widespread use of this drug has been limited by significant neurologic toxicity. "( Suramin analogs inhibit human angiogenesis in vitro.
Flattmann, GJ; Gagliardi, AR; Meyers, MO; Su, JL; Wang, YZ; Woltering, EA, 2000
)
3.19
"Suramin was found to be a potent inhibitor of the lactate dehydrogenase activity."( Inhibition of lactate dehydrogenase activity from Dirofilaria immitis by suramin.
Walter, RD, 1979
)
1.21
"Suramin is a polysulfonated naphthyl-urea with antineoplastic activity that binds various peptide growth factors. "( Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop.
Helman, LJ; Maggi, M; Minniti, CP, 1992
)
3.17
"Suramin is an anticancer agent with a narrow therapeutic window and a terminal half-life of 45 to 55 days. "( Suramin: rapid loading and weekly maintenance regimens for cancer patients.
Heimans, JJ; Lopez, R; Meijer, E; Pinedo, HM; van Groeningen, CJ; van Loenen, AC; van Rijswijk, RE; Wagstaff, J, 1992
)
3.17
"Suramin is a polyanionic compound used clinically for the treatment of trypanosomiasis, which is known to inhibit the action of many protein factors in vitro. "( Suramin interference with transforming growth factor-beta inhibition of human renal cell carcinoma in culture.
Gomella, LG; Kasid, A; LaRocca, RV; Linehan, WM; Myers, CE; Sargent, ER; Stein, CA; Wade, TP, 1992
)
3.17
"Suramin is a polyanionic compound recently noted to inhibit growth factor action and proliferation of several types of neoplastic cells in vitro. "( Suramin inhibits growth factor binding and proliferation by urothelial carcinoma cell cultures.
Gansler, T; Graham, SD; Olson, JJ; Vaghmar, N, 1992
)
3.17
"Suramin is a polysulfonated urea recently tested in clinical trials as an anticancer agent."( Effects of suramin on in vitro growth of fresh human tumors.
Fanta, P; Lui, R; Salmon, SE; Taylor, CW, 1992
)
2.12
"Suramin is a synthetic polyanionic compound which is capable of altering the function of a number of biologic systems and inhibiting the activity of a variety of protein and growth factors."( Inhibitory effects of suramin on a human renal cell carcinoma line, causing nephrogenic hepatic dysfunction.
Chang, SY; Kozlowski, JM; Lee, C; Sherwood, ER; Yu, DS, 1992
)
1.32
"Suramin is an anti-cancer drug which induces the differentiation of the human colon cancer clone HT29-D4. "( Short-term suramin treatment followed by the removal of the drug induces terminal differentiation of HT29-D4 cells.
Baghdiguian, S; Fantini, J; Marvaldi, J; Verrier, B, 1992
)
2.12
"Suramin is an anti-helminthic drug that has been shown to antagonize the effects of a variety of growth factors including EGF, PDGF and TGF beta. "( [Suramin inhibits the proliferation and stimulates the differentiation of tumoral cell lines HT29-D4 and C6].
Baghdiguian, S; Fantini, J; Marvaldi, J; Pichon, J, 1991
)
2.63
"Suramin is a polyanionic compound currently used under evaluation for antineoplastic activity. "( Double screening of suramin derivatives on human colon cancer cells and on neural cells provides new therapeutic agents with reduced toxicity.
Baghdiguian, S; Fantini, J; Nickel, P, 1991
)
2.05
"Suramin is a polyanionic compound which has been used in the treatment of trypanosomiasis and acquired immunodeficiency syndrome (AIDS), while preliminary success has been reported in the treatment of cancer. "( Effects of suramin on hormone release by cultured rat anterior pituitary cells.
Abou-Hashim, EM; de Jong, FH; den Holder, FH; el-Kannishy, MH; Hofland, LJ; Lamberts, SW; Marzouk, HF; Steenbergen, J; van Koetsveld, PM; Zuiderwijk, J, 1990
)
2.11
"Suramin sodium is an aromatic polysulfonated compound that was originally introduced as an antiparasitic agent in the 1920s. "( A pilot study of suramin in the treatment of metastatic renal cell carcinoma.
Cooper, MR; Danesi, R; La Rocca, RV; Myers, CE; Stein, CA; Uhrich, M, 1991
)
2.06
"Suramin is a trypanocidal drug that has generated recent interest as an antineoplastic agent because of its ability to inhibit the binding of growth factors to their cell surface receptors. "( Inhibition of prostatic tumor cell proliferation by suramin: alterations in TGF alpha-mediated autocrine growth regulation and cell cycle distribution.
Kim, JH; Kozlowski, JM; Lee, C; Sherwood, ER; Sutkowski, DM, 1991
)
1.97
"Suramin is a polysulfonated naphthylurea currently investigated for the treatment of advanced malignancy. "( A suramin derivative induces enterocyte-like differentiation of human colon cancer cells without lysosomal storage disorder.
Baghdiguian, S; Fantini, J; Marvaldi, J; Nickel, P, 1990
)
2.44
"Suramin is a polysulfonated compound originally developed nearly 75 years ago for use as a trypanocidal agent. "( Suramin: prototype of a new generation of antitumor compounds.
La Rocca, RV; Myers, CE; Stein, CA, 1990
)
3.16
"Suramin is a polysulfonated drug with several biological activities including inhibition of binding of some growth factors to cells, inhibition of tumor cell growth, and of glycosaminoglycan metabolism. "( Suramin inhibits laminin- and thrombospondin-mediated melanoma cell adhesion and migration and binding of these adhesive proteins to sulfatide.
Kohn, EC; Roberts, DD; Zabrenetzky, VS, 1990
)
3.16
"Suramin is an active antiretroviral agent whose effect on retroviral propagation is reversible."( Suppression of retroviral propagation and disease by suramin in murine systems.
Broder, S; Haseltine, WA; Rossoni, LD; Ruprecht, RM, 1985
)
1.24
"Suramin is a potent inhibitor of the reverse transcriptase (RNA-directed DNA polymerase) of retroviruses, including the HTLV-III/LAV (human T-cell lymphotropic virus type III/lymphadenopathy-associated virus) reverse transcriptase. "( Suramin in the treatment of AIDS: mechanism of action.
De Clercq, E, 1987
)
3.16
"Suramin is a toxic agent that shows no virologic, immunologic, or clinical benefit in patients with HIV-related disease."( Lack of response to suramin in patients with AIDS and AIDS-related complex.
Abrams, DI; Feorino, P; Gottlieb, MS; Kaplan, LD; Kaufman, L; Kiprov, D; Levy, JA; Volberding, PA; Wolfe, PR; Wong, R, 1987
)
1.32
"Suramin sodium is a reverse transcriptase inhibitor with in vitro activity against the human immunodeficiency virus (HIV), the causative agent of acquired immunodeficiency syndrome (AIDS). "( Suramin therapy in AIDS and related disorders. Report of the US Suramin Working Group.
Cheson, BD; Gill, P; Groopman, JE; Kaplan, LD; Levine, AM; Mildvan, D; Poiesz, BJ; Rios, A; Volberding, PA; Wolfe, P, 1987
)
3.16

Effects

Suramin has an inhibitory effect on the neointimal thickening and intimal smooth muscle cell proliferation after intimal injury in the rabbit aorta. It has no effect on platelet function.

Suramin has long been used for the treatment of Gambian and Rhodesian trypanosomiasis and oncocerciasis. Suramin has also been extensively trialed recently to treat a number of other diseases, including many cancers.

ExcerptReferenceRelevance
"Suramin has an inhibitory effect on the neointimal thickening and intimal smooth muscle cell proliferation after intimal injury in the rabbit aorta, but has no effect on platelet function."( Suramin inhibits intimal thickening following intimal injury in the rabbit aorta in vivo.
Asada, Y; Marutsuka, K; Sumiyoshi, A; Tsuneyoshi, A, 1994
)
3.17
"Suramin has a distinct effect on the wound healing process and expression of growth factors and may be a promising substance for clinical use."( A mouse model to study the wound healing response following filtration surgery.
Chévez-Barrios, P; Lieberman, MW; Mietz, H, 1998
)
1.02
"Suramin has been reported to enhance chondrogenic differentiation."( Suramin ameliorates osteoarthritis by acting on the Nrf2/HO-1 and NF-κB signaling pathways in chondrocytes and promoting M2 polarization in macrophages.
Chou, SH; Huang, SH; Liu, ZM; Lu, CC; Shen, PC; Tien, YC, 2023
)
3.07
"Suramin has been a primary early-stage treatment for African trypanosomiasis for nearly 100 yr. "( Structure of trypanosome coat protein VSGsur and function in suramin resistance.
Hälg, S; Hashemi, H; Hempelmann, A; Jeffrey, PD; Mäser, P; Papavasiliou, FN; Perez, K; Stebbins, CE; van Straaten, M; Verdi, J; Wiedemar, N; Zeelen, J, 2021
)
2.31
"Suramin has long been used in the treatment of various human diseases. "( The effects of Suramin on Ca
Posterino, GS; Stephenson, DG; Williams, DW, 2017
)
2.25
"Suramin has been used previously to treat trypanosomiasis in Africa."( Inhibition of Rift Valley fever virus replication and perturbation of nucleocapsid-RNA interactions by suramin.
Ellenbecker, M; Lanchy, JM; Lodmell, JS, 2014
)
1.34
"Suramin has been shown to bind to hFGF1, and might block the interaction between hFGF1 and FGFR2 D2."( Suramin blocks interaction between human FGF1 and FGFR2 D2 domain and reduces downstream signaling activity.
Chou, RH; Fu, B; Liu, CF; Wu, ZS; Yu, C, 2016
)
2.6
"Suramin has been widely used as an antagonist at P2X receptors, and its analog 4,4',4'',4'''-[carbonylbis(imino-5,1,3-benzenetriylbis(carbonylimino))] tetrakis-benzene-1,3-disulfonic acid (NF449) is selective for the P2X(1) subtype."( Ectodomain lysines and suramin block of P2X1 receptors.
Broomhead, HE; North, RA; Sim, JA, 2008
)
1.38
"Suramin has also been extensively trialed recently to treat a number of other diseases, including many cancers."( Suramin: clinical uses and structure-activity relationships.
Bennett, AJ; Cosgrove, KL; McGeary, RP; Ross, BP; Tran, QB, 2008
)
2.51
"Suramin has been reported to inhibit the growth of certain tumor cells via various pathways."( Suramin inhibits the growth of nasopharyngeal carcinoma cells via the downregulation of osteopontin.
Chen, X; Jiang, S; Li, C; Yang, G; Yue, Y; Zhang, T; Zhang, X, 2012
)
2.54
"Suramin has in the last two decades been used as salvage therapy in some cancers."( Suramin suppresses growth, alkaline-phosphatase and telomerase activity of human osteosarcoma cells in vitro.
Blahovec, H; Trieb, K, 2003
)
2.48
"Suramin has been found to inhibit transforming growth factor (TGF)-beta1 expression by competitively binding to the growth factor receptor."( Antifibrotic effects of suramin in injured skeletal muscle after laceration.
Chan, YS; Foster, W; Fu, FH; Horaguchi, T; Huard, J; Li, Y; Somogyi, G, 2003
)
1.35
"Suramin has been shown to inhibit growth factor signaling pathways; however, its effect on apoptosis is unknown."( Suramin inhibits death receptor-induced apoptosis in vitro and fulminant apoptotic liver damage in mice.
Bilzer, M; Eichhorst, ST; Fas, SC; Gerbes, AL; Golks, A; Gruetzner, U; Krammer, PH; Krueger, A; Müerköster, S; Opelz, C; Schubert, L, 2004
)
2.49
"Suramin has proven to be useful as an antitumor drug, but there was not any report on the effect of suramin on CHO-cells."( Inhibition of proteinase 3 (PR3) by suramin and fetal calf serum (FCS): effect of PR3 and suramin on Chinese hamster ovary cells (CHO-cells).
Karam, GA; Khaksari, M; Mahmoodi, M; Rasaee, MJ, 2005
)
1.32
"Suramin has synergetic inhibitory effect with DDP on growth and metastasis of lung adenocarcinoma LA795 cell xenografts in mice through inhibiting angiogenesis and inducing cell apoptosis."( [Effects of suramin in combination with cisplatin on growth and metastasis of lung adenocarcinoma xenografts in mice].
He, JB; Ou, LW; Wang, XH; Zhang, P, 2006
)
2.16
"As suramin has been reported to induce hyperglycaemia, its effect on glucose formation has been studied in isolated rabbit hepatocytes and kidney-cortex tubules."( Suramin-induced reciprocal changes in glucose and lactate synthesis in renal tubules contribute to its hyperglycaemic action.
Bryła, J; Jagielski, AK; Kryśkiewicz, E, 2006
)
2.29
"Suramin has been previously reported to inhibit distinct cell enzymes and to affect the synthesis and distribution of cytoskeleton proteins. "( Effect of suramin on trypomastigote forms of Trypanosoma cruzi: changes on cell motility and on the ultrastructure of the flagellum-cell body attachment region.
Bisaggio, DF; Campanati, L; Pinto, RC; Souto-Padrón, T, 2006
)
2.18
"Suramin has not been evaluated as a chemosensitizing agent in dogs with cancer."( Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with naturally occurring cancers.
Au, JL; Couto, CG; Green, EM; Hu, X; Kisseberth, WC; Kosarek, CE; Wientjes, MG,
)
1.14
"Suramin has been previously reported to inhibit distinct cellular enzymes and to affect the synthesis and distribution of cytoskeleton proteins, cell differentiation and proliferation. "( In vitro effects of suramin on Trypanosoma cruzi.
Adade, CM; Bisaggio, DF; Souto-Padrón, T, 2008
)
2.11
"Suramin has now been found to block in vitro the infectivity and cytopathic effect of HTLV-III at doses that are clinically attainable in human beings."( Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III.
Broder, S; Gallo, RC; Matsushita, S; Mitsuya, H; Popovic, M; Yarchoan, R, 1984
)
2.43
"Suramin has been reintroduced in trials of chemohormonal intervention."( [Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma].
Crawford, ED; DeAntoni, E, 1995
)
1.01
"Suramin has limited efficacy in patients with androgen-independent prostate cancer who have had disease progression after hydrocortisone."( Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.
Curley, T; Dnistrian, A; Kelly, WK; Leibretz, C; Scher, HI; Schwartz, M, 1995
)
1.99
"Suramin has been reported to have major antiproliferative effects in a variety of lymphoid cell lines."( Dexamethasone and suramin inhibit cell proliferation and interleukin-6-mediated immunoglobulin secretion in human lymphoid and multiple myeloma cell lines.
Freter, CE; Khera, SY; Miglietta, L; Shiao, RT; Wolfson, A, 1995
)
1.35
"Suramin has shown antitumour activity in vitro and in vivo. "( The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin.
Lopez Lopez, R; Peters, GJ; Pinedo, HM; van Rijswijk, RE; Wagstaff, J, 1994
)
1.94
"Suramin has an inhibitory effect on the neointimal thickening and intimal smooth muscle cell proliferation after intimal injury in the rabbit aorta, but has no effect on platelet function."( Suramin inhibits intimal thickening following intimal injury in the rabbit aorta in vivo.
Asada, Y; Marutsuka, K; Sumiyoshi, A; Tsuneyoshi, A, 1994
)
3.17
"Suramin has shown promising activity against prostate and breast cancer but is severely neurotoxic. "( Suramin for breast and prostate cancer: a pilot study of intermittent short infusions without adaptive control.
George, N; Howell, A; Margison, J; Ranson, M; Thomson, Y; van der Water, L; Woll, PJ, 1994
)
3.17
"Suramin has long been used in the treatment of onchocerciasis and trypanosomiasis. "( [Cutaneous drug reaction caused by suramin in 4 patients with metastatic prostate cancer].
Dieckmann, KP; Gollnick, H; Handke, A; Tebbe, B; Wichterich, K, 1994
)
2.01
"Suramin has long been used for the treatment of Gambian and Rhodesian trypanosomiasis and oncocerciasis. "( Suramin, an experimental chemotherapeutic drug, irreversibly blocks T cell CD45-protein tyrosine phosphatase in vitro.
Ghosh, J; Miller, RA, 1993
)
3.17
"Suramin has recently surfaced as a potential antineoplastic agent on the basis of its ability to exert a cytostatic effect on human prostate carcinoma cells. "( Combined antitumor effect of suramin plus irradiation in human prostate cancer cells: the role of apoptosis.
Eddy, HA; Jacobs, SC; Kyprianou, N; Sklar, GN, 1993
)
2.02
"Suramin has antitumor activity in metastatic prostate carcinoma independent of the therapeutic effect of hydrocortisone administration or flutamide withdrawal. "( Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables.
Bergan, RC; Cooper, MR; Dawson, NA; Figg, WD; Headlee, DJ; Myers, CE; Sartor, O; Sausville, EA; Steinberg, SM; Thibault, A, 1995
)
2.05
"Suramin has been used as an antagonist of ATP at P2 purinoceptors, however, we find that suramin does not antagonize the effect of ATP at skeletal or cardiac ryanodine receptor channels."( Modification of the conductance and gating properties of ryanodine receptors by suramin.
Sitsapesan, R; Williams, AJ, 1996
)
1.24
"Suramin has been shown to block the binding of epidermal growth factor (EGF) to its receptors, which are found in large amounts in bladder cancers."( Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder.
Figg, WD; Linehan, WM; Walther, MM, 1996
)
1.38
"Suramin, which has been used for more than 50 years as an anthelmintic in humans, has recently been shown to inhibit P2 purinoceptors in the CNS and to block glutamate-evoked excitatory potentials in hippocampus. "( Inhibition of [3H]CGP 39653 binding to NMDA receptors by a P2 antagonist, suramin.
Balcar, VJ; Bennett, MR; Dias, LS; Li, Y, 1995
)
1.96
"Suramin has demonstrated modest activity against prostate cancer and is being investigated in clinical trials. "( Acute renal failure in a patient receiving treatment with suramin.
Harbour, D; Liebmann, J; Smith, A, 1997
)
1.98
"Suramin has a distinct effect on the wound healing process and expression of growth factors and may be a promising substance for clinical use."( A mouse model to study the wound healing response following filtration surgery.
Chévez-Barrios, P; Lieberman, MW; Mietz, H, 1998
)
1.02
"Suramin has been shown to be of interest as a potential new anticancer agent because of its capacity to inhibit the binding of several growth factors to their receptors and to inhibit the growth of cancer cells in vitro. "( Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+LV-based chemotherapy.
Allegrini, G; Antonuzzo, A; Brunetti, I; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Galli, C; Lencioni, M; Masi, G; Pfanner, E,
)
3.02
"Suramin has limited, but significant, efficacy even in chemotherapy- and hormone-refractory prostate cancer, without serious toxicity."( Suramin treatment in hormone- and chemotherapy-refractory prostate cancer.
Allolio, B; Garcia-Schürmann, JM; Haupt, G; Pastor, J; Schulze, H; Senge, T, 1999
)
3.19
"Suramin has been reported to inhibit tumor growth by blocking angiogenesis and has been used in clinical trials."( Effects of suramin on anastomotic colon tumors in a rat model.
De Clerck, LS; Dirix, L; Eyskens, E; Hendriks, J; Hubens, A; Hubens, G; Lauwers, P; Schuerwegh, A; Stevens, WJ; Van Marck, E; Vermeulen, P, 1999
)
1.41
"Suramin has shown promising antitumour activity against several tumour types, both in vitro and in vivo, but the clinical utility of this compound is hampered by its unfavourable toxicity profile. "( Antitumour activity of suramin analogues in human tumour cell lines and primary cultures of tumour cells from patients.
Csoka, K; Dhar, S; Eriksson, E; Gullbo, J; Larsson, R; Nickel, P; Nilsson, K; Nygren, P, 2000
)
2.06
"Suramin has been shown to have efficacy in treatment of prostate cancer. "( Distribution of [14C]suramin in tissues of male rats following a single intravenous dose.
DeHart, PD; Lathia, C; McNally, WP; Whitfield, LR, 2000
)
2.07
"Suramin has been shown to have an effect on bone resorption in in vitro models. "( Suramin administration is associated with a decrease in serum calcium levels.
Figg, WD; Linehan, WM; Myers, CE; Rehak, NN; Venzon, D; Walther, MM, 2000
)
3.19
"Suramin has been shown to produce diverse cellular effects via the simultaneous block of the action of several growth factors."( Neural retina of chick embryo in organ culture: effects of blockade of growth factors by suramin.
Chifflet, S; Cirillo, A; Villar, B, 2001
)
1.25
"Suramin has been extensively studied, but due to its poor activity seen in recent randomized trials, as well as the toxicity and inconvenience, it will likely not be further developed in HRPC."( Treatment of hormone refractory prostate cancer.
Knox, JJ; Moore, MJ, 2001
)
1.03
"Suramin has significantly enhanced the evolution of our knowledge in several areas of prostate cancer biology and treatment."( Suramin's development: what did we learn?
Dahut, W; Figg, WD; Kaur, M; Reed, E; Sartor, O, 2002
)
2.48
"Suramin, which has been reported to be a P2-receptor antagonist, inhibited ATP-induced phospholipase C activation in a competitive fashion, but did not affect ATP-induced adenylate cyclase modulation."( Extracellular ATP stimulates three different receptor-signal transduction systems in FRTL-5 thyroid cells. Activation of phospholipase C, and inhibition and activation of adenylate cyclase.
Kondo, Y; Okajima, F; Sato, K, 1992
)
1
"Suramin has recently been described to possess antineoplastic activity in animals and humans, and it has been proposed that an important role in this activity is played by antagonism of growth factors and especially bFGF."( Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity.
Grandi, M; Mongelli, N; Pesenti, E; Sola, F; Spreafico, F, 1992
)
2.45
"Suramin has been shown to have antitumor activity in patients with advanced, hormone refractory prostate cancer."( Suramin inhibits bone resorption and reduces osteoblast number in a neonatal mouse calvarial bone resorption assay.
Blair, HC; Ewing, MW; Jamai-Dow, C; Kragel, PJ; Linehan, WM; Myers, CE; Schlesinger, PH; Trahan, E; Venzon, D; Walther, MM, 1992
)
2.45
"Suramin has been shown to have antiproliferative activity, either by blocking the binding of growth factors to their receptors or by inhibiting critical cellular enzymes. "( The effect of schedule, protein binding and growth factors on the activity of suramin.
Lopez Lopez, R; Peters, GJ; Pinedo, HM; Pizao, PE; van Loenen, AC; van Rijswijk, RE; Wagstaff, J, 1992
)
1.95
"Suramin has been shown to inhibit the binding of various growth factors to their receptors. "( Effect of suramin on growth of androgen-responsive mouse tumor (Shionogi carcinoma 115) and its autonomous subline (Chiba subline 2).
Furuya, Y; Sato, N; Shimazaki, J; Watabe, Y, 1990
)
2.12
"Suramin has recently been used to treat patients with acquired immune deficiency syndrome because of the action of this drug on reverse transcriptase. "( The inhibition of human adrenal steroidogenic enzyme activities by suramin.
Albertson, BD; Ashby, H; DiMattina, M; Linehan, WM; Queenan, JT; Robertson, CN, 1989
)
1.96
"- Suramin has antiphagocytic properties at 1 mM concentration which were explained by its anticomplementary activity."( Side effects of the trypanocidal chemotherapeutics trypan blue and suramin.
Ehlers, D, 1989
)
1.07
"Suramin has been reported to inhibit the reverse transcriptase activity of a number of retroviruses and to reduce the in vitro infectivity and cytopathic effect of HTLV-III/LAV, the etiologic agent of acquired immune deficiency syndrome (AIDS). "( Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection.
Broder, S; Collins, JM; Fauci, AS; Klecker, RW; Lane, HC; Myers, CE; Redfield, RR; Yarchoan, R, 1986
)
2
"Suramin has recently been shown to inhibit the activity of the duck hepatitis B virus DNA polymerase (DHBV DNAp) in vitro. "( Suramin treatment for chronic active hepatitis B--toxic and ineffective.
Anderson, MG; Coleman, JC; Loke, RH; Murray-Lyon, IM; Tsiquaye, KN; Zuckerman, AJ, 1987
)
3.16

Actions

Suramin was found to inhibit the recombinant enzyme with an IC(50) value of 7 microM. Suramin will also inhibit induction in animal-vegetal combinations with no intervening membranes while heparin does not.

ExcerptReferenceRelevance
"Suramin could inhibit NLRP3/caspase-1/GSDMD canonical pyroptosis pathway in LPS-induced MH-S alveolar macrophages."( RNA-seq revealed the anti-pyroptotic effect of suramin by suppressing NLRP3/caspase-1/GSDMD pathway in LPS-induced MH-S alveolar macrophages.
Chen, Y; Huang, C; Wang, J; Wang, Z; Zheng, J; Zhou, H; Zhu, Y, 2024
)
3.14
"Suramin did not inhibit lipopolysaccharide- or Pam3CSK4-induced IL-6 mRNA expression."( Suramin potently inhibits cGAMP synthase, cGAS, in THP1 cells to modulate IFN-β levels.
Mikek, C; Opoku-Temeng, C; Sintim, HO; Sooreshjani, MA; Wang, M, 2018
)
2.64
"Suramin tended to increase CAM vasculature at 50 microg but caused dramatic reductions both in vessel length and CAM growth at 100 microg."( A novel early chorioallantoic membrane assay demonstrates quantitative and qualitative changes caused by antiangiogenic substances.
Hazel, SJ, 2003
)
1.04
"Suramin was shown to inhibit both merozoite invasion and MSP142 proteolytic cleavage."( Suramin and suramin analogues inhibit merozoite surface protein-1 secondary processing and erythrocyte invasion by the malaria parasite Plasmodium falciparum.
Angov, E; Babon, J; Birdsall, B; Blackman, MJ; Dluzewski, AR; Feeney, J; Fleck, SL; Holder, AA; Kettleborough, CA; Martin, SR; Morgan, WD, 2003
)
2.48
"The suramin-induced increase in P(o) and conductance are both concentration-dependent."( Functional regulation of the cardiac ryanodine receptor by suramin and calmodulin involves multiple binding sites.
Hill, AP; Kingston, O; Sitsapesan, R, 2004
)
1.05
"Suramin was found to inhibit the recombinant enzyme with an IC(50) value of 7 microM."( Biochemical characterization and crystallization of recombinant 3-phosphoglycerate kinase of Plasmodium falciparum.
Chattopadhyay, D; Muccio, DD; Pal, B; Pybus, B, 2004
)
1.04
"Suramin can inhibit the bFGF induced proliferation of RPE cells. "( [The inhibiting effects of suramin on bFGF induced proliferation of cultured human RPE cells].
Huang, XK; Luo, Y; Tang, SB; Zhu, XB, 2005
)
2.07
"Suramin inhibit more strongly ATP hydrolysis than ADP hydrolysis whereas Evans blue almost abolish both hydrolysis."( E-NTPDases and ecto-5'-nucleotidase expression profile in rat heart left ventricle and the extracellular nucleotide hydrolysis by their nerve terminal endings.
Almeida, ME; Libermann, TA; Rücker, B; Sarkis, JJ; Wink, MR; Zerbini, LF, 2008
)
1.07
"Suramin could inhibit the proliferation and metastasis of LA795 cells in T739 mice through regulating the expression of EGFR, P-selectin and PCNA."( [Inhibitory effects of suramin on growth of transplanted lung adencarcinoma in mice and its mechanisms].
He, JB; Xiang, Z; Xie, MF; Yang, K; Yi, GZ; Zhang, P, 2008
)
2.1
"Suramin was found to inhibit the activity of malic enzyme from both filarial worms."( Inhibition of NADP-linked malic enzyme from Onchocerca volvulus and Dirofilaria immitis by suramin.
Albiez, EJ; Walter, RD, 1981
)
1.2
"Suramin did not inhibit the glucose-induced increase in NAD(P)H fluorescence."( Suramin inhibits glucose-induced Ca2+ response in single rat pancreatic beta cells.
Kuromi, H; Seino, S, 1997
)
2.46
"Suramin is known to inhibit proliferation of various tumor cells. "( Suramin inhibits proliferation of human arterial smooth muscle cells in vitro: potential drug for prevention of restenosis by local drug delivery.
Bienert, H; Engisch, R; Günther, RW; Schürmann, K; vom Dahl, J; Vorwerk, D; Voss, M, 2000
)
3.19
"Suramin did inhibit GRK2 with IC50 32 microM (pA26.39 for competitive inhibition of ATP)."( Molecular modeling of G-protein coupled receptor kinase 2: docking and biochemical evaluation of inhibitors.
Graul, RC; Gschwend, DA; Haga, T; Högger, P; Kameyama, K; Kassack, MU; Sadée, W, 2000
)
1.03
"As Suramin is known to inhibit lysosomal hydrolases required for the degradation of proteins, glycolipids and mucopolysaccharides, the membranous inclusions could form as a result of the accumulation of these substances within lysosomes."( Membranous neuronal and neuroglial inclusions produced by intracerebral injection of Suramin.
Rees, S, 1978
)
1
"Suramin was shown to cause haematological changes in normal animals which became evident several days before use of the drug."( [Chemotherapeutic studies on litomosoides carinii infection of mastomys natalensis. 5. Alterations of haematological parameters after the administration of filaricidal compounds (author's transl)].
Grüner, D; Lämmler, G; Zahner, H, 1975
)
0.98
"Suramin is known to inhibit the growth of malignant prostate carcinoma cells in vitro. "( Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.
Choyke, P; Cooper, M; Dawson, N; LaRocca, R; Myers, C; Stein, C; Steinberg, S; Uhrich, MM; Walther, MM; Weiss, G, 1992
)
3.17
"Suramin did not inhibit vasopressin-induced PLC activity."( Discrimination between two types of P2 purinoceptors by suramin in rat hepatocytes.
Kondo, Y; Okajima, F; Tomura, H, 1992
)
1.25
"Suramin will also inhibit induction in animal-vegetal combinations with no intervening membranes while heparin does not."( The nature of the mesoderm-inducing signal in Xenopus: a transfilter induction study.
Slack, JM, 1991
)
1
"Suramin was found to produce a positive DAT in vitro at concentrations of 2100 mg/L or greater but did not cause a positive DAT in five patients with acquired immunodeficiency syndrome who were treated with suramin, probably because the serum levels of suramin were too low in these patients (peak therapeutic blood levels ranged from 171 to 443 mg/L)."( Production of a positive direct antiglobulin test due to suramin.
Aguilar, S; Cohen, J; Gill, P; Jamin, D; Lam, HT; Levine, A; Shields, M; Shulman, I, 1988
)
1.24
"Suramin did not inhibit fibrin degradation by the fibrinolytic system in plasma."( Effects of suramin on complement, blood clotting, fibrinolysis and kinin formation.
Eisen, V; Loveday, C, 1973
)
1.36

Treatment

Suramin treatment failures has been observed among HAT patients in Tbr foci in Uganda. Suramin treatment suppressed PA-SMC proliferation and attenuated both the inflammatory response and the deposition of collagen.

ExcerptReferenceRelevance
"Suramin treatment significantly suppressed the increase in the urinary albumin-to-creatinine ratio, glomerular hypertrophy, mesangial matrix expansion, and glomerular fibrosis in KK-Ay mice. "( Suramin prevents the development of diabetic kidney disease by inhibiting NLRP3 inflammasome activation in KK-Ay mice.
Kodera, R; Miyamoto, S; Oda, K; Shikata, K; Wada, J, 2023
)
3.8
"Suramin treatment did not affect VPA-induced upregulation of P2X4 and P2Y2 receptor expression in the hippocampus, and P2X4 receptor expression in the medial prefrontal cortex, but normalized an increased level of interleukin 6 (IL-6)."( Effects of single-dose antipurinergic therapy on behavioral and molecular alterations in the valproic acid-induced animal model of autism.
Bambini-Junior, V; Bauer-Negrini, G; Brum Schwingel, G; Carello-Collar, G; Castillo, ARG; Corrêa-Velloso, J; Deckmann, I; Fontes-Dutra, M; Gonçalves, MCB; Gottfried, C; Hirsch, MM; Körbes-Rockenbach, M; Naaldijk, Y; Rabelo, B; Santos-Terra, J; Schneider, T; Staevie, GZ; Ulrich, H, 2020
)
1.28
"Suramin treatment failures has been observed among HAT patients in Tbr foci in Uganda."( Physiological and proteomic profiles of Trypanosoma brucei rhodesiense parasite isolated from suramin responsive and non-responsive HAT patients in Busoga, Uganda.
Adung'a, VO; Akoth, MO; Awuoche, EO; Bateta, R; Mang'era, CM; Mireji, PO; Mutuku, CN; Ndung'u, K; Njunge, JM; Ondigo, BN; Rono, MK, 2021
)
1.56
"Suramin treatment suppressed PA-SMC proliferation and attenuated both the inflammatory response and the deposition of collagen."( The beneficial effect of suramin on monocrotaline-induced pulmonary hypertension in rats.
Dartevelle, P; Dorfmüller, P; Eddahibi, S; Fadel, E; Guin, LL; Hoang, E; Humbert, M; Izikki, M; Lecerf, F; Mercier, O; Perros, F; Simonneau, G, 2013
)
1.41
"Suramin treatment before cisplatin administration reduced cisplatin-induced decreases in kidney function and injury."( Suramin protects from cisplatin-induced acute kidney injury.
Arteel, GE; Beverly, LJ; Casson, L; Doll, MA; Dupre, TV; Jenson, AB; Kiefer, A; Megyesi, J; Saforo, D; Saurabh, K; Scherzer, MT; Schnellmann, RG; Shah, PP; Sharp, CN; Siow, D; Siskind, LJ, 2016
)
2.6
"Suramin or saline-pretreated human mononuclear THP-1 cells were treated with 100 ng/mL LPS in vitro."( [Inhibitory effect of suramin on inflammatory response in pulmonary tissue and peripheral blood in LPS-induced septic mice].
Fang, XM; Han, L; Hou, JC, 2015
)
1.45
"Suramin treatment exerted negligible effect on the RAS pathway in the adult male offspring kidneys."( N-Acetylcysteine Prevents Programmed Hypertension in Male Rat Offspring Born to Suramin-Treated Mothers.
Hsu, CN; Lee, CT; Lin, YJ; Tain, YL; Tsai, CC, 2016
)
1.38
"Suramin-treated animals had a significant reduction in apoptotic tubular cells and infiltrating leukocytes."( Suramin promotes recovery from renal ischemia/reperfusion injury in mice.
Chavin, KD; Daubert, RA; Lu, B; Schnellmann, RG; Wang, L; Zhuang, S, 2009
)
2.52
"Suramin- and saline-treated (control) mdx mice performed exercise on a treadmill to worsen disease progression."( Prevention of muscle fibrosis and myonecrosis in mdx mice by suramin, a TGF-β1 blocker.
Marques, MJ; Matsumura, CY; Pertille, A; Santo Neto, H; Taniguti, AP, 2011
)
1.33
"Suramin treatment also inhibited activation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1 and 2, two signaling pathways associated with renal fibrogenesis."( Delayed administration of suramin attenuates the progression of renal fibrosis in obstructive nephropathy.
Liu, N; Ponnusamy, M; Tolbert, E; Yan, H; Zhuang, S, 2011
)
1.39
"Suramin treatment decreased interleukin-1β (IL-1β) mRNA, transforming growth factor-β(1) (TGF-β(1)), phospho-p65 of nuclear factor-κB (NF-κB), and cleaved caspase-3 at 48 h compared with glycerol alone."( Recovery from glycerol-induced acute kidney injury is accelerated by suramin.
Korrapati, MC; Schnellmann, RG; Shaner, BE, 2012
)
1.33
"Suramin treatment initiated at 2 weeks post-injury was observed to promote muscle regeneration and muscle strength, and to decrease fibrosis. "( Timing of the administration of suramin treatment after muscle injury.
Fu, FH; Gharaibeh, B; Huard, J; Li, Y; Nozaki, M; Ota, S; Terada, S; Uehara, K, 2012
)
2.11
"Suramin treatment inhibited in vivo growth in the REN intraperitoneal model shown grossly by necropsy of same day deaths comparing treatment and control animals."( Suramin inhibits the growth of malignant mesothelioma in vitro, and in vivo, in murine flank and intraperitoneal models.
Cook, JW; Kaiser, LR; Singhal, S; Smythe, WR; Sterman, DH, 2003
)
2.48
"In suramin-treated cells, the 10E4 epitope was destroyed by ascorbate-released nitric oxide with concomitant formation of anhydromannose-containing heparan sulfate oligosaccharides."( The heparan sulfate-specific epitope 10E4 is NO-sensitive and partly inaccessible in glypican-1.
Cheng, F; Ding, K; Fransson, LA; Havsmark, B; Mani, K; Sandgren, S; Van Den Born, J, 2004
)
0.84
"Suramin treatment resulted in a more normal phenotype as judged by growth rate, cell cycle parameters, and morphology."( The propeptide domain of lysyl oxidase induces phenotypic reversion of ras-transformed cells.
Guo, Y; Jeay, S; Palamakumbura, AH; Pischon, N; Sommer, P; Sonenshein, GE; Trackman, PC, 2004
)
1.04
"Suramin treatment decreased the interface, and vitamin E further decreased the interface in the diabetic U rats, whereas neither treatment affected the maternal-fetal interface in the diabetic H rats."( Suramin-restricted blood volume in the placenta of normal and diabetic rats is normalized by vitamin E treatment.
Eriksson, UJ; Nash, P,
)
2.3
"Suramin treatment caused profound changes in the yeast ultrastructure as shown by transmission electron microscopy."( Effect of suramin on the human pathogen Candida albicans: implications on the fungal development and virulence.
Braga-Silva, LA; de Araújo Soares, RM; dos Santos, AL; Portela, MB; Souto-Padrón, T, 2007
)
1.46
"The suramin-treated rat may be a useful experimental animal model of mucopolysaccharidosis."( Experimental animal model for mucopolysaccharidosis: suramin-induced glycosaminoglycan and sphingolipid accumulation in the rat.
Barranger, JA; Brady, RO; Constantopoulos, G; Cragg, BG; Rees, S, 1980
)
0.99
"Suramin treatment (250 mg/kg bw) 24 and 48 h after administration is followed by the decreased rate of intralysosomal digestion of 14C-bovine albumin. "( [Decrease in the rats of intraliposomal proteolysis and labilization of rat liver lysosomes following suramin administration].
Korolenko, TA; Malygin, AE; Pupyshev, AB, 1980
)
1.92
"3. Suramin (0.3 mM) pretreatment abolished the potentiating effect of ADP but left that of PMA unchanged."( Additive effect of ADP and CGRP in modulation of the acetylcholine receptor channel in Xenopus embryonic myocytes.
Fu, WM; Liou, JC, 1995
)
0.81
"Suramin treatment was without direct influence on steroid excess."( Suramin in adrenocortical cancer: limited efficacy and serious toxicity.
Allolio, B; Arlt, W; Reincke, M; Siekmann, L; Winkelmann, W, 1994
)
2.45
"Suramin treatment was well tolerated. "( Suramin for breast and prostate cancer: a pilot study of intermittent short infusions without adaptive control.
George, N; Howell, A; Margison, J; Ranson, M; Thomson, Y; van der Water, L; Woll, PJ, 1994
)
3.17
"Suramin treatment increased the 125I-FGF-2 binding capacity of undifferentiated F9 cells threefold but had little effect on the binding capacity of differentiated cells."( Autocrine downregulation of fibroblast growth factor receptors in F9 teratocarcinoma cells.
Moscatelli, D, 1994
)
1.01
"Suramin pretreatment of Pekin ducklings completely prevented DHBV infection."( Suramin prevents duck hepatitis B virus infection in vivo.
Blum, HE; Gerok, W; Offensperger, S; Offensperger, WB; Walter, E, 1993
)
2.45
"Suramin treatment prior to irradiation inhibited this radiation-induced cell death."( Combined antitumor effect of suramin plus irradiation in human prostate cancer cells: the role of apoptosis.
Eddy, HA; Jacobs, SC; Kyprianou, N; Sklar, GN, 1993
)
1.3
"Suramin treatment resulted in a time- and dose-dependent decrease in [3H]thymidine incorporation, except in one adenocarcinoma cell line where DNA synthesis was highly stimulated."( In vitro effect of suramin on lung tumour cells.
Lauber, B; Mórocz, IA; Schmitter, D; Stahel, RA, 1993
)
1.34
"Suramin treatment was most effective in suppressing EAU when started concurrently with immunization (afferent)."( Suramin treatment suppresses induction of experimental autoimmune uveoretinitis (EAU) in rodents.
Caspi, RR; Chan, CC; Sartani, G; Silver, PB; Strassmann, G, 1995
)
2.46
"Suramin treatment induced a 2-fold increase in immunoreactive FGFR and a 1.5-fold increase in 125I-bFGF binding sites, indicating that FGFRs are chronically down-regulated by endogenous bFGF in U87-MG cells."( Basic fibroblast growth factor binding and processing by human glioma cells.
Knee, RS; Murphy, PR, 1995
)
1.01
"Suramin treatment causes a moderate decrease in IgM mRNA, and this is associated with a decreased intracellular level of IgM in SKW 6.4 cells."( Mechanisms of inhibition of IL-6-mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines.
Freter, CE; Khera, SY; McLeskey, SB; Shiao, RT; Wolfson, A, 1996
)
1.24
"In suramin-treated animals the evaluation of Alcian blue recovery from gastric-bound mucus showed that the levels of adherent mucus were significantly lower than those detected in untreated rats."( Suramin enhances ethanol-induced injury to gastric mucosa in rats.
Blandizzi, C; Carignani, D; Colucci, R; Del Tacca, M; Gherardi, G; Lazzeri, G; Marveggio, C; Natale, G, 1997
)
2.25
"Suramin treatment is completely reversible; intact eggs exhibit the electrical response an average of 11 minutes after the drug is washed out."( Ascidian eggs block polyspermy by two independent mechanisms: one at the egg plasma membrane, the other involving the follicle cells.
Franchet, C; Goudeau, H; Goudeau, M; Lambert, C; Lambert, G, 1997
)
1.02
"Suramin-treated wounds showed a decrease of cells and delay in fibroblast maturation."( A mouse model to study the wound healing response following filtration surgery.
Chévez-Barrios, P; Lieberman, MW; Mietz, H, 1998
)
1.02
"Suramin treated dorsal root ganglion cultures revealed an accumulation of the GM1 ganglioside and ceramide."( Suramin induced ceramide accumulation leads to apoptotic cell death in dorsal root ganglion neurons.
Gill, JS; Windebank, AJ, 1998
)
2.46
"(c) Suramin-treated rats had markedly decreased lymphocyte stimulation, pointing to a possible immunosuppressive effect."( Effects of suramin on anastomotic colon tumors in a rat model.
De Clerck, LS; Dirix, L; Eyskens, E; Hendriks, J; Hubens, A; Hubens, G; Lauwers, P; Schuerwegh, A; Stevens, WJ; Van Marck, E; Vermeulen, P, 1999
)
1.17
"Suramin treatment reduced the neointima hyperplasia 50% to 70% compared with untreated controls."( Inhibition of neointima hyperplasia of mouse vein grafts by locally applied suramin.
Dietrich, H; Hu, Y; Wick, G; Xu, Q; Zou, Y, 1999
)
1.25
"Suramin-treated animals showed an obvious reduction in several parameters of CNS inflammation: cellular proliferation, GFAP levels, and tenascin-C immunoreactivity were reduced in suramin-treated as compared to control animals at early time points."( Suramin disrupts the gliotic response following a stab wound injury to the adult rat brain.
Di Prospero, NA; Geller, HM; Ho, SY; McAuliffe, WG; Meiners, S; Zhou, XR, 1998
)
2.46
"Suramin pretreatment did not alter the ingestion or intracellular killing of Staphylococcus aureus or of a strain of L."( Suramin effects on macrophage phagolysosome formation and antimicrobial activity.
Pesanti, EL, 1978
)
2.42
"Suramin treatment markedly reduced tyrosine-phosphorylated cell surface PDGFRs, but had no effect on the tyrosine-phosphorylated intracellular receptor species."( Platelet-derived growth factor (PDGF) receptor activation in cell transformation and human malignancy.
Aaronson, SA; Fleming, TP; Matsui, T,
)
0.85
"Suramin treatment led to a significant, but transient, disappearance of p24 antigen and did not affect the titre of anti-p24 and anti-gp51 antibodies."( Treatment of bovine leukaemia virus-infected sheep with suramin: an animal model for the development of antiretroviral compounds.
Burkhardt, H; De Clercq, E; Karge, E; Rosenthal, HA; Rosenthal, S, 1989
)
1.24
"Suramin treatment resulted in a marked reduction in tyrosine phosphorylated cell surface PDGF receptors but had no effect on the level of tyrosine phosphorylation of intracellular receptor species."( Autocrine mechanism for v-sis transformation requires cell surface localization of internally activated growth factor receptors.
Aaronson, SA; Fleming, TP; Matsui, T; Molloy, CJ; Robbins, KC, 1989
)
1
"Suramin treatment at the onset of the CBL coculture with a lethally irradiated HTLV-I donor cell line (MT-2) reduced virus transmission, evaluated as number of p19+ cells, and the consequent amount of integrated provirus in the host genome."( Low concentrations of suramin can reduce in vitro infection of human cord blood lymphocytes with HTLV-I during long-term culture.
Alvino, E; Bonmassar, E; Caliò, R; Ciprani, F; D'Onofrio, C; Perno, CF; Pesce, CD, 1987
)
1.31
"Suramin treatments were administered (IV) to 2 healthy adult cats infected with naturally acquired feline leukemia virus. "( Effect of suramin on serum viral replication in feline leukemia virus-infected pet cats.
Cogan, DC; Cotter, SM; Kitchen, LW, 1986
)
2.12
"Suramin treatment resulted in prolongation of the prothrombin time in all cases and a rise in bilirubin in two and it may have led to haemorrhage from oesophageal varices in one patient and to hepatic encephalopathy in another."( Suramin treatment for chronic active hepatitis B--toxic and ineffective.
Anderson, MG; Coleman, JC; Loke, RH; Murray-Lyon, IM; Tsiquaye, KN; Zuckerman, AJ, 1987
)
2.44
"Treatment with suramin (20 mg/kg, intraperitoneal) restored sociability in the three-chamber apparatus and decreased anxiety measured by elevated plus maze apparatus, but had no impact on decreased reciprocal social interactions or higher nociceptive threshold in VPA rats."( Effects of single-dose antipurinergic therapy on behavioral and molecular alterations in the valproic acid-induced animal model of autism.
Bambini-Junior, V; Bauer-Negrini, G; Brum Schwingel, G; Carello-Collar, G; Castillo, ARG; Corrêa-Velloso, J; Deckmann, I; Fontes-Dutra, M; Gonçalves, MCB; Gottfried, C; Hirsch, MM; Körbes-Rockenbach, M; Naaldijk, Y; Rabelo, B; Santos-Terra, J; Schneider, T; Staevie, GZ; Ulrich, H, 2020
)
0.9
"Treatment with suramin from day 1 to day 21 after monocrotaline injection attenuated PH development, as shown by lower values for pulmonary artery pressure, right ventricular hypertrophy, and distal vessel muscularization on day 21 compared to control rats."( The beneficial effect of suramin on monocrotaline-induced pulmonary hypertension in rats.
Dartevelle, P; Dorfmüller, P; Eddahibi, S; Fadel, E; Guin, LL; Hoang, E; Humbert, M; Izikki, M; Lecerf, F; Mercier, O; Perros, F; Simonneau, G, 2013
)
1.03
"Treatment with suramin resulted in marked alterations in the cell biology of the macrophage: (i) increased vacuolization and protein content, (ii) suppressed intracellular phagosome-lysosome fusion, (iii) decreased activity of the lysosomal enzymes beta-glucuronidase and N-acetyl-glucosaminidase, and (iv) enhanced exocytosis of acid phosphatase during phagocytosis."( Lung macrophage defense responses during suramin-induced lysosomal dysfunction.
Jakab, GJ; Warr, GA, 1983
)
0.87
"Treatment with suramin also decreased the levels of FGF receptor-1 mRNA to a similar extent, whereas it appeared not to affect the levels of beta-actin mRNA."( Suramin interrupts androgen-inducible autocrine loop involving heparin binding growth factor in mouse mammary cancer (Shionogi carcinoma 115) cells.
Kasayama, S; Kouhara, H; Saito, H; Sato, B; Sumitani, S, 1993
)
2.07
"Treatment with suramin, a polyanionic compound that disrupts ligand/receptor interactions at the cell surface, was able to revert the transformed phenotype induced by the mutant sis-E1 constructs described here."( The v-sis oncoprotein loses transforming activity when targeted to the early Golgi complex.
Donoghue, DJ; Hart, KC; Lee, BA; Meyer, AN; Xu, YF, 1994
)
0.63
"Pretreatment with suramin may have changed the biology of the tumor, sensitizing it to fluoropyrimidines."( Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study.
Brunetti, I; Cianci, C; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Pfanner, E, 1995
)
2.06
"Treatment with suramin, which interferes with the interaction of fibroblast growth factors with their cell surface receptors, did not decrease the drug resistance properties of K-fgf transfected cells."( Fibroblast growth factor mediated alterations in drug resistance, and evidence of gene amplification.
Huang, A; Wright, JA, 1994
)
0.63
"Treatment with suramin or suramin plus rIL-6 does not alter the IL-6 protein level or the mRNA levels for IL-6 and IL-6 receptor."( Mechanisms of inhibition of IL-6-mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines.
Freter, CE; Khera, SY; McLeskey, SB; Shiao, RT; Wolfson, A, 1996
)
0.86
"Pretreatment with suramin, which binds to growth factor, results in increased EGFR tyrosine phosphorylation after stimulation, suggesting disruption of normal autocrine receptor downregulation."( The epidermal growth factor receptor network in type 2 pneumocytes exposed to hyperoxia in vitro.
Frackelton, AR; Medina, M; Nici, L, 1996
)
0.62
"Cotreatment with suramin and glycyrrhetinic acid was found to completely block the mechanically induced Ca2+ wave in both cell lines."( Propagation of mechanically induced intercellular calcium waves via gap junctions and ATP receptors in rat liver epithelial cells.
de Feijter, AW; Frame, MK, 1997
)
0.63
"Pretreatment with suramin resulted in the loss of Raf-1 from c-N-ras immunoprecipitates."( Ha-ras and N-ras regulate MAPK activity by distinct mechanisms in vivo.
Hamilton, M; Wolfman, A, 1998
)
0.62
"Pretreatment with suramin (0.3 mM) significantly prolonged the blocking time by three-fold."( Suramin inhibits the toxic effects of presynaptic neurotoxins at the mouse motor nerve terminals.
Lin, MJ; Lin-Shiau, SY, 1999
)
2.07
"Pretreatment with suramin (0.3 mM) significantly reduced the inhibitory effect of nerve-evoked muscle contractions and Ca(2+) current induced by either omega-conotoxin MVIIC or omega-agatoxin IVA but not that induced by the non-selective Ca(2+) channel blocker, Cd(2+)."( Suramin protects the murine motor nerves from the toxic effects of presynaptic Ca(2+) channel inhibitors.
Lee, SY; Lin, MJ; Lin-Shiau, SY; Tan, CT, 2000
)
2.07
"(3) Treatment with suramin or heparin resulted in decreased deposition of proteoglycan in the pericellular matrix but increased accumulation of cell-associated proteoglycan."( Effects of cycloheximide, brefeldin A, suramin, heparin and primaquine on proteoglycan and glycosaminoglycan biosynthesis in human embryonic skin fibroblasts.
Fransson, LA; Karlsson, P; Schmidtchen, A, 1992
)
0.87
"Treatment with suramin effectively released mature int-1 proteins into the culture fluid, which suggests that secreted int-1 protein associates with the cell surface or extracellular matrix."( Secreted int-1 protein is associated with the cell surface.
Papkoff, J; Schryver, B, 1990
)
0.62
"Treatment with suramin resulted in decreases in hepatitis B surface antigen production and hepatitis B-virus associated DNA polymerase activity."( Effects of suramin on in vitro HBsAg production by PLC/PRF/5 cells and hepatitis B virus DNA polymerase activity.
Benson, CA; Kessler, HA; Levin, S; Pottage, JC; Trenholme, GM, 1986
)
1
"Treatment with suramin (Germanin) was begun in August 1987."( [Treatment of metastatic adrenal carcinoma with suramin].
Allolio, B; Arlt, W; Jaursch-Hancke, C; Metzler, U; Reincke, M; Winkelmann, W, 1989
)
0.87
"Treatment with suramin, concomitantly or 1 day before, enhanced markedly the bacterial growth in spleen and liver, detected as early as 3 to 6 h after the challenge, the maximum being observed at 48 h in the liver."( Effects of suramin on the in vivo antimicrobial resistance against Listeria monocytogenes and Mycobacterium bovis (BCG) in mice.
Brandely, M; Hurtrel, B; Lagrange, PH, 1986
)
1

Toxicity

Suramin reduced HepG2 cells survival and showed cell cytotoxicity in a dose-dependent manner with LD50 45. These findings in humans correlate with the authors' in vitro observations that suramin causes toxic mitochondrial changes.

ExcerptReferenceRelevance
" One of the main problems encountered during clinical trials was an adverse neurotoxic effect, probably due to a direct cytotoxic effect on neural cells."( Double screening of suramin derivatives on human colon cancer cells and on neural cells provides new therapeutic agents with reduced toxicity.
Baghdiguian, S; Fantini, J; Nickel, P, 1991
)
0.6
" These findings in humans correlate with the authors' in vitro observations that suramin causes toxic mitochondrial changes, indicating a mechanism of suramin's toxicity and possibly its antitumor effect."( Suramin-induced weakness from hypophosphatemia and mitochondrial myopathy. Association of suramin with mitochondrial toxicity in humans.
Miles, JM; Rago, RP; Spriggs, DR; Sufit, RL; Wilding, G, 1994
)
1.96
"Peripheral neurotoxicity is a crucial side effect of chemotherapeutic agents."( [Peripheral nervous system neurotoxicity secondary to chemotherapy treatment] .
Iñiguez, C; Larrodé, P; Mauri, JA; Mayordomo, JI; Morales, F; Trés, A, 2000
)
0.31
" Suramin reduced HepG2 cells survival and showed cell cytotoxicity in a dose-dependent manner with LD50 45."( Cytotoxic effects of suramin against HepG2 cells through activation of intrinsic apoptotic pathway.
Al-Gayyar, MM; Ebrahim, MA; El-Gayar, AM; Ibrahim, AS; Tayel, A,
)
1.36
" Safety was assessed by clinical examinations and adverse events."( Phase I, Single-Dose Study to Assess the Pharmacokinetics and Safety of Suramin in Healthy Chinese Volunteers.
Gu, L; Hong, N; Kai, J; Lv, D; Shentu, J; Wu, G; Wu, L; Xu, N; Yu, S; Zheng, R; Zhou, H, 2023
)
1.14

Pharmacokinetics

Suramin was administered to 49 patients in a Phase I cancer trial with real-time pharmacokinetic monitoring. After the last dose, the plasma half-life of suramin was 44 to 54 days.

ExcerptReferenceRelevance
" Pharmacokinetic parameters were determined by the ADAPT II MAP-Bayesian parameter estimation program."( Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression.
Albino, AP; Bajorin, DF; Iversen, J; Louison, C; Motzer, RJ; Nanus, DM; O'Moore, P; Reuter, V; Scher, HI; Tong, WP, 1992
)
0.62
" After the last dose, the plasma half-life of suramin was 44 to 54 days."( Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection.
Broder, S; Collins, JM; Fauci, AS; Klecker, RW; Lane, HC; Myers, CE; Redfield, RR; Yarchoan, R, 1986
)
0.82
" In all cases, considerable effort has gone into detailed pharmacokinetic studies conducted before and during the clinical phase I studies."( Pharmacokinetics and early clinical studies of selected new drugs.
Cassidy, J; Graham, MA; Jodrell, D; Kaye, SB; Workman, P, 1993
)
0.29
"This study aimed to (1) develop a population pharmacokinetic model for suramin; (2) use Bayesian methods to assess suramin pharmacokinetics in individual patients; (3) use individual patients' pharmacokinetic parameter estimates to individualize suramin dose and schedule and maintain plasma suramin concentrations within predetermined target ranges; and (4) assess the feasibility of outpatient administration of suramin by intermittent, short infusions."( Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
Egorin, MJ; Eisenberger, MA; Jodrell, DI; Novak, MJ; Reyno, LM; Sinibaldi, VJ; Sridhara, R; Tkaczuk, KH; Zuhowski, EG, 1994
)
1.96
"Plasma suramin concentrations were measured by high-performance liquid chromatography (HPLC), and compartmental pharmacokinetic models were fit using a Bayesian algorithm."( Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
Egorin, MJ; Eisenberger, MA; Jodrell, DI; Novak, MJ; Reyno, LM; Sinibaldi, VJ; Sridhara, R; Tkaczuk, KH; Zuhowski, EG, 1994
)
2.19
" Population pharmacokinetic estimates generated for two- and three-compartment pharmacokinetic models demonstrated modest interpatient pharmacokinetic variability and the long terminal half-life of suramin."( Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
Egorin, MJ; Eisenberger, MA; Jodrell, DI; Novak, MJ; Reyno, LM; Sinibaldi, VJ; Sridhara, R; Tkaczuk, KH; Zuhowski, EG, 1994
)
1.92
" Population pharmacokinetic parameters generated in men with hormone-refractory prostate cancer will facilitate rational design of such schedules."( Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
Egorin, MJ; Eisenberger, MA; Jodrell, DI; Novak, MJ; Reyno, LM; Sinibaldi, VJ; Sridhara, R; Tkaczuk, KH; Zuhowski, EG, 1994
)
1.73
"Retrospective population pharmacokinetic analysis."( Pharmacometric analysis of the effect of furosemide on suramin pharmacokinetics.
Figg, WD; Forrest, A; Lush, RM; Piscitelli, SC; Ryan, N; Whitfield, LR,
)
0.38
"Optimum suramin regimens were achieved by adaptive feedback control, and pharmacokinetic data were collected both in the presence and absence of furosemide."( Pharmacometric analysis of the effect of furosemide on suramin pharmacokinetics.
Figg, WD; Forrest, A; Lush, RM; Piscitelli, SC; Ryan, N; Whitfield, LR,
)
0.81
"Suramin was administered to 49 patients in a Phase I cancer trial with real-time pharmacokinetic monitoring and dose individualization to achieve targeted mean plasma concentrations of 210 and 155 mg/liter during the 7-day period between days 15 and 22."( Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin.
Alberti, D; Arzoomanian, R; Cheng, AL; Church, D; Hutson, PR; Kehrli, N; Marnocha, R; Pomplun, M; Rago, R; Tutsch, KD; Wilding, G, 1998
)
1.97
"2 ml x h(-1), median terminal elimination half-life 91."( Clinical pharmacokinetics of suramin in patients with onchocerciasis.
Chijioke, CP; Fleckenstein, LL; Mbah, AU; Nwonu, P; Okonkwo, PO; Umeh, RE, 1998
)
0.59
" Regular pharmacokinetic sampling of plasma and ascites fluid was carried out."( Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy.
Baars, JP; Beijnen, JH; Dubbelman, R; Moolenaar, WH; Rodenhuis, S; Westermann, AM, 2000
)
0.56
" infusion in patients with ascites confers the largest pharmacokinetic advantage."( Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy.
Baars, JP; Beijnen, JH; Dubbelman, R; Moolenaar, WH; Rodenhuis, S; Westermann, AM, 2000
)
0.56
" The pharmacokinetic parameters derived for the 300 mg/kg oral and 50 microCi/kg intravenous doses were used to calculate the bioavailability and AUC at the three oral dose levels."( Suramin as a chemosensitizer: oral pharmacokinetics in rats.
Au, JL; Ogden, A; Wientjes, MG, 2004
)
1.77
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
", undetectable at low dose or a peak concentration that was 6,000× lower than urine concentrations), and (c) disproportionally higher drug penetration and concentrations in bladder tissues at the higher dose."( Bladder tissue pharmacokinetics of intravesical mitomycin C and suramin in dogs.
Au, JL; Hu, L; Li, J; Wientjes, MG, 2010
)
0.6
" Blood and urine samples were collected at the designated time points for pharmacokinetic analysis."( Phase I, Single-Dose Study to Assess the Pharmacokinetics and Safety of Suramin in Healthy Chinese Volunteers.
Gu, L; Hong, N; Kai, J; Lv, D; Shentu, J; Wu, G; Wu, L; Xu, N; Yu, S; Zheng, R; Zhou, H, 2023
)
1.14

Compound-Compound Interactions

Non-cytotoxic doses of suramin in combination with weekly paclitaxel were well tolerated. MRPCs can attenuate renal damage and promote renal recovery after ischemia/reperfusion injury.

ExcerptReferenceRelevance
" Suramin alone inhibited the cell proliferation of only 19% of the prostate organ culture under study, while in combination with DHT and/or PDGF this inhibition level reached 48%."( Influence of suramin alone or in combination with DHT and PDGF on the cell proliferation of benign and malignant human prostatic tissues in organ cultures.
Etievant, C; Gras, S; Kiss, R; Michel, P; Pasteels, JL; Petein, M; Van Velthoven, R,
)
1.41
" Both inhibitors cured the TREU 667 and LUMP 1001 isolates if used in combination with a single (20 mg/kg) injection of suramin, a trypanocide in current clinical use."( Effects of the ornithine decarboxylase inhibitors DL-alpha-difluoromethylornithine and alpha-monofluoromethyldehydroornithine methyl ester alone and in combination with suramin against Trypanosoma brucei brucei central nervous system models.
Bacchi, CJ; Bienen, EJ; Bitonti, AJ; Clarkson, AB; McCann, PP; Nathan, HC; Sjoerdsma, A, 1987
)
0.68
" This trial was undertaken to investigate the value of mitomycin C given with low dose suramin."( Suramin in combination with mitomycin C in hormone-resistant prostate cancer. A phase II clinical study.
de Wet, M; Falkson, G; Lotz, BP; Potgieter, HC; Raats, JI; Rapoport, BL, 1993
)
1.95
" Susceptibility patterns of sensitive and resistant parasites were evaluated against calcium antagonists of several chemical classes (verapamil, cyproheptidine, desipramine and chlopromazine), alone and in combination with suramin, diminazene aceturate or melarsen oxide cyteamine."( Trypanocidal resistance in Trypanosoma evansi in vitro: effects of verapamil, cyproheptidine, desipramine and chlorpromazine alone and in combination with trypanocides.
Anene, BM; Anika, SM; Chukwu, CC; Ross, CA, 1996
)
0.48
"In this study, we determined the maximum tolerated plasma concentration of suramin (within the predetermined study target range) when combined with doxorubicin in the treatment of androgen-independent prostate cancer."( Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer.
Amato, RJ; Banks, ME; Bugazia, NA; Logothetis, CJ; Madden, T; Millikan, RE; Newman, RA; Pagliaro, LC; Tu, SM, 1998
)
0.87
" Additionally, we compared the antitumoral effect of protamine with that of another inhibitor of angiogenesis, suramin, and investigated a potential synergistic antitumoral action of low doses of protamine combined with the antineoplastic carmustine."( Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine.
Arrieta, O; Guevara, P; Ortiz, A; Rembao, D; Reyes, S; Sotelo, J, 1998
)
0.51
" The authors conducted this Phase II study to determine the feasibility, toxicity, and antitumor activity of suramin in combination with epirubicin."( Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma.
Allegrini, G; Antonuzzo, A; Conte, P; Danesi, R; Del Tacca, M; Falcone, A; Masi, G; Monica, L; Pfanner, E; Ricci, S, 1999
)
1.96
" This study was to explore the inhibitory effect of angiogenesis inhibitor Suramin in combination with cisplatin (DDP) on the growth and lung metastasis of lung adenocarcinoma LA795 cell xenografts in mice."( [Effects of suramin in combination with cisplatin on growth and metastasis of lung adenocarcinoma xenografts in mice].
He, JB; Ou, LW; Wang, XH; Zhang, P, 2006
)
0.94
" We hypothesized that suramin at non-cytotoxic doses in combination with weekly paclitaxel would be well tolerated and demonstrate anti-tumor activity."( Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes.
Au, JL; Berger, M; Brenner, L; Chen, L; Grever, M; Jensen, RR; Lustberg, MB; Mrozek, E; Pant, S; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shen, T; Shiels, D; Wei, Y; Wientjes, MG, 2012
)
0.97
" The primary objective of the phase I was to determine the dose of intravenous (IV) weekly suramin that resulted in plasma concentrations between 10 and 50 umol/l over 8-48 h (or the target range) in combination with IV 80 mg/m(2) of weekly paclitaxel."( Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes.
Au, JL; Berger, M; Brenner, L; Chen, L; Grever, M; Jensen, RR; Lustberg, MB; Mrozek, E; Pant, S; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shen, T; Shiels, D; Wei, Y; Wientjes, MG, 2012
)
0.88
"Non-cytotoxic doses of suramin in combination with weekly paclitaxel were well tolerated."( Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes.
Au, JL; Berger, M; Brenner, L; Chen, L; Grever, M; Jensen, RR; Lustberg, MB; Mrozek, E; Pant, S; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shen, T; Shiels, D; Wei, Y; Wientjes, MG, 2012
)
0.97
" Their results revealed that MRPCs in combination with EPO or suramin are able to attenuate renal damage and promote renal recovery after ischemia/reperfusion injury in a mouse model."( Mouse adult renal progenitor cells in combination with erythropoietin or suramin--a potential new strategy for the treatment of acute kidney injury.
Wang, PR, 2013
)
0.86

Bioavailability

Suramin's large molecular size and negative charge should make it poorly absorbed through the bladder mucosa, a desired characteristic for an intravesical chemotherapeutic agent. Low bioavailability limits the usefulness of oral administration.

ExcerptReferenceRelevance
" We conclude that the bioavailability of VEGF may be regulated at the genetic level by alternative splicing that determines whether VEGF will be soluble or incorporated into a biological reservoir and also through proteolysis following plasminogen activation."( Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms.
Ferrara, N; Houck, KA; Leung, DW; Rowland, AM; Winer, J, 1992
)
0.28
" It therefore appears that drug bioavailability is altered or drug biotransformation occurs during the in vivo test."( In vivo and in vitro sensitivity of Trypanosoma evansi and T. equiperdum to diminazene, suramin, MelCy, quinapyramine and isometamidium.
Baltz, T; Giroud, C; Zhang, ZQ, 1991
)
0.5
" Suramin's large molecular size and negative charge should make it poorly absorbed through the bladder mucosa, a desired characteristic for an intravesical chemotherapeutic agent."( Suramin inhibits proliferation and DNA synthesis in transitional carcinoma cell lines.
Cooper, M; Linehan, WM; Trahan, EE; Venzon, D; Walther, MM, 1994
)
2.64
" The pharmacokinetic parameters derived for the 300 mg/kg oral and 50 microCi/kg intravenous doses were used to calculate the bioavailability and AUC at the three oral dose levels."( Suramin as a chemosensitizer: oral pharmacokinetics in rats.
Au, JL; Ogden, A; Wientjes, MG, 2004
)
1.77
"While plasma concentrations resulting from the 300 and 500 mg/kg oral doses of suramin were in the concentration range required to produce chemosensitization, the low bioavailability limits the usefulness of oral administration."( Suramin as a chemosensitizer: oral pharmacokinetics in rats.
Au, JL; Ogden, A; Wientjes, MG, 2004
)
1.99
" This report using fluorescein isothiocyanate dextran 4000 (FD-4) as the model compound is the first to investigate the effects of purine nucleotides on absorption of poorly absorbed drugs from intestine."( Activation of P2Y receptor enhances high-molecular compound absorption from rat ileum.
Kinoshita, N; Mizuno, N; Shinozuka, K; Tada, S; Takahashi, K; Takahashi, T, 2006
)
0.33
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

A higher dosage of suramin had a cytotoxic effect on PC-3M cells, while lower dosages from 10 to 100 mumol/L produced a predominant inhibiting effect. Suradista was also shown to be as effective as suramin at inhibiting the growth of sp-hst/KS3:FGF1-154-transformed NIH/3T3 xenografts grown in athymic nude mice.

ExcerptRelevanceReference
"Twenty-six patients with advanced renal cell carcinoma were treated with suramin administered by continuous infusion, with dosing determined by a nomogram."( Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression.
Albino, AP; Bajorin, DF; Iversen, J; Louison, C; Motzer, RJ; Nanus, DM; O'Moore, P; Reuter, V; Scher, HI; Tong, WP, 1992
)
0.85
" Subsequently, computer-assisted dosing that used Bayesian pharmacokinetic modeling was used."( Suramin: rapid loading and weekly maintenance regimens for cancer patients.
Heimans, JJ; Lopez, R; Meijer, E; Pinedo, HM; van Groeningen, CJ; van Loenen, AC; van Rijswijk, RE; Wagstaff, J, 1992
)
1.73
" Bayesian modeling based on individual serum levels and population pharmacokinetics allows accurate dosing to maintain suramin levels within the therapeutic window."( Suramin: rapid loading and weekly maintenance regimens for cancer patients.
Heimans, JJ; Lopez, R; Meijer, E; Pinedo, HM; van Groeningen, CJ; van Loenen, AC; van Rijswijk, RE; Wagstaff, J, 1992
)
1.93
" The dose-response curve for the stimulation by ATP gamma S of phospholipase C was shifted to the right by the presence of UTP, indicating that both compounds act on the same receptors."( Neuronal "nucleotide" receptor linked to phospholipase C and phospholipase D? Stimulation of PC12 cells by ATP analogues and UTP.
Boarder, MR; Murrin, RJ, 1992
)
0.28
" The activity of each drug was expressed as: 1) in vitro: the minimal effective concentration which killed trypanosome population by 100% within 24 h of drug exposure (MEC100); the maximum tolerated concentration in which trypanosomes could propagate at the same rate as the controls during 48 h of drug exposure (MTC100); 2) in vivo: the curative dosage in 100% of infected mice (CD100); the highest ineffective dosage: 100% of infected mice remain infected (ID100)."( In vivo and in vitro sensitivity of Trypanosoma evansi and T. equiperdum to diminazene, suramin, MelCy, quinapyramine and isometamidium.
Baltz, T; Giroud, C; Zhang, ZQ, 1991
)
0.5
" In the present investigation we studied the pH dependency and dose-response effects of suramin on islet lysosomal enzyme activities as well as the effect of suramin treatment on the insulin-secretory response to various secretagogues in mice."( Effect of the lysosomotropic drug suramin on islet lysosomal enzyme activities and the insulin-secretory response induced by various secretagogues.
Lundquist, I; Panagiotidis, G; Salehi, AA, 1991
)
0.78
" On the basis of the current results, suramin does not appear to be an active single agent against metastatic renal cell carcinoma when administered by this dosing schedule."( A pilot study of suramin in the treatment of metastatic renal cell carcinoma.
Cooper, MR; Danesi, R; La Rocca, RV; Myers, CE; Stein, CA; Uhrich, M, 1991
)
0.89
" The same dosing regimen found to be ineffective in blocking the restoration of the involuted prostate of castrated rats resulted in a significant reduction in the growth rate of AT-2 tumors."( Differential effects of growth factor antagonists on neoplastic and normal prostatic cells.
Isaacs, JT; Isaacs, WB; Morton, RA, 1990
)
0.28
"The dose-response curve for the vasopressor effect of alpha, beta-methylene ATP in pithed rats was influenced by four suramin-related drugs (each at 100 mumol/kg)."( Antagonistic properties of four suramin-related compounds at vascular purine P2X receptors in the pithed rat.
Nickel, P; Schlicker, E; Urbanek, E, 1990
)
0.77
" Three classes of dose-response curves could be discriminated."( Inhibition of human immunodeficiency virus type I reverse transcriptase by suramin-related compounds.
Hartmann, H; Hunsmann, G; Jentsch, KD; Nickel, P, 1987
)
0.5
" A (donor) mouse, infected for 28 days, is dosed with a drug, or combination of drugs, and samples of blood, cerebral cortex, choroid plexus and lining of ventricle are injected into clean (recipient) mice."( Screening compounds for sleeping sickness therapy without relapse.
Ormerod, WE; Raseroka, BH, 1988
)
0.27
" Two other goats appeared to be cured with this dosage of suramin but later developed abnormal central nervous system (CNS) signs and parasitaemia."( Experimental infection of goats with Trypanosoma brucei ssp. and effects of treatment with suramin and Mel-B.
Chumo, DA; Muriithi, RM; Mwangi, J; Reardon, MJ; Towett, S; Wellde, BT, 1989
)
0.74
" Increased dosage arrested further growth, but achieved no regression of the metastases."( [Treatment of metastatic adrenal carcinoma with suramin].
Allolio, B; Arlt, W; Jaursch-Hancke, C; Metzler, U; Reincke, M; Winkelmann, W, 1989
)
0.53
" The results from these initial clinical pharmacokinetic studies might assist the design of further therapeutic trials of suramin, especially the selection of frequency of dosing and adjustments for renal impairment."( Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection.
Broder, S; Collins, JM; Fauci, AS; Klecker, RW; Lane, HC; Myers, CE; Redfield, RR; Yarchoan, R, 1986
)
0.77
" Inhibition of DNA polymerase activity associated with core particles from infected liver and circulating virions is irreversible, occurs in a dose-response fashion and suggests that inhibition results from suramin-virus interaction."( Suramin inhibits duck hepatitis B virus DNA polymerase activity.
Tsiquaye, K; Zuckerman, A, 1985
)
1.9
" It is therefore important to determine the suramin dosage schedules that will produce parasitological cures with minimal concomitant risks of toxic reactions."( The effects of drugs on Onchocerca volvulus. 3. Trials of suramin at different dosages and a comparison of the brands Antrypol, Moranyl and Naganol.
Duke, BO, 1968
)
0.75
"Previous work on monkeys and on human volunteers led to the development of a schedule of diethylcarbamazine dosage suitable for the chemoprophylaxis of loiasis."( Experiments on the chemoprophylaxis of Onchocerca volvulus infection.
Duke, BO, 1968
)
0.25
" At the time of disease progression, suramin was administered on a pharmacokinetically derived, 2-week dosing schedule."( Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.
Curley, T; Dnistrian, A; Kelly, WK; Leibretz, C; Scher, HI; Schwartz, M, 1995
)
0.82
"This phase I study was designed with the following objectives: (1) to describe the overall and dose-limiting toxicity (DLT) of suramin administered by intermittent short intravenous infusions until DLT or disease progression; (2) to determine the ability of an adaptive control with feedback (ACF) dosing strategy to maintain suramin plasma concentrations within a preselected range; (3) to develop a population model of suramin pharmacokinetics; and (4) to identify preliminary evidence of antitumor activity."( Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.
Eisenberger, MA; Hemady, RK; Jacobs, SC; Jodrell, DI; Lowitt, MH; Reyno, LM; Sinibaldi, VJ; Sridhara, R; Tkaczuk, KH; Zuhowski, EG, 1995
)
0.73
"We used population pharmacokinetic-parameter estimates and designed a fixed dosing schedule to maintain plasma suramin concentrations between 100 and 300 micrograms/mL and then evaluated its performance."( Development and validation of a pharmacokinetically based fixed dosing scheme for suramin.
Egorin, MJ; Eisenberger, MA; Reyno, LM; Sinibaldi, VJ; Sridhara, R; Zuhowski, EG, 1995
)
0.73
" Patients were to be removed from the fixed dosing schedule if, after day 5, three consecutive peak plasma suramin concentrations were greater than 300 micrograms/mL."( Development and validation of a pharmacokinetically based fixed dosing scheme for suramin.
Egorin, MJ; Eisenberger, MA; Reyno, LM; Sinibaldi, VJ; Sridhara, R; Zuhowski, EG, 1995
)
0.73
" The fixed dosing schedule was precise, unbiased, and well tolerated."( Development and validation of a pharmacokinetically based fixed dosing scheme for suramin.
Egorin, MJ; Eisenberger, MA; Reyno, LM; Sinibaldi, VJ; Sridhara, R; Zuhowski, EG, 1995
)
0.52
" To test the adaptive-control hypothesis, we designed a phase I study that relied on clinical end points, using a fixed dosing scheme that did not rely on adaptive control."( Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
Janish, L; Kobayashi, K; Ratain, MJ; Soliven, B; Vogelzang, NJ; Vokes, EE, 1995
)
0.63
"In a phase I dose-escalation study using fixed dosing without adaptive control, gradually decreasing doses of suramin were administered to 63 patients on days 1 (loading dose), 2, 8, and 9 of a 28-day cycle."( Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
Janish, L; Kobayashi, K; Ratain, MJ; Soliven, B; Vogelzang, NJ; Vokes, EE, 1995
)
0.84
" Further studies to establish the optimal empiric dosing regimen are needed."( Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
Janish, L; Kobayashi, K; Ratain, MJ; Soliven, B; Vogelzang, NJ; Vokes, EE, 1995
)
0.63
"Three cohorts of patients with advanced prostate cancer that progressed despite castrate levels of testosterone received oral hydrocortisone plus suramin administered in the following manners: (1) a loading dose of suramin followed by a continuous infusion using an adaptive control program (cohort A); (2) an intermittent schedule using a simplified adaptive control schedule (cohort B); and (3) an empiric dosing regimen (cohort C)."( Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.
Cohen, L; Curley, T; Dnistrian, A; Kelly, WK; Leibertz, C; Mazumdar, M; Pfister, D; Scher, HI; Schwartz, M; Vlamis, V, 1995
)
1.93
" In this cohort of patients with advanced prostate cancer, the clinical activity of suramin using these dosing schedules was limited."( Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.
Cohen, L; Curley, T; Dnistrian, A; Kelly, WK; Leibertz, C; Mazumdar, M; Pfister, D; Scher, HI; Schwartz, M; Vlamis, V, 1995
)
1.96
"Significant neurologic toxicity can result from therapy with suramin, even when dosing is designed to avoid exposure to plasma concentrations greater than 350 micrograms/mL."( Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin.
Bitton, RJ; Bowden, C; Cooper, MR; Dalakas, MC; Figg, WD; Headlee, D; Myers, CE; Reed, E; Venzon, DJ, 1995
)
0.75
"Suramin was administered as a 6-day continuous infusion every week for 8 consecutive weeks by using a computer-assisted dosing of Bayesan pharmacokinetics to maintain suramin plasma concentrations of 200-250 micrograms/ml."( Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study.
Brunetti, I; Cianci, C; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Pfanner, E, 1995
)
3.18
" The dose-response interactions were evaluated using the median-effect analysis with the Chou and Talalay computer programme."( The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin.
Lopez Lopez, R; Peters, GJ; Pinedo, HM; van Rijswijk, RE; Wagstaff, J, 1994
)
0.5
"We conclude that suramin can be safely and conveniently administered to outpatients by intermittent infusion without using complex adaptive dosing strategies."( Suramin for breast and prostate cancer: a pilot study of intermittent short infusions without adaptive control.
George, N; Howell, A; Margison, J; Ranson, M; Thomson, Y; van der Water, L; Woll, PJ, 1994
)
2.07
" A dose-response experiment in the B16F10 melanoma model showed that inhibition of lung colony formation was still significant with 50 mg/kg pretreatment, whereas a borderline effect was observed at 10 mg/kg."( Inhibition of lung and liver tumor colonies in mice pretreated with suramin.
Farao, M; Grandi, M; Mariani, M; Marsiglio, A; Sola, F, 1993
)
0.52
" Weekly dosing was adjusted to achieve mean plasma concentrations of 210 micrograms/ml."( Suramin-induced weakness from hypophosphatemia and mitochondrial myopathy. Association of suramin with mitochondrial toxicity in humans.
Miles, JM; Rago, RP; Spriggs, DR; Sufit, RL; Wilding, G, 1994
)
1.73
" Dosing was determined by a nomogram based on weekly serum concentrations."( Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial.
Bajorin, DF; Bost, GJ; Dmitrovsky, E; Miller, WH; Motzer, RJ; Scher, HI; Tong, WP, 1993
)
1.73
" Although the dosing of suramin by the nomogram was not associated with neurotoxicity, the time needed to achieve therapeutic levels was lengthy, and the levels, once achieved, were of short duration."( Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial.
Bajorin, DF; Bost, GJ; Dmitrovsky, E; Miller, WH; Motzer, RJ; Scher, HI; Tong, WP, 1993
)
2.04
" Adaptive-control-with-feedback dosing facilitated precise control of plasma suramin concentrations and allowed a number of different concentration ranges to be studied."( Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
Egorin, MJ; Eisenberger, MA; Jodrell, DI; Novak, MJ; Reyno, LM; Sinibaldi, VJ; Sridhara, R; Tkaczuk, KH; Zuhowski, EG, 1994
)
1.96
" Furthermore, NPY was without effect on the dose-response curve to ATP in resting conditions."( Failure of the putative neuropeptide Y antagonists, benextramine and PYX-2, to inhibit Y2 receptors in rat isolated prostatic vas deferens.
Corsi, M; Palea, S; Ratti, E; Rimland, JM; Trist, DG, 1995
)
0.29
"Using this dosing schedule, suramin has limited activity against hormone-refractory metastatic prostate cancer."( Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy.
Belldegrun, A; deKernion, J; Graves, MC; Landaw, EM; McBride, JH; Mendoza, EF; Mondino, B; Rosen, PJ; Turcillo, P, 1996
)
2.03
" Suramin was given as intermittent infusions at fixed doses on days 1-5 and thereafter dosing was guided by adaptive control with feedback to maintain plasma suramin concentrations between 300-175 micrograms/ml."( Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables.
Bergan, RC; Cooper, MR; Dawson, NA; Figg, WD; Headlee, DJ; Myers, CE; Sartor, O; Sausville, EA; Steinberg, SM; Thibault, A, 1995
)
1.52
" Dose-response curves on the production of inositol-1,4,5-trisphosphate and Ca2+ by ATP and UTP were consistently similar."( Expression cloning and signal transduction pathway of P2U receptor in mammary tumor cells.
Enomoto, K; Furuya, K; Maeno, T; Moore, RC; Oka, T; Yamagishi, S,
)
0.13
" Suramin (3 x 10(-5) M) caused a rightward shift of the dose-response curves for constriction caused by alpha, beta-methylene ATP (27-fold) and 2-methylthio ATP (5-fold), whereas the ATP curve was shifted to the left (20-fold)."( Characterization of vascular P2 purinoceptors in the rat isolated perfused kidney.
Eltze, M; Ullrich, B, 1996
)
1.2
" We conclude that: (1) serial electrophysiologic monitoring is helpful for early detection of suramin-induced neuropathy; and (2) fixed dosing schedule of suramin without adaptive control does not lead to an increased incidence of demyelinating neuropathy when compared to adaptively controlled dosing schedules."( Evaluation of neuropathy in patients on suramin treatment.
Arora, R; Dhand, UK; Janisch, L; Kobayashi, K; Martin, B; Petersen, MV; Ratain, MJ; Soliven, B; Vogelzang, NJ; Vokes, EE, 1997
)
0.78
"Patients with stage D2 and poor-prognosis stage D1 prostate cancer were given suramin on a pharmacokinetically derived dosing schedule to maintain suramin concentrations between 175 and 300 micrograms/mL."( Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer.
Bergan, RC; Cooper, MR; Dawson, NA; Figg, WD; Myers, CE; Reed, E; Sartor, O; Sausville, EA; Senderowicz, AM; Steinberg, SM; Tompkins, A; Weinberger, B, 1997
)
0.86
"Ten patients with hormone-refractory prostate cancer received a fixed dosing scheme of suramin infusion in combination with weekly epidoxorubicin at 25 mg/m2."( Suramin/epidoxorubicin association in hormone-refractory prostate cancer: preliminary results of a pilot phase II study.
Boccardo, F; Canobbio, L; Esposito, M; Granetto, C; Miglietta, L; Vannozzi, MO, 1997
)
1.96
" Furthermore, Suradista was also shown to be as effective as suramin at inhibiting the growth of sp-hst/KS3:FGF1-154-transformed NIH/3T3 xenografts grown in athymic nude mice when given at only 50% the dosage used for suramin (50 mg/kg for Suradista versus 100 mg/kg for suramin)."( Inhibition of growth factor mitogenicity and growth of tumor cell xenografts by a sulfonated distamycin A derivative.
Calabresi, P; Chen, TM; Chu, MY; Epstein, MH; Finch, PW; Friedman, S; Lipsky, MH; Maciag, T; Yee, LK, 1997
)
0.54
" At this juncture, additional phase I and II trials are required to evaluate the toxicity and efficacy of topotecan in combination with other agents and address critical issues related to optimal drug dosing and sequencing."( Topotecan in combination chemotherapy.
Kaufmann, SH; Rowinsky, EK, 1997
)
0.3
" Future studies on suramin combined with doxorubicin or other agents could be performed using a fixed dosing scheme with a targeted suramin steady-state plasma concentration of 200 microg/ml."( Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer.
Amato, RJ; Banks, ME; Bugazia, NA; Logothetis, CJ; Madden, T; Millikan, RE; Newman, RA; Pagliaro, LC; Tu, SM, 1998
)
0.97
" A 200-mg test dose was not effective in prospectively determining individual pharmacokinetic parameters and dosage requirements."( Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin.
Alberti, D; Arzoomanian, R; Cheng, AL; Church, D; Hutson, PR; Kehrli, N; Marnocha, R; Pomplun, M; Rago, R; Tutsch, KD; Wilding, G, 1998
)
0.53
" Suramin was administered for eight weeks at doses determined by means of a computer-assisted dosing algorithm that used Bayesian pharmacokinetics to maintain suramin plasma concentrations of 200-250 microg/ml."( Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+LV-based chemotherapy.
Allegrini, G; Antonuzzo, A; Brunetti, I; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Galli, C; Lencioni, M; Masi, G; Pfanner, E,
)
2.48
" Dose-response analysis yielded an EC50 of 14."( Ca2+-permeable P2X receptor channels in cultured rat retinal ganglion cells.
Grantyn, R; Jüttner, R; Taschenberger, H, 1999
)
0.3
" Doses were determined by a computer-assisted dosing system that used Bayesian pharmacokinetics to maintain suramin plasma concentrations of 200-250 microg/mL."( Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma.
Allegrini, G; Antonuzzo, A; Conte, P; Danesi, R; Del Tacca, M; Falcone, A; Masi, G; Monica, L; Pfanner, E; Ricci, S, 1999
)
1.96
" The efficacy of combination therapy as a function of alternative dosing regimens was determined by tumor growth inhibition (TGI) studies."( Combining suramin and a chimeric toxin directed to basic fibroblast growth factor receptors increases therapeutic efficacy against human melanoma in an animal model.
Davol, PA; Frackelton, AR; Garza, S, 1999
)
0.71
" The fixed dosage schedule was well tolerated with minimal to moderate toxicity."( Phase II trial of suramin in patients with metastatic renal cell carcinoma.
Dreicer, R; See, WA; Smith, DC; Williams, RD, 1999
)
0.64
" Suramin was administered on a 78-day fixed dosing schedule (one cycle), and suramin treatment cycles were repeated every 6 months for a total of four cycles."( Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study.
Crawford, ED; Eisenberger, MA; Fisher, EI; Hussain, M; O'Connor, J; Petrylak, DP; Small, EJ; Wood, DP, 2000
)
1.46
"5 mmol/L, which is approximately twice the dosage used for systemic application, was sufficient for complete neutralization of proliferation stimulation by 10% HWBS added to the cell culture medium."( Suramin inhibits proliferation of human arterial smooth muscle cells in vitro: potential drug for prevention of restenosis by local drug delivery.
Bienert, H; Engisch, R; Günther, RW; Schürmann, K; vom Dahl, J; Vorwerk, D; Voss, M, 2000
)
1.75
" Using an established fixed dosing scheme for the administration of suramin in patients, a pilot study was conducted in patients with progressive, metastatic breast cancer."( A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients.
Benson, AB; Bouck, N; Cisneros, A; French, S; Gradishar, WJ; Liu, J; Rademaker, A; Soff, G, 2000
)
0.88
" Increasing the external Ca(2+) concentration to 10 mM shifted the dose-response relationship to the right."( Excitatory effect of ATP on acutely dissociated ventromedial hypothalamic neurons of the rat.
Akaike, N; Ishibashi, H; Moritoyo, T; Sorimachi, M, 2001
)
0.31
" Neurotoxicity has been the most significant complication and appears to be related to the intensity of the dosing regimen."( Suramin's development: what did we learn?
Dahut, W; Figg, WD; Kaur, M; Reed, E; Sartor, O, 2002
)
1.76
" The purpose of this study was to determine the maximum tolerated dose and toxicities of suramin when administered using a fixed dosing scheme on a once- or twice-monthly schedule."( A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer.
Janisch, L; Kobayashi, K; Ratain, MJ; Ryan, CW; Vogelzang, NJ; Vokes, EE, 2002
)
0.86
" There was a dose-response relationship between dose and toxicity."( Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
Halabi, S; Hars, V; Marshall, E; Palchak, D; Petrylak, D; Rago, R; Ratain, MJ; Rosner, G; Small, EJ; Stadler, W; Vogelzang, NJ; Wilding, G, 2002
)
0.57
" Overall, no dose-response relationship was observed for survival or progression-free survival, but toxicity was increased with the higher dose."( Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
Halabi, S; Hars, V; Marshall, E; Palchak, D; Petrylak, D; Rago, R; Ratain, MJ; Rosner, G; Small, EJ; Stadler, W; Vogelzang, NJ; Wilding, G, 2002
)
0.57
"A higher dosage of suramin (200 mumol/L) had a cytotoxic effect on PC-3M cells, while lower dosages from 10 to 100 mumol/L produced a predominant inhibiting effect."( [Influence of suramin on the proliferation of prostatic carcinoma cells PC-3M].
Feng, W; Lu, GC; Xiao, YJ; Xing, YF; Zeng, FQ; Zhang, QJ, 2003
)
1.01
" In vivo experiments in mice with selected isolates showed that the isolate most resistant to suramin was not cured at a dosage of 10 mg/kg, while the isolate that was most resistant to antrycide showed only 50% cure rate at a dose rate of 5 mg/kg."( Resistance to drug by different isolates Trypanosoma evansi in China.
Liao, D; Lin, J; Shen, J; Zhou, J; Zhou, Y, 2004
)
0.54
" A dosing nomogram was developed by using population-based pharmacokinetic analysis of phase I results (15 patients, 85 treatment cycles), and evaluated in phase II patients (19 females, 28 males, 196 treatment cycles)."( Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development.
Au, JL; Chen, D; Grever, M; Jensen, R; Murgo, AJ; Otterson, GA; Song, SH; Villalona-Calero, M; Wientjes, MG; Yeh, TK; Zhao, L, 2006
)
0.75
" The dosing nomogram, incorporating body surface area as the major covariate of intersubject variability and the time elapsed since the previous dose (to account for the residual concentrations due to the slow elimination), delivered the target concentrations in >95% of treatments."( Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development.
Au, JL; Chen, D; Grever, M; Jensen, R; Murgo, AJ; Otterson, GA; Song, SH; Villalona-Calero, M; Wientjes, MG; Yeh, TK; Zhao, L, 2006
)
0.75
"The present study identified and validated a dosing nomogram and schedule to deliver low and nontoxic suramin concentrations that produce chemosensitization in preclinical models."( Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development.
Au, JL; Chen, D; Grever, M; Jensen, R; Murgo, AJ; Otterson, GA; Song, SH; Villalona-Calero, M; Wientjes, MG; Yeh, TK; Zhao, L, 2006
)
0.97
" Our results suggest that the association between an antimuscarinic drug and an antagonist of P2X purinoceptors such as suramin might be helpful to reduce the therapeutic dosage of the antimuscarinic drug, along with its side effects."( Altered neurogenic and mechanical responses to acetylcholine, ATP and substance P in detrusor from rat with outlet obstruction.
Pinna, C; Puglisi, L; Sanvito, P, 2006
)
0.54
" Dose-response curves for fchi increases evoked by intra-stream boluses of acetylcholine, nicotine and ATP were studied."( Effects of combined cholinergic-purinergic block upon cat carotid body chemoreceptors in vitro.
Fernández, R; Larraín, C; Reyes, EP; Zapata, P, 2007
)
0.34
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
" All four bears were treated twice at 3-day intervals with suramin sodium by using almost twice the dosage recommended for common domestic animals (10 mg/kg)."( Trypanosoma evansi infections in Himalayan black bears (Selenarctos thibetanus).
Muhammad, G; Naureen, A; Sajid, MS; Saqib, M, 2007
)
0.58
"C6 rat glioma cells were treated with suramin at doses of 175 and 250 microM, and also with an increasing dosage for 96 hours."( The inhibitory effect of suramin on telomerase activity and spheroid growth of C6 glioma cells.
Akev, N; Bilir, A; Erguven, M; Karabulut, E; Ozdemir, A, 2008
)
0.92
"Suramin levels expected to reverse fibroblast growth factor-induced resistance can be achieved with the dosing regimen used in this study."( Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma.
Au, JJ; Bukowski, RM; Cooney, MM; Dreicer, R; Elson, P; Ganapathi, R; George, S; Mekhail, T; Rini, BI; Roman, S; Shen, T; Wientjes, GM, 2008
)
2.02
" At higher dosage (500 microM) AP height was reduced, conduction velocity slowed, and conduction failure occurred, especially during hypoxia, producing the appearance of a decreased response to hypoxia."( Nicotinic acetylcholine receptors do not mediate excitatory transmission in young rat carotid body.
Donnelly, DF, 2009
)
0.35
" Target plasma concentrations were correctly predicted by our previously described dosing nomogram."( Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.
Au, JL; Bekaii-Saab, T; Chen, L; Grever, M; Guillaume Wientjes, M; Jensen, RR; Lam, ET; Li, X; Murgo, AJ; Otterson, GA; Shen, T; Villalona-Calero, MA; Wei, Y, 2010
)
0.65
" A dose-response experiment showed an EC(50) of 11."( Functional ligand-gated purinergic receptors (P2X) in rat vestibular ganglion neurons.
Chihara, Y; Ito, K; Iwasaki, S; Komuta, Y; Sahara, Y; Sugasawa, M, 2010
)
0.36
" The dosing volume was 20 ml."( Bladder tissue pharmacokinetics of intravesical mitomycin C and suramin in dogs.
Au, JL; Hu, L; Li, J; Wientjes, MG, 2010
)
0.6
" The implementation of this assay to the screening of a highly diverse academic chemical library of 14,300 molecules yielded, after secondary assays and generation of dose-response curves, the identification of two natural product inhibitors, cyanidin and delphinidin."( Identification by high-throughput screening of inhibitors of Schistosoma mansoni NAD(+) catabolizing enzyme.
Haiech, J; Hibert, M; Kellenberger, E; Kuhn, I; Lobstein, A; Muller-Steffner, H; Rognan, D; Said-Hassane, F; Schuber, F; Villa, P, 2010
)
0.36
" NF449 produced a greater rightward shift of the dose-response inhibition curve for d-TC than did suramin."( Study of the reversal effect of NF449 on neuromuscular blockade induced by d-tubocurarine.
Chen, YH; Hsiao, G; Huang, SS; Hung, YS; Lin, MJ; Su, CC; Su, HH; Su, TR, 2011
)
0.59
"It has been reported that suramin treatment can improve muscle healing; however, details about optimizing the dosing requirements remain unclear."( Timing of the administration of suramin treatment after muscle injury.
Fu, FH; Gharaibeh, B; Huard, J; Li, Y; Nozaki, M; Ota, S; Terada, S; Uehara, K, 2012
)
0.96
" The dose-response relationship for an inhibitor is studied using images of endothelial cells captured in vitro by Matrigel assay."( Mesh-loosening quantification of inhibition of angiogenic tube formation through image analysis.
Gotoh, T; Minamikawa-Tachino, R; Ogura, K, 2013
)
0.39
" The dose-response of ATP revealed a hyperbolic profile with maximal velocity of 25."( Characterization of ecto-ATPase activity in the surface of LLC-PK1 cells and its modulation by ischemic conditions.
Caruso-Neves, C; Costa-Alves, MS; Meyer-Fernandes, JR; Pinheiro, AA; Ribeiro, MC; Wengert, M; Zancan, P, 2012
)
0.38
" Suramin did not alter the dose-response curve of cisplatin in lung adenocarcinoma cells in vitro."( Suramin protects from cisplatin-induced acute kidney injury.
Arteel, GE; Beverly, LJ; Casson, L; Doll, MA; Dupre, TV; Jenson, AB; Kiefer, A; Megyesi, J; Saforo, D; Saurabh, K; Scherzer, MT; Schnellmann, RG; Shah, PP; Sharp, CN; Siow, D; Siskind, LJ, 2016
)
2.79
" Three of the primary hits were verified by dose-response assay and confirmed as inhibitors by a secondary mass spectrometry assay for TPST activity."( A fluorescence-based high-throughput assay to identify inhibitors of tyrosylprotein sulfotransferase activity.
Geraghty, RJ; Wang, Y; Xie, J; Zhou, W, 2017
)
0.46
" STATEMENT OF SIGNIFICANCE: The doxorubicin-loaded glycol chitosan-suramin nanoparticle (GCS-SM/DOX) is novel in the following aspects: SM acts as not only a gelator for the first time in the preparation of the nanoparticle but also an active pharmaceutical agent in the dosage form."( Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan-based nanoparticles.
Cheng, B; Gao, F; Maissy, E; Xu, P, 2019
)
1.13
"In vivo, results showed that the hepatoprotective effect of P2Y2R blockade by significantly suppressed liver structural abnormalities and lipid infiltration, and decreased levels of ALT/AST and TNF-α/IL-1β in the high dosage group of suramin (20 mg/kg) compared to control diet (CD)-fed mice."( Blockade of the P2Y2 Receptor Attenuates Alcoholic Liver Inflammation by Targeting the EGFR-ERK1/2 Signaling Pathway.
Liu, ZN; Lv, XW; Su, QQ; Wang, YH; Wu, X, 2022
)
0.9
" Heparin and other polyanions can neutralize histones but challenges with dosing or side effects such as bleeding limit clinical application."( The Polyanionic Drug Suramin Neutralizes Histones and Prevents Endotheliopathy.
Bouchard, BA; Boyson, JE; Chen, YL; Freeman, K; Haines, L; Lawson, MA; Li, J; Ma, YT; Majumdar, D; Nelson, MT; Poynter, ME; Sackheim, AM; Sonkusare, SK; Villalba, N, 2023
)
1.23
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (10)

RoleDescription
antinematodal drugA substance used in the treatment or control of nematode infestations.
trypanocidal drugA drug used to treat or prevent infections caused by protozoal organisms belonging to the suborder Trypanosomatida.
ryanodine receptor agonistA ryanodine receptor modulator which activates the receptor. Ryanodine receptors (RyRs) act as selective ion channels, modulating the release of calcium. Activating the receptors causes the release of calcium, so depleting internal calcium and ultimately preventing further muscle contraction.
GABA-gated chloride channel antagonistnull
GABA antagonistA compound that inhibits the action of gamma-aminobutyric acid.
apoptosis inhibitorAny substance that inhibits the process of apoptosis (programmed cell death) in multi-celled organisms.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
angiogenesis inhibitorAn agent and endogenous substances that antagonize or inhibit the development of new blood vessels.
purinergic receptor P2 antagonistAn antagonist at purinergic P2 receptors
EC 2.7.11.13 (protein kinase C) inhibitorAn EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of protein kinase C (EC 2.7.11.13).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
naphthalenesulfonic acid
phenylureasAny member of the class of ureas in which at least one of the nitrogens of the urea moiety is substituted by a phenyl or substituted phenyl group.
secondary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Nsp9 interactions (COVID-19 Disease Map)8330
Purinergic signaling053

Protein Targets (64)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency14.12540.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency2.67910.004023.8416100.0000AID485290; AID489007
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency11.23230.125919.1169125.8920AID2549; AID2708
LuciferasePhotinus pyralis (common eastern firefly)Potency27.53630.007215.758889.3584AID1224835; AID624030
phosphopantetheinyl transferaseBacillus subtilisPotency19.95260.141337.9142100.0000AID1490
USP1 protein, partialHomo sapiens (human)Potency7.94330.031637.5844354.8130AID504865
GLS proteinHomo sapiens (human)Potency8.91250.35487.935539.8107AID624170
Microtubule-associated protein tauHomo sapiens (human)Potency21.45090.180013.557439.8107AID1460; AID1468
regulator of G-protein signaling 4Homo sapiens (human)Potency0.00750.531815.435837.6858AID504845
EWS/FLI fusion proteinHomo sapiens (human)Potency10.47590.001310.157742.8575AID1259252; AID1259256
glucocerebrosidaseHomo sapiens (human)Potency22.38720.01268.156944.6684AID2101
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.41250.035520.977089.1251AID504332
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency35.48130.354828.065989.1251AID504847
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency14.12540.010323.856763.0957AID2662
DNA polymerase kappa isoform 1Homo sapiens (human)Potency0.03160.031622.3146100.0000AID588579
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency36.12540.005612.367736.1254AID624032
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency3.16231.000010.475628.1838AID1457
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency7.07950.060110.745337.9330AID492961
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-dependent 6-phosphofructokinaseTrypanosoma brucei bruceiIC50 (µMol)3.00003.00003.00003.0000AID1064827
Serine/threonine-protein kinase D3Homo sapiens (human)IC50 (µMol)29.00000.00011.170110.0000AID165262
Protein kinase C gamma typeHomo sapiens (human)IC50 (µMol)29.00000.00011.035410.0000AID165262
Protein kinase C beta typeHomo sapiens (human)IC50 (µMol)29.00000.00010.554210.0000AID165262
Cathepsin BHomo sapiens (human)IC50 (µMol)30.00000.00021.845310.0000AID312631
Protein kinase C alpha typeHomo sapiens (human)IC50 (µMol)29.00000.00010.972010.0000AID165262
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)9.76000.00053.49849.7600AID1802584
D(3) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)18.10000.00030.39075.4000AID280501
Protein kinase C eta typeHomo sapiens (human)IC50 (µMol)29.00000.00010.797110.0000AID165262
P2Y purinoceptor 2Homo sapiens (human)IC50 (µMol)50.00005.61005.71005.8100AID366506
Protein kinase C iota typeHomo sapiens (human)IC50 (µMol)29.00000.00012.037810.0000AID165262
P2X purinoceptor 2Rattus norvegicus (Norway rat)IC50 (µMol)21.90530.69001.65804.0000AID570116
DNA-dependent protein kinase catalytic subunitHomo sapiens (human)IC50 (µMol)1.70000.00051.350010.0000AID53307
DNA primaseMycobacterium tuberculosis CDC1551IC50 (µMol)8.20007.10007.65008.2000AID1800407
Protein kinase C epsilon typeHomo sapiens (human)IC50 (µMol)29.00000.00010.802910.0000AID165262
Protein kinase C theta typeHomo sapiens (human)IC50 (µMol)29.00000.00010.989710.0000AID165262
Protein kinase C zeta typeHomo sapiens (human)IC50 (µMol)29.00000.00012.445310.0000AID165262
Protein kinase C delta typeHomo sapiens (human)IC50 (µMol)29.00000.00010.844810.0000AID165262
P2Y purinoceptor 6Homo sapiens (human)IC50 (µMol)27.00002.79002.79002.7900AID366510
Serine/threonine-protein kinase D1Homo sapiens (human)IC50 (µMol)29.00000.00011.231910.0000AID165262
Dual specificity protein phosphatase 5Homo sapiens (human)Ki0.02500.02500.02500.0250AID1802735
RmtAAspergillus nidulansIC50 (µMol)5.90005.90005.90005.9000AID280502
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)12.20000.00011.076810.0000AID199658; AID199661
NAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)IC50 (µMol)1.15000.50003.848110.0000AID712590; AID735756
NAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)IC50 (µMol)1.56670.00601.62509.0000AID1233459; AID455742; AID657109; AID707852; AID712589; AID735757
P2Y purinoceptor 11Homo sapiens (human)Ki0.20710.11220.20710.3020AID254593; AID254595
Protein arginine N-methyltransferase 1Homo sapiens (human)IC50 (µMol)344.81000.25003.61679.4000AID280501; AID527461; AID527462
NAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)IC50 (µMol)20.60000.10003.38006.6000AID1194530; AID1194531; AID1194534; AID1194535; AID699752; AID712586; AID712587; AID723627
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nuclear receptor subfamily 1 group I member 2Homo sapiens (human)EC50 (µMol)1.30000.00203.519610.0000AID1215094
Mu-type opioid receptorHomo sapiens (human)EC50 (µMol)100.00000.00000.32639.4000AID150172
Delta-type opioid receptorHomo sapiens (human)EC50 (µMol)100.00000.00000.43328.3000AID150172
Kappa-type opioid receptorHomo sapiens (human)EC50 (µMol)100.00000.00000.22448.9900AID150172
P2Y purinoceptor 2Homo sapiens (human)EC50 (µMol)48.00000.00560.682810.0000AID150321
P2X purinoceptor 1Rattus norvegicus (Norway rat)EC50 (µMol)1.00000.05402.761310.0000AID152481
P2Y purinoceptor 1Meleagris gallopavo (turkey)EC50 (µMol)10.00000.00251.70498.0000AID150472
P2X purinoceptor 2Rattus norvegicus (Norway rat)EC50 (µMol)10.40001.50001.50001.5000AID150145
P2X purinoceptor 4Rattus norvegicus (Norway rat)EC50 (µMol)100.00002.30006.566710.0000AID150165
P2X purinoceptor 5Rattus norvegicus (Norway rat)EC50 (µMol)4.00000.60002.05004.0000AID150170
P2X purinoceptor 6Rattus norvegicus (Norway rat)EC50 (µMol)100.00000.60000.95001.3000AID150172
P2Y purinoceptor 4Homo sapiens (human)EC50 (µMol)100.00000.02301.362310.0000AID150627
P2X purinoceptor 3Homo sapiens (human)EC50 (µMol)8.95000.24002.80229.2000AID150151; AID150155
P2Y purinoceptor 11Homo sapiens (human)EC50 (µMol)16.00000.06313.77049.0000AID150490
P2X purinoceptor 7Homo sapiens (human)EC50 (µMol)92.00000.03400.03400.0340AID150173
P2Y purinoceptor 12Rattus norvegicus (Norway rat)EC50 (µMol)4.00000.00111.09044.0000AID150495
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (611)

Processvia Protein(s)Taxonomy
negative regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
signal transductionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
steroid metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of gene expressionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic catabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic transportNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
cell differentiationNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase D3Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwaySerine/threonine-protein kinase D3Homo sapiens (human)
sphingolipid biosynthetic processSerine/threonine-protein kinase D3Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase D3Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwaySerine/threonine-protein kinase D3Homo sapiens (human)
protein phosphorylationProtein kinase C gamma typeHomo sapiens (human)
chemical synaptic transmissionProtein kinase C gamma typeHomo sapiens (human)
learning or memoryProtein kinase C gamma typeHomo sapiens (human)
chemosensory behaviorProtein kinase C gamma typeHomo sapiens (human)
response to toxic substanceProtein kinase C gamma typeHomo sapiens (human)
phosphorylationProtein kinase C gamma typeHomo sapiens (human)
negative regulation of protein ubiquitinationProtein kinase C gamma typeHomo sapiens (human)
regulation of response to foodProtein kinase C gamma typeHomo sapiens (human)
positive regulation of mismatch repairProtein kinase C gamma typeHomo sapiens (human)
negative regulation of protein catabolic processProtein kinase C gamma typeHomo sapiens (human)
regulation of circadian rhythmProtein kinase C gamma typeHomo sapiens (human)
response to morphineProtein kinase C gamma typeHomo sapiens (human)
negative regulation of neuron apoptotic processProtein kinase C gamma typeHomo sapiens (human)
response to painProtein kinase C gamma typeHomo sapiens (human)
rhythmic processProtein kinase C gamma typeHomo sapiens (human)
regulation of phagocytosisProtein kinase C gamma typeHomo sapiens (human)
long-term synaptic potentiationProtein kinase C gamma typeHomo sapiens (human)
innervationProtein kinase C gamma typeHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionProtein kinase C gamma typeHomo sapiens (human)
negative regulation of proteasomal protein catabolic processProtein kinase C gamma typeHomo sapiens (human)
response to psychosocial stressProtein kinase C gamma typeHomo sapiens (human)
regulation of synaptic vesicle exocytosisProtein kinase C gamma typeHomo sapiens (human)
intracellular signal transductionProtein kinase C gamma typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C gamma typeHomo sapiens (human)
adaptive immune responseProtein kinase C beta typeHomo sapiens (human)
chromatin remodelingProtein kinase C beta typeHomo sapiens (human)
regulation of transcription by RNA polymerase IIProtein kinase C beta typeHomo sapiens (human)
protein phosphorylationProtein kinase C beta typeHomo sapiens (human)
calcium ion transportProtein kinase C beta typeHomo sapiens (human)
intracellular calcium ion homeostasisProtein kinase C beta typeHomo sapiens (human)
apoptotic processProtein kinase C beta typeHomo sapiens (human)
mitotic nuclear membrane disassemblyProtein kinase C beta typeHomo sapiens (human)
signal transductionProtein kinase C beta typeHomo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayProtein kinase C beta typeHomo sapiens (human)
response to xenobiotic stimulusProtein kinase C beta typeHomo sapiens (human)
response to glucoseProtein kinase C beta typeHomo sapiens (human)
regulation of glucose transmembrane transportProtein kinase C beta typeHomo sapiens (human)
negative regulation of glucose transmembrane transportProtein kinase C beta typeHomo sapiens (human)
regulation of dopamine secretionProtein kinase C beta typeHomo sapiens (human)
dibenzo-p-dioxin metabolic processProtein kinase C beta typeHomo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayProtein kinase C beta typeHomo sapiens (human)
positive regulation of insulin secretionProtein kinase C beta typeHomo sapiens (human)
response to vitamin DProtein kinase C beta typeHomo sapiens (human)
regulation of growthProtein kinase C beta typeHomo sapiens (human)
B cell activationProtein kinase C beta typeHomo sapiens (human)
positive regulation of odontogenesis of dentin-containing toothProtein kinase C beta typeHomo sapiens (human)
lipoprotein transportProtein kinase C beta typeHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionProtein kinase C beta typeHomo sapiens (human)
post-translational protein modificationProtein kinase C beta typeHomo sapiens (human)
response to ethanolProtein kinase C beta typeHomo sapiens (human)
positive regulation of angiogenesisProtein kinase C beta typeHomo sapiens (human)
positive regulation of DNA-templated transcriptionProtein kinase C beta typeHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayProtein kinase C beta typeHomo sapiens (human)
B cell receptor signaling pathwayProtein kinase C beta typeHomo sapiens (human)
positive regulation of B cell receptor signaling pathwayProtein kinase C beta typeHomo sapiens (human)
cellular response to carbohydrate stimulusProtein kinase C beta typeHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionProtein kinase C beta typeHomo sapiens (human)
regulation of synaptic vesicle exocytosisProtein kinase C beta typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C beta typeHomo sapiens (human)
intracellular signal transductionProtein kinase C beta typeHomo sapiens (human)
proteolysisCathepsin BHomo sapiens (human)
thyroid hormone generationCathepsin BHomo sapiens (human)
collagen catabolic processCathepsin BHomo sapiens (human)
epithelial cell differentiationCathepsin BHomo sapiens (human)
regulation of apoptotic processCathepsin BHomo sapiens (human)
decidualizationCathepsin BHomo sapiens (human)
symbiont entry into host cellCathepsin BHomo sapiens (human)
proteolysis involved in protein catabolic processCathepsin BHomo sapiens (human)
cellular response to thyroid hormone stimulusCathepsin BHomo sapiens (human)
angiogenesisProtein kinase C alpha typeHomo sapiens (human)
positive regulation of endothelial cell proliferationProtein kinase C alpha typeHomo sapiens (human)
desmosome assemblyProtein kinase C alpha typeHomo sapiens (human)
chromatin remodelingProtein kinase C alpha typeHomo sapiens (human)
protein phosphorylationProtein kinase C alpha typeHomo sapiens (human)
mitotic nuclear membrane disassemblyProtein kinase C alpha typeHomo sapiens (human)
cell adhesionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of endothelial cell migrationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyProtein kinase C alpha typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C alpha typeHomo sapiens (human)
peptidyl-threonine phosphorylationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of cell migrationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of lipopolysaccharide-mediated signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
negative regulation of glial cell apoptotic processProtein kinase C alpha typeHomo sapiens (human)
regulation of mRNA stabilityProtein kinase C alpha typeHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationProtein kinase C alpha typeHomo sapiens (human)
post-translational protein modificationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of macrophage differentiationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of angiogenesisProtein kinase C alpha typeHomo sapiens (human)
positive regulation of bone resorptionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of cell adhesionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of mitotic cell cycleProtein kinase C alpha typeHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeProtein kinase C alpha typeHomo sapiens (human)
response to interleukin-1Protein kinase C alpha typeHomo sapiens (human)
regulation of platelet aggregationProtein kinase C alpha typeHomo sapiens (human)
apoptotic signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
positive regulation of angiotensin-activated signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
positive regulation of dense core granule biogenesisProtein kinase C alpha typeHomo sapiens (human)
intracellular signal transductionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of insulin secretionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphorylationProtein kinase C eta typeHomo sapiens (human)
signal transductionProtein kinase C eta typeHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationProtein kinase C eta typeHomo sapiens (human)
cell differentiationProtein kinase C eta typeHomo sapiens (human)
negative regulation of glial cell apoptotic processProtein kinase C eta typeHomo sapiens (human)
positive regulation of keratinocyte differentiationProtein kinase C eta typeHomo sapiens (human)
positive regulation of B cell receptor signaling pathwayProtein kinase C eta typeHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityProtein kinase C eta typeHomo sapiens (human)
positive regulation of glial cell proliferationProtein kinase C eta typeHomo sapiens (human)
protein kinase C signalingProtein kinase C eta typeHomo sapiens (human)
positive regulation of protein localization to plasma membraneProtein kinase C eta typeHomo sapiens (human)
regulation of bicellular tight junction assemblyProtein kinase C eta typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C eta typeHomo sapiens (human)
intracellular signal transductionProtein kinase C eta typeHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
immune responseDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerDelta-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
adult locomotory behaviorDelta-type opioid receptorHomo sapiens (human)
negative regulation of gene expressionDelta-type opioid receptorHomo sapiens (human)
negative regulation of protein-containing complex assemblyDelta-type opioid receptorHomo sapiens (human)
positive regulation of CREB transcription factor activityDelta-type opioid receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationDelta-type opioid receptorHomo sapiens (human)
response to nicotineDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
eating behaviorDelta-type opioid receptorHomo sapiens (human)
regulation of mitochondrial membrane potentialDelta-type opioid receptorHomo sapiens (human)
regulation of calcium ion transportDelta-type opioid receptorHomo sapiens (human)
cellular response to growth factor stimulusDelta-type opioid receptorHomo sapiens (human)
cellular response to hypoxiaDelta-type opioid receptorHomo sapiens (human)
cellular response to toxic substanceDelta-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayDelta-type opioid receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
intracellular monoatomic ion homeostasisP2Y purinoceptor 2Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayP2Y purinoceptor 2Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayP2Y purinoceptor 2Homo sapiens (human)
positive regulation of mucus secretionP2Y purinoceptor 2Homo sapiens (human)
cellular response to ATPP2Y purinoceptor 2Homo sapiens (human)
blood vessel diameter maintenanceP2Y purinoceptor 2Homo sapiens (human)
G protein-coupled receptor signaling pathwayP2Y purinoceptor 2Homo sapiens (human)
protein phosphorylationProtein kinase C iota typeHomo sapiens (human)
protein targeting to membraneProtein kinase C iota typeHomo sapiens (human)
cytoskeleton organizationProtein kinase C iota typeHomo sapiens (human)
actin filament organizationProtein kinase C iota typeHomo sapiens (human)
positive regulation of neuron projection developmentProtein kinase C iota typeHomo sapiens (human)
vesicle-mediated transportProtein kinase C iota typeHomo sapiens (human)
cell migrationProtein kinase C iota typeHomo sapiens (human)
cellular response to insulin stimulusProtein kinase C iota typeHomo sapiens (human)
negative regulation of glial cell apoptotic processProtein kinase C iota typeHomo sapiens (human)
establishment of apical/basal cell polarityProtein kinase C iota typeHomo sapiens (human)
eye photoreceptor cell developmentProtein kinase C iota typeHomo sapiens (human)
negative regulation of apoptotic processProtein kinase C iota typeHomo sapiens (human)
negative regulation of neuron apoptotic processProtein kinase C iota typeHomo sapiens (human)
establishment or maintenance of epithelial cell apical/basal polarityProtein kinase C iota typeHomo sapiens (human)
cell-cell junction organizationProtein kinase C iota typeHomo sapiens (human)
positive regulation of Notch signaling pathwayProtein kinase C iota typeHomo sapiens (human)
positive regulation of glucose importProtein kinase C iota typeHomo sapiens (human)
secretionProtein kinase C iota typeHomo sapiens (human)
Golgi vesicle buddingProtein kinase C iota typeHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityProtein kinase C iota typeHomo sapiens (human)
positive regulation of glial cell proliferationProtein kinase C iota typeHomo sapiens (human)
membrane organizationProtein kinase C iota typeHomo sapiens (human)
cellular response to chemical stressProtein kinase C iota typeHomo sapiens (human)
response to interleukin-1Protein kinase C iota typeHomo sapiens (human)
regulation of postsynaptic membrane neurotransmitter receptor levelsProtein kinase C iota typeHomo sapiens (human)
positive regulation of protein localization to plasma membraneProtein kinase C iota typeHomo sapiens (human)
positive regulation of endothelial cell apoptotic processProtein kinase C iota typeHomo sapiens (human)
intracellular signal transductionProtein kinase C iota typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C iota typeHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayP2Y purinoceptor 4Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationP2Y purinoceptor 4Homo sapiens (human)
transepithelial chloride transportP2Y purinoceptor 4Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayP2Y purinoceptor 4Homo sapiens (human)
cellular response to ATPP2Y purinoceptor 4Homo sapiens (human)
cellular response to prostaglandin E stimulusP2Y purinoceptor 4Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationP2Y purinoceptor 4Homo sapiens (human)
regulation of synaptic vesicle exocytosisP2Y purinoceptor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayP2Y purinoceptor 4Homo sapiens (human)
response to hypoxiaP2X purinoceptor 3Homo sapiens (human)
signal transductionP2X purinoceptor 3Homo sapiens (human)
neuromuscular synaptic transmissionP2X purinoceptor 3Homo sapiens (human)
response to heatP2X purinoceptor 3Homo sapiens (human)
response to coldP2X purinoceptor 3Homo sapiens (human)
response to mechanical stimulusP2X purinoceptor 3Homo sapiens (human)
response to carbohydrateP2X purinoceptor 3Homo sapiens (human)
positive regulation of calcium ion transport into cytosolP2X purinoceptor 3Homo sapiens (human)
urinary bladder smooth muscle contractionP2X purinoceptor 3Homo sapiens (human)
peristalsisP2X purinoceptor 3Homo sapiens (human)
purinergic nucleotide receptor signaling pathwayP2X purinoceptor 3Homo sapiens (human)
regulation of synaptic plasticityP2X purinoceptor 3Homo sapiens (human)
behavioral response to painP2X purinoceptor 3Homo sapiens (human)
positive regulation of calcium-mediated signalingP2X purinoceptor 3Homo sapiens (human)
sensory perception of tasteP2X purinoceptor 3Homo sapiens (human)
establishment of localization in cellP2X purinoceptor 3Homo sapiens (human)
excitatory postsynaptic potentialP2X purinoceptor 3Homo sapiens (human)
protein homotrimerizationP2X purinoceptor 3Homo sapiens (human)
cellular response to ATPP2X purinoceptor 3Homo sapiens (human)
inorganic cation transmembrane transportP2X purinoceptor 3Homo sapiens (human)
calcium ion transmembrane transportP2X purinoceptor 3Homo sapiens (human)
peptidyl-serine phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
maturation of 5.8S rRNADNA-dependent protein kinase catalytic subunitHomo sapiens (human)
somitogenesisDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
negative regulation of protein phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
activation of innate immune responseDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
B cell lineage commitmentDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
immature B cell differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
pro-B cell differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
T cell lineage commitmentDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
double-strand break repairDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
double-strand break repair via nonhomologous end joiningDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
chromatin remodelingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
DNA damage responseDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
brain developmentDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
heart developmentDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
response to gamma radiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
telomere cappingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
peptidyl-serine phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
peptidyl-threonine phosphorylationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
mitotic G1 DNA damage checkpoint signalingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein destabilizationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
cellular response to insulin stimulusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
T cell differentiation in thymusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
T cell receptor V(D)J recombinationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
small-subunit processome assemblyDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
ectopic germ cell programmed cell deathDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein modification processDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
regulation of circadian rhythmDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of apoptotic processDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
negative regulation of apoptotic processDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
innate immune responseDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of lymphocyte differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of erythrocyte differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of translationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
rhythmic processDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
regulation of smooth muscle cell proliferationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
regulation of epithelial cell proliferationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
double-strand break repair via alternative nonhomologous end joiningDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
negative regulation of cGAS/STING signaling pathwayDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
regulation of hematopoietic stem cell differentiationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of platelet formationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
positive regulation of double-strand break repair via nonhomologous end joiningDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
immunoglobulin V(D)J recombinationDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
telomere maintenanceDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
MAPK cascadeProtein kinase C epsilon typeHomo sapiens (human)
macrophage activation involved in immune responseProtein kinase C epsilon typeHomo sapiens (human)
protein phosphorylationProtein kinase C epsilon typeHomo sapiens (human)
apoptotic processProtein kinase C epsilon typeHomo sapiens (human)
signal transductionProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of epithelial cell migrationProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of fibroblast migrationProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of cell-substrate adhesionProtein kinase C epsilon typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C epsilon typeHomo sapiens (human)
insulin secretionProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of actin filament polymerizationProtein kinase C epsilon typeHomo sapiens (human)
negative regulation of protein ubiquitinationProtein kinase C epsilon typeHomo sapiens (human)
cell-substrate adhesionProtein kinase C epsilon typeHomo sapiens (human)
lipopolysaccharide-mediated signaling pathwayProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of insulin secretionProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of cytokinesisProtein kinase C epsilon typeHomo sapiens (human)
locomotory exploration behaviorProtein kinase C epsilon typeHomo sapiens (human)
TRAM-dependent toll-like receptor 4 signaling pathwayProtein kinase C epsilon typeHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionProtein kinase C epsilon typeHomo sapiens (human)
response to morphineProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of MAPK cascadeProtein kinase C epsilon typeHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of lipid catabolic processProtein kinase C epsilon typeHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosolProtein kinase C epsilon typeHomo sapiens (human)
cell divisionProtein kinase C epsilon typeHomo sapiens (human)
establishment of localization in cellProtein kinase C epsilon typeHomo sapiens (human)
synaptic transmission, GABAergicProtein kinase C epsilon typeHomo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusProtein kinase C epsilon typeHomo sapiens (human)
mucus secretionProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of mucus secretionProtein kinase C epsilon typeHomo sapiens (human)
cellular response to ethanolProtein kinase C epsilon typeHomo sapiens (human)
cellular response to prostaglandin E stimulusProtein kinase C epsilon typeHomo sapiens (human)
cellular response to hypoxiaProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of wound healingProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of protein localization to plasma membraneProtein kinase C epsilon typeHomo sapiens (human)
negative regulation of sodium ion transmembrane transporter activityProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of cellular glucuronidationProtein kinase C epsilon typeHomo sapiens (human)
intracellular signal transductionProtein kinase C epsilon typeHomo sapiens (human)
regulation of cell growthProtein kinase C theta typeHomo sapiens (human)
regulation of DNA-templated transcriptionProtein kinase C theta typeHomo sapiens (human)
protein phosphorylationProtein kinase C theta typeHomo sapiens (human)
membrane protein ectodomain proteolysisProtein kinase C theta typeHomo sapiens (human)
inflammatory responseProtein kinase C theta typeHomo sapiens (human)
axon guidanceProtein kinase C theta typeHomo sapiens (human)
positive regulation of telomere maintenance via telomeraseProtein kinase C theta typeHomo sapiens (human)
positive regulation of interleukin-17 productionProtein kinase C theta typeHomo sapiens (human)
positive regulation of interleukin-2 productionProtein kinase C theta typeHomo sapiens (human)
positive regulation of interleukin-4 productionProtein kinase C theta typeHomo sapiens (human)
intracellular signal transductionProtein kinase C theta typeHomo sapiens (human)
CD4-positive, alpha-beta T cell proliferationProtein kinase C theta typeHomo sapiens (human)
Fc-epsilon receptor signaling pathwayProtein kinase C theta typeHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayProtein kinase C theta typeHomo sapiens (human)
positive regulation of T cell activationProtein kinase C theta typeHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityProtein kinase C theta typeHomo sapiens (human)
positive regulation of telomerase activityProtein kinase C theta typeHomo sapiens (human)
cell chemotaxisProtein kinase C theta typeHomo sapiens (human)
negative regulation of T cell apoptotic processProtein kinase C theta typeHomo sapiens (human)
regulation of platelet aggregationProtein kinase C theta typeHomo sapiens (human)
positive regulation of telomere cappingProtein kinase C theta typeHomo sapiens (human)
positive regulation of T-helper 17 type immune responseProtein kinase C theta typeHomo sapiens (human)
positive regulation of CD4-positive, alpha-beta T cell proliferationProtein kinase C theta typeHomo sapiens (human)
positive regulation of T-helper 2 cell activationProtein kinase C theta typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C theta typeHomo sapiens (human)
microtubule cytoskeleton organizationProtein kinase C zeta typeHomo sapiens (human)
positive regulation of cell-matrix adhesionProtein kinase C zeta typeHomo sapiens (human)
protein phosphorylationProtein kinase C zeta typeHomo sapiens (human)
inflammatory responseProtein kinase C zeta typeHomo sapiens (human)
signal transductionProtein kinase C zeta typeHomo sapiens (human)
cell surface receptor signaling pathwayProtein kinase C zeta typeHomo sapiens (human)
long-term memoryProtein kinase C zeta typeHomo sapiens (human)
positive regulation of cell population proliferationProtein kinase C zeta typeHomo sapiens (human)
cell migrationProtein kinase C zeta typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C zeta typeHomo sapiens (human)
establishment of cell polarityProtein kinase C zeta typeHomo sapiens (human)
negative regulation of protein-containing complex assemblyProtein kinase C zeta typeHomo sapiens (human)
positive regulation of interleukin-10 productionProtein kinase C zeta typeHomo sapiens (human)
positive regulation of interleukin-13 productionProtein kinase C zeta typeHomo sapiens (human)
positive regulation of interleukin-4 productionProtein kinase C zeta typeHomo sapiens (human)
positive regulation of interleukin-5 productionProtein kinase C zeta typeHomo sapiens (human)
cellular response to insulin stimulusProtein kinase C zeta typeHomo sapiens (human)
negative regulation of apoptotic processProtein kinase C zeta typeHomo sapiens (human)
establishment or maintenance of epithelial cell apical/basal polarityProtein kinase C zeta typeHomo sapiens (human)
positive regulation of T-helper 2 cell differentiationProtein kinase C zeta typeHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayProtein kinase C zeta typeHomo sapiens (human)
positive regulation of insulin receptor signaling pathwayProtein kinase C zeta typeHomo sapiens (human)
vesicle transport along microtubuleProtein kinase C zeta typeHomo sapiens (human)
negative regulation of peptidyl-tyrosine phosphorylationProtein kinase C zeta typeHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityProtein kinase C zeta typeHomo sapiens (human)
positive regulation of protein transportProtein kinase C zeta typeHomo sapiens (human)
membrane depolarizationProtein kinase C zeta typeHomo sapiens (human)
membrane hyperpolarizationProtein kinase C zeta typeHomo sapiens (human)
long-term synaptic potentiationProtein kinase C zeta typeHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeProtein kinase C zeta typeHomo sapiens (human)
protein kinase C signalingProtein kinase C zeta typeHomo sapiens (human)
protein localization to plasma membraneProtein kinase C zeta typeHomo sapiens (human)
regulation of neurotransmitter receptor localization to postsynaptic specialization membraneProtein kinase C zeta typeHomo sapiens (human)
neuron projection extensionProtein kinase C zeta typeHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialProtein kinase C zeta typeHomo sapiens (human)
positive regulation of T-helper 2 cell cytokine productionProtein kinase C zeta typeHomo sapiens (human)
intracellular signal transductionProtein kinase C zeta typeHomo sapiens (human)
protein phosphorylationProtein kinase C delta typeHomo sapiens (human)
apoptotic processProtein kinase C delta typeHomo sapiens (human)
DNA damage responseProtein kinase C delta typeHomo sapiens (human)
signal transductionProtein kinase C delta typeHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressProtein kinase C delta typeHomo sapiens (human)
regulation of signaling receptor activityProtein kinase C delta typeHomo sapiens (human)
immunoglobulin mediated immune responseProtein kinase C delta typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C delta typeHomo sapiens (human)
peptidyl-threonine phosphorylationProtein kinase C delta typeHomo sapiens (human)
termination of signal transductionProtein kinase C delta typeHomo sapiens (human)
negative regulation of actin filament polymerizationProtein kinase C delta typeHomo sapiens (human)
positive regulation of endodeoxyribonuclease activityProtein kinase C delta typeHomo sapiens (human)
negative regulation of protein bindingProtein kinase C delta typeHomo sapiens (human)
activation of protein kinase activityProtein kinase C delta typeHomo sapiens (human)
positive regulation of superoxide anion generationProtein kinase C delta typeHomo sapiens (human)
regulation of actin cytoskeleton organizationProtein kinase C delta typeHomo sapiens (human)
negative regulation of glial cell apoptotic processProtein kinase C delta typeHomo sapiens (human)
cellular response to UVProtein kinase C delta typeHomo sapiens (human)
positive regulation of protein dephosphorylationProtein kinase C delta typeHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisProtein kinase C delta typeHomo sapiens (human)
B cell proliferationProtein kinase C delta typeHomo sapiens (human)
neutrophil activationProtein kinase C delta typeHomo sapiens (human)
positive regulation of protein import into nucleusProtein kinase C delta typeHomo sapiens (human)
defense response to bacteriumProtein kinase C delta typeHomo sapiens (human)
negative regulation of MAP kinase activityProtein kinase C delta typeHomo sapiens (human)
regulation of mRNA stabilityProtein kinase C delta typeHomo sapiens (human)
post-translational protein modificationProtein kinase C delta typeHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayProtein kinase C delta typeHomo sapiens (human)
negative regulation of inflammatory responseProtein kinase C delta typeHomo sapiens (human)
negative regulation of peptidyl-tyrosine phosphorylationProtein kinase C delta typeHomo sapiens (human)
protein stabilizationProtein kinase C delta typeHomo sapiens (human)
negative regulation of filopodium assemblyProtein kinase C delta typeHomo sapiens (human)
cell chemotaxisProtein kinase C delta typeHomo sapiens (human)
cellular response to hydrogen peroxideProtein kinase C delta typeHomo sapiens (human)
cellular response to hydroperoxideProtein kinase C delta typeHomo sapiens (human)
negative regulation of platelet aggregationProtein kinase C delta typeHomo sapiens (human)
cellular senescenceProtein kinase C delta typeHomo sapiens (human)
positive regulation of phospholipid scramblase activityProtein kinase C delta typeHomo sapiens (human)
cellular response to angiotensinProtein kinase C delta typeHomo sapiens (human)
regulation of ceramide biosynthetic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of ceramide biosynthetic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of glucosylceramide catabolic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of sphingomyelin catabolic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of apoptotic signaling pathwayProtein kinase C delta typeHomo sapiens (human)
intracellular signal transductionProtein kinase C delta typeHomo sapiens (human)
phagocytosisP2Y purinoceptor 6Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayP2Y purinoceptor 6Homo sapiens (human)
activation of phospholipase C activityP2Y purinoceptor 6Homo sapiens (human)
positive regulation of smooth muscle cell migrationP2Y purinoceptor 6Homo sapiens (human)
transepithelial chloride transportP2Y purinoceptor 6Homo sapiens (human)
positive regulation of inositol 1,4,5-trisphosphate-sensitive calcium-release channel activityP2Y purinoceptor 6Homo sapiens (human)
positive regulation of inositol trisphosphate biosynthetic processP2Y purinoceptor 6Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayP2Y purinoceptor 6Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeP2Y purinoceptor 6Homo sapiens (human)
cellular response to prostaglandin E stimulusP2Y purinoceptor 6Homo sapiens (human)
cellular response to purine-containing compoundP2Y purinoceptor 6Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationP2Y purinoceptor 6Homo sapiens (human)
cellular response to pyrimidine ribonucleotideP2Y purinoceptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathwayP2Y purinoceptor 6Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase D1Homo sapiens (human)
angiogenesisSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of endothelial cell proliferationSerine/threonine-protein kinase D1Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase D1Homo sapiens (human)
inflammatory responseSerine/threonine-protein kinase D1Homo sapiens (human)
Golgi organizationSerine/threonine-protein kinase D1Homo sapiens (human)
signal transductionSerine/threonine-protein kinase D1Homo sapiens (human)
integrin-mediated signaling pathwaySerine/threonine-protein kinase D1Homo sapiens (human)
nervous system developmentSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of autophagySerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of endothelial cell migrationSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of gene expressionSerine/threonine-protein kinase D1Homo sapiens (human)
regulation of keratinocyte proliferationSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of neuron projection developmentSerine/threonine-protein kinase D1Homo sapiens (human)
regulation of skeletal muscle contraction by modulation of calcium ion sensitivity of myofibrilSerine/threonine-protein kinase D1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase D1Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase D1Homo sapiens (human)
sphingolipid biosynthetic processSerine/threonine-protein kinase D1Homo sapiens (human)
cell differentiationSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to amino acid starvationSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to oxidative stressSerine/threonine-protein kinase D1Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of protein import into nucleusSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationSerine/threonine-protein kinase D1Homo sapiens (human)
innate immune responseSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of osteoblast differentiationSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of angiogenesisSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of cell sizeSerine/threonine-protein kinase D1Homo sapiens (human)
negative regulation of endocytosisSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISerine/threonine-protein kinase D1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of protein export from nucleusSerine/threonine-protein kinase D1Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwaySerine/threonine-protein kinase D1Homo sapiens (human)
Golgi vesicle transportSerine/threonine-protein kinase D1Homo sapiens (human)
defense response to Gram-negative bacteriumSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activitySerine/threonine-protein kinase D1Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of sarcomere organizationSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to hydroperoxideSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to norepinephrine stimulusSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of peptide hormone secretionSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of NLRP3 inflammasome complex assemblySerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to angiotensinSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to phorbol 13-acetate 12-myristateSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to endothelinSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of endothelial cell chemotaxisSerine/threonine-protein kinase D1Homo sapiens (human)
regulation of integrin-mediated signaling pathwaySerine/threonine-protein kinase D1Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwaySerine/threonine-protein kinase D1Homo sapiens (human)
MAPK cascadeDual specificity protein phosphatase 5Homo sapiens (human)
protein dephosphorylationDual specificity protein phosphatase 5Homo sapiens (human)
dephosphorylationDual specificity protein phosphatase 5Homo sapiens (human)
peptidyl-tyrosine dephosphorylationDual specificity protein phosphatase 5Homo sapiens (human)
peptidyl-threonine dephosphorylationDual specificity protein phosphatase 5Homo sapiens (human)
ERK1 and ERK2 cascadeDual specificity protein phosphatase 5Homo sapiens (human)
endoderm formationDual specificity protein phosphatase 5Homo sapiens (human)
negative regulation of MAPK cascadeDual specificity protein phosphatase 5Homo sapiens (human)
nucleoside monophosphate biosynthetic processEctonucleoside triphosphate diphosphohydrolase 8Homo sapiens (human)
nucleoside diphosphate biosynthetic processEctonucleoside triphosphate diphosphohydrolase 8Homo sapiens (human)
nucleoside diphosphate catabolic processEctonucleoside triphosphate diphosphohydrolase 8Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
rDNA heterochromatin formationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
protein deacetylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
autophagyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
mitotic nuclear membrane reassemblyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of exit from mitosisNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of autophagyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of peptidyl-threonine phosphorylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
substantia nigra developmentNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
myelination in peripheral nervous systemNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
heterochromatin formationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
subtelomeric heterochromatin formationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of myelinationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to oxidative stressNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
peptidyl-lysine deacetylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
epigenetic regulation of gene expressionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of protein catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of phosphorylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of DNA bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
post-translational protein modificationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular lipid catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NLRP3 inflammasome complex assemblyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
innate immune responseNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of fat cell differentiationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of fatty acid biosynthetic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of meiotic nuclear divisionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of striated muscle tissue developmentNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of DNA-templated transcriptionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cell divisionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
meiotic cell cycleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of cell cycleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
response to redox stateNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of cell divisionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of attachment of spindle microtubules to kinetochoreNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to caloric restrictionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of oligodendrocyte progenitor proliferationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to hypoxiaNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to epinephrine stimulusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
tubulin deacetylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of execution phase of apoptosisNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of oocyte maturationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of NLRP3 inflammasome complex assemblyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of satellite cell differentiationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
single strand break repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
rDNA heterochromatin formationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
pyrimidine dimer repair by nucleotide-excision repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA synthesis involved in DNA repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
angiogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
ovulation from ovarian follicleNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
intracellular glucose homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of protein phosphorylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of endothelial cell proliferationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of adaptive immune responseNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
chromatin organizationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA methylation-dependent heterochromatin formationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein deacetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
triglyceride mobilizationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA damage responseNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to oxidative stressNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
spermatogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of mitotic cell cycleNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
muscle organ developmentNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cell population proliferationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to starvationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of gene expressionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of centrosome duplicationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of triglyceride biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cholesterol effluxNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of lipid storageNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of glucose metabolic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of macroautophagyNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein ubiquitinationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
peptidyl-lysine acetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
macrophage differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of prostaglandin biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
heterochromatin formationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein destabilizationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of TOR signalingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of endodeoxyribonuclease activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to insulinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
circadian regulation of gene expressionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
leptin-mediated signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of smooth muscle cell apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
intracellular triglyceride homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of peroxisome proliferator activated receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of cell population proliferationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to glucose starvationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of phosphorylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to hydrogen peroxideNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
behavioral response to starvationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cholesterol homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of DNA-binding transcription factor activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of neuron apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to leptinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of MHC class II biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of fat cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of gluconeogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of DNA repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of angiogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cell cycleNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of DNA-templated transcriptionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of transcription by glucoseNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of insulin receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
white fat cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of helicase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of smooth muscle cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
maintenance of nucleus locationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
fatty acid homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of androgen receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of macrophage cytokine productionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to hydrogen peroxideNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of bile acid biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
UV-damage excision repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to tumor necrosis factorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to hypoxiaNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to ionizing radiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of protein serine/threonine kinase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of brown fat cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
stress-induced premature senescenceNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
energy homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein depropionylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA repair-dependent chromatin remodelingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of cellular response to heatNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of signal transduction by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of protein acetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of adipose tissue developmentNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to leukemia inhibitory factorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of macrophage apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cAMP-dependent protein kinase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cAMP-dependent protein kinase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cellular response to testosterone stimulusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of peptidyl-lysine acetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cellular senescenceNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cellular senescenceNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of double-strand break repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
defense responseP2Y purinoceptor 11Homo sapiens (human)
G protein-coupled receptor signaling pathwayP2Y purinoceptor 11Homo sapiens (human)
activation of adenylate cyclase activityP2Y purinoceptor 11Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayP2Y purinoceptor 11Homo sapiens (human)
calcium-mediated signalingP2Y purinoceptor 11Homo sapiens (human)
neuronal signal transductionP2Y purinoceptor 11Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayP2Y purinoceptor 11Homo sapiens (human)
cellular response to ATPP2Y purinoceptor 11Homo sapiens (human)
MAPK cascadeP2X purinoceptor 7Homo sapiens (human)
cell morphogenesisP2X purinoceptor 7Homo sapiens (human)
phagolysosome assemblyP2X purinoceptor 7Homo sapiens (human)
T cell mediated cytotoxicityP2X purinoceptor 7Homo sapiens (human)
positive regulation of T cell mediated cytotoxicityP2X purinoceptor 7Homo sapiens (human)
positive regulation of protein phosphorylationP2X purinoceptor 7Homo sapiens (human)
regulation of sodium ion transportP2X purinoceptor 7Homo sapiens (human)
response to ischemiaP2X purinoceptor 7Homo sapiens (human)
membrane protein ectodomain proteolysisP2X purinoceptor 7Homo sapiens (human)
phospholipid transfer to membraneP2X purinoceptor 7Homo sapiens (human)
vesicle budding from membraneP2X purinoceptor 7Homo sapiens (human)
inflammatory responseP2X purinoceptor 7Homo sapiens (human)
mitochondrion organizationP2X purinoceptor 7Homo sapiens (human)
cell surface receptor signaling pathwayP2X purinoceptor 7Homo sapiens (human)
protein secretionP2X purinoceptor 7Homo sapiens (human)
response to xenobiotic stimulusP2X purinoceptor 7Homo sapiens (human)
response to mechanical stimulusP2X purinoceptor 7Homo sapiens (human)
response to zinc ionP2X purinoceptor 7Homo sapiens (human)
positive regulation of calcium ion transport into cytosolP2X purinoceptor 7Homo sapiens (human)
positive regulation of gene expressionP2X purinoceptor 7Homo sapiens (human)
glutamate secretionP2X purinoceptor 7Homo sapiens (human)
positive regulation of glutamate secretionP2X purinoceptor 7Homo sapiens (human)
gamma-aminobutyric acid secretionP2X purinoceptor 7Homo sapiens (human)
positive regulation of gamma-aminobutyric acid secretionP2X purinoceptor 7Homo sapiens (human)
synaptic vesicle exocytosisP2X purinoceptor 7Homo sapiens (human)
protein processingP2X purinoceptor 7Homo sapiens (human)
plasma membrane phospholipid scramblingP2X purinoceptor 7Homo sapiens (human)
sensory perception of painP2X purinoceptor 7Homo sapiens (human)
calcium-mediated signalingP2X purinoceptor 7Homo sapiens (human)
protein catabolic processP2X purinoceptor 7Homo sapiens (human)
positive regulation of bone mineralizationP2X purinoceptor 7Homo sapiens (human)
bleb assemblyP2X purinoceptor 7Homo sapiens (human)
positive regulation of prostaglandin secretionP2X purinoceptor 7Homo sapiens (human)
prostaglandin secretionP2X purinoceptor 7Homo sapiens (human)
response to lipopolysaccharideP2X purinoceptor 7Homo sapiens (human)
positive regulation of interleukin-1 alpha productionP2X purinoceptor 7Homo sapiens (human)
positive regulation of interleukin-1 beta productionP2X purinoceptor 7Homo sapiens (human)
positive regulation of interleukin-6 productionP2X purinoceptor 7Homo sapiens (human)
collagen metabolic processP2X purinoceptor 7Homo sapiens (human)
response to ATPP2X purinoceptor 7Homo sapiens (human)
response to fluid shear stressP2X purinoceptor 7Homo sapiens (human)
positive regulation of monoatomic ion transmembrane transportP2X purinoceptor 7Homo sapiens (human)
purinergic nucleotide receptor signaling pathwayP2X purinoceptor 7Homo sapiens (human)
T cell proliferationP2X purinoceptor 7Homo sapiens (human)
T cell homeostasisP2X purinoceptor 7Homo sapiens (human)
NAD transportP2X purinoceptor 7Homo sapiens (human)
negative regulation of MAPK cascadeP2X purinoceptor 7Homo sapiens (human)
positive regulation of MAPK cascadeP2X purinoceptor 7Homo sapiens (human)
negative regulation of bone resorptionP2X purinoceptor 7Homo sapiens (human)
negative regulation of cell volumeP2X purinoceptor 7Homo sapiens (human)
positive regulation of glycolytic processP2X purinoceptor 7Homo sapiens (human)
ceramide biosynthetic processP2X purinoceptor 7Homo sapiens (human)
pore complex assemblyP2X purinoceptor 7Homo sapiens (human)
skeletal system morphogenesisP2X purinoceptor 7Homo sapiens (human)
homeostasis of number of cells within a tissueP2X purinoceptor 7Homo sapiens (human)
positive regulation of protein secretionP2X purinoceptor 7Homo sapiens (human)
defense response to Gram-positive bacteriumP2X purinoceptor 7Homo sapiens (human)
release of sequestered calcium ion into cytosolP2X purinoceptor 7Homo sapiens (human)
positive regulation of cytoskeleton organizationP2X purinoceptor 7Homo sapiens (human)
response to calcium ionP2X purinoceptor 7Homo sapiens (human)
response to electrical stimulusP2X purinoceptor 7Homo sapiens (human)
mitochondrial depolarizationP2X purinoceptor 7Homo sapiens (human)
membrane depolarizationP2X purinoceptor 7Homo sapiens (human)
positive regulation of mitochondrial depolarizationP2X purinoceptor 7Homo sapiens (human)
excitatory postsynaptic potentialP2X purinoceptor 7Homo sapiens (human)
positive regulation of macrophage cytokine productionP2X purinoceptor 7Homo sapiens (human)
T cell apoptotic processP2X purinoceptor 7Homo sapiens (human)
positive regulation of T cell apoptotic processP2X purinoceptor 7Homo sapiens (human)
cellular response to ATPP2X purinoceptor 7Homo sapiens (human)
cellular response to dsRNAP2X purinoceptor 7Homo sapiens (human)
reactive oxygen species metabolic processP2X purinoceptor 7Homo sapiens (human)
apoptotic signaling pathwayP2X purinoceptor 7Homo sapiens (human)
extrinsic apoptotic signaling pathwayP2X purinoceptor 7Homo sapiens (human)
positive regulation of bleb assemblyP2X purinoceptor 7Homo sapiens (human)
calcium ion transmembrane transportP2X purinoceptor 7Homo sapiens (human)
in utero embryonic developmentProtein arginine N-methyltransferase 1Homo sapiens (human)
protein methylationProtein arginine N-methyltransferase 1Homo sapiens (human)
DNA damage responseProtein arginine N-methyltransferase 1Homo sapiens (human)
cell surface receptor signaling pathwayProtein arginine N-methyltransferase 1Homo sapiens (human)
positive regulation of cell population proliferationProtein arginine N-methyltransferase 1Homo sapiens (human)
RNA splicingProtein arginine N-methyltransferase 1Homo sapiens (human)
peptidyl-arginine methylationProtein arginine N-methyltransferase 1Homo sapiens (human)
viral protein processingProtein arginine N-methyltransferase 1Homo sapiens (human)
regulation of BMP signaling pathwayProtein arginine N-methyltransferase 1Homo sapiens (human)
neuron projection developmentProtein arginine N-methyltransferase 1Homo sapiens (human)
positive regulation of erythrocyte differentiationProtein arginine N-methyltransferase 1Homo sapiens (human)
regulation of megakaryocyte differentiationProtein arginine N-methyltransferase 1Homo sapiens (human)
negative regulation of megakaryocyte differentiationProtein arginine N-methyltransferase 1Homo sapiens (human)
positive regulation of translationProtein arginine N-methyltransferase 1Homo sapiens (human)
negative regulation of JNK cascadeProtein arginine N-methyltransferase 1Homo sapiens (human)
positive regulation of hemoglobin biosynthetic processProtein arginine N-methyltransferase 1Homo sapiens (human)
cardiac muscle tissue developmentProtein arginine N-methyltransferase 1Homo sapiens (human)
protein homooligomerizationProtein arginine N-methyltransferase 1Homo sapiens (human)
cellular response to methionineProtein arginine N-methyltransferase 1Homo sapiens (human)
positive regulation of p38MAPK cascadeProtein arginine N-methyltransferase 1Homo sapiens (human)
positive regulation of TORC1 signalingProtein arginine N-methyltransferase 1Homo sapiens (human)
positive regulation of double-strand break repair via homologous recombinationProtein arginine N-methyltransferase 1Homo sapiens (human)
chromatin remodelingProtein arginine N-methyltransferase 1Homo sapiens (human)
peptidyl-arginine methylation, to asymmetrical-dimethyl arginineProtein arginine N-methyltransferase 1Homo sapiens (human)
protein deacetylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein deacetylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrion organizationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
regulation of ketone biosynthetic processNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
negative regulation of cardiac muscle cell apoptotic processNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
response to nutrient levelsNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein demalonylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
peptidyl-lysine demalonylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein desuccinylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
peptidyl-lysine desuccinylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein deglutarylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
negative regulation of reactive oxygen species metabolic processNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
epigenetic regulation of gene expressionNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (144)

Processvia Protein(s)Taxonomy
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
protein bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activitySerine/threonine-protein kinase D3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase D3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase D3Homo sapiens (human)
kinase activitySerine/threonine-protein kinase D3Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase D3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase D3Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase D3Homo sapiens (human)
protein kinase activityProtein kinase C gamma typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C gamma typeHomo sapiens (human)
calcium,diacylglycerol-dependent serine/threonine kinase activityProtein kinase C gamma typeHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityProtein kinase C gamma typeHomo sapiens (human)
protein bindingProtein kinase C gamma typeHomo sapiens (human)
ATP bindingProtein kinase C gamma typeHomo sapiens (human)
zinc ion bindingProtein kinase C gamma typeHomo sapiens (human)
protein serine kinase activityProtein kinase C gamma typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C gamma typeHomo sapiens (human)
chromatin bindingProtein kinase C beta typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C beta typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C beta typeHomo sapiens (human)
protein kinase C bindingProtein kinase C beta typeHomo sapiens (human)
calcium channel regulator activityProtein kinase C beta typeHomo sapiens (human)
protein bindingProtein kinase C beta typeHomo sapiens (human)
ATP bindingProtein kinase C beta typeHomo sapiens (human)
zinc ion bindingProtein kinase C beta typeHomo sapiens (human)
nuclear receptor coactivator activityProtein kinase C beta typeHomo sapiens (human)
histone H3T6 kinase activityProtein kinase C beta typeHomo sapiens (human)
histone bindingProtein kinase C beta typeHomo sapiens (human)
nuclear androgen receptor bindingProtein kinase C beta typeHomo sapiens (human)
protein serine kinase activityProtein kinase C beta typeHomo sapiens (human)
cysteine-type endopeptidase activityCathepsin BHomo sapiens (human)
protein bindingCathepsin BHomo sapiens (human)
collagen bindingCathepsin BHomo sapiens (human)
peptidase activityCathepsin BHomo sapiens (human)
cysteine-type peptidase activityCathepsin BHomo sapiens (human)
proteoglycan bindingCathepsin BHomo sapiens (human)
protein kinase activityProtein kinase C alpha typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C alpha typeHomo sapiens (human)
calcium,diacylglycerol-dependent serine/threonine kinase activityProtein kinase C alpha typeHomo sapiens (human)
integrin bindingProtein kinase C alpha typeHomo sapiens (human)
protein bindingProtein kinase C alpha typeHomo sapiens (human)
ATP bindingProtein kinase C alpha typeHomo sapiens (human)
zinc ion bindingProtein kinase C alpha typeHomo sapiens (human)
enzyme bindingProtein kinase C alpha typeHomo sapiens (human)
histone H3T6 kinase activityProtein kinase C alpha typeHomo sapiens (human)
protein serine kinase activityProtein kinase C alpha typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C alpha typeHomo sapiens (human)
diacylglycerol bindingProtein kinase C alpha typeHomo sapiens (human)
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase activityProtein kinase C eta typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C eta typeHomo sapiens (human)
diacylglycerol-dependent, calcium-independent serine/threonine kinase activityProtein kinase C eta typeHomo sapiens (human)
protein bindingProtein kinase C eta typeHomo sapiens (human)
ATP bindingProtein kinase C eta typeHomo sapiens (human)
enzyme bindingProtein kinase C eta typeHomo sapiens (human)
small GTPase bindingProtein kinase C eta typeHomo sapiens (human)
metal ion bindingProtein kinase C eta typeHomo sapiens (human)
protein serine kinase activityProtein kinase C eta typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C eta typeHomo sapiens (human)
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityDelta-type opioid receptorHomo sapiens (human)
protein bindingDelta-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled enkephalin receptor activityDelta-type opioid receptorHomo sapiens (human)
neuropeptide bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
protein bindingP2Y purinoceptor 2Homo sapiens (human)
signaling receptor activityP2Y purinoceptor 2Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityP2Y purinoceptor 2Homo sapiens (human)
A1 adenosine receptor bindingP2Y purinoceptor 2Homo sapiens (human)
G protein-coupled UTP receptor activityP2Y purinoceptor 2Homo sapiens (human)
protein kinase activityProtein kinase C iota typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C iota typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C iota typeHomo sapiens (human)
protein bindingProtein kinase C iota typeHomo sapiens (human)
ATP bindingProtein kinase C iota typeHomo sapiens (human)
phospholipid bindingProtein kinase C iota typeHomo sapiens (human)
metal ion bindingProtein kinase C iota typeHomo sapiens (human)
protein serine kinase activityProtein kinase C iota typeHomo sapiens (human)
protein bindingP2Y purinoceptor 4Homo sapiens (human)
ATP bindingP2Y purinoceptor 4Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityP2Y purinoceptor 4Homo sapiens (human)
G protein-coupled UTP receptor activityP2Y purinoceptor 4Homo sapiens (human)
purinergic nucleotide receptor activityP2X purinoceptor 3Homo sapiens (human)
extracellularly ATP-gated monoatomic cation channel activityP2X purinoceptor 3Homo sapiens (human)
ATP bindingP2X purinoceptor 3Homo sapiens (human)
double-stranded DNA bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
RNA bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein serine/threonine kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
DNA-dependent protein kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
ATP bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
enzyme bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein domain specific bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
U3 snoRNA bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
histone H2AXS139 kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein serine kinase activityDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
actin monomer bindingProtein kinase C epsilon typeHomo sapiens (human)
protein kinase activityProtein kinase C epsilon typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C epsilon typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C epsilon typeHomo sapiens (human)
diacylglycerol-dependent, calcium-independent serine/threonine kinase activityProtein kinase C epsilon typeHomo sapiens (human)
protein bindingProtein kinase C epsilon typeHomo sapiens (human)
ATP bindingProtein kinase C epsilon typeHomo sapiens (human)
enzyme activator activityProtein kinase C epsilon typeHomo sapiens (human)
enzyme bindingProtein kinase C epsilon typeHomo sapiens (human)
signaling receptor activator activityProtein kinase C epsilon typeHomo sapiens (human)
ethanol bindingProtein kinase C epsilon typeHomo sapiens (human)
metal ion bindingProtein kinase C epsilon typeHomo sapiens (human)
14-3-3 protein bindingProtein kinase C epsilon typeHomo sapiens (human)
protein serine kinase activityProtein kinase C epsilon typeHomo sapiens (human)
protein kinase activityProtein kinase C theta typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C theta typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C theta typeHomo sapiens (human)
protein bindingProtein kinase C theta typeHomo sapiens (human)
ATP bindingProtein kinase C theta typeHomo sapiens (human)
metal ion bindingProtein kinase C theta typeHomo sapiens (human)
protein serine kinase activityProtein kinase C theta typeHomo sapiens (human)
protein kinase activityProtein kinase C zeta typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C zeta typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C zeta typeHomo sapiens (human)
protein bindingProtein kinase C zeta typeHomo sapiens (human)
ATP bindingProtein kinase C zeta typeHomo sapiens (human)
potassium channel regulator activityProtein kinase C zeta typeHomo sapiens (human)
protein kinase bindingProtein kinase C zeta typeHomo sapiens (human)
phospholipase bindingProtein kinase C zeta typeHomo sapiens (human)
insulin receptor substrate bindingProtein kinase C zeta typeHomo sapiens (human)
protein-containing complex bindingProtein kinase C zeta typeHomo sapiens (human)
metal ion bindingProtein kinase C zeta typeHomo sapiens (human)
14-3-3 protein bindingProtein kinase C zeta typeHomo sapiens (human)
protein serine kinase activityProtein kinase C zeta typeHomo sapiens (human)
protein kinase activityProtein kinase C delta typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C delta typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C delta typeHomo sapiens (human)
diacylglycerol-dependent, calcium-independent serine/threonine kinase activityProtein kinase C delta typeHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityProtein kinase C delta typeHomo sapiens (human)
protein bindingProtein kinase C delta typeHomo sapiens (human)
ATP bindingProtein kinase C delta typeHomo sapiens (human)
enzyme activator activityProtein kinase C delta typeHomo sapiens (human)
enzyme bindingProtein kinase C delta typeHomo sapiens (human)
protein kinase bindingProtein kinase C delta typeHomo sapiens (human)
insulin receptor substrate bindingProtein kinase C delta typeHomo sapiens (human)
metal ion bindingProtein kinase C delta typeHomo sapiens (human)
protein serine kinase activityProtein kinase C delta typeHomo sapiens (human)
G protein-coupled ADP receptor activityP2Y purinoceptor 6Homo sapiens (human)
G protein-coupled receptor activityP2Y purinoceptor 6Homo sapiens (human)
protein bindingP2Y purinoceptor 6Homo sapiens (human)
G protein-coupled UDP receptor activityP2Y purinoceptor 6Homo sapiens (human)
G protein-coupled UTP receptor activityP2Y purinoceptor 6Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase D1Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activitySerine/threonine-protein kinase D1Homo sapiens (human)
protein kinase C bindingSerine/threonine-protein kinase D1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase D1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase D1Homo sapiens (human)
kinase activitySerine/threonine-protein kinase D1Homo sapiens (human)
heat shock protein bindingSerine/threonine-protein kinase D1Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase D1Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase D1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase D1Homo sapiens (human)
phosphatidylinositol 3-kinase activator activitySerine/threonine-protein kinase D1Homo sapiens (human)
protein tyrosine phosphatase activityDual specificity protein phosphatase 5Homo sapiens (human)
protein bindingDual specificity protein phosphatase 5Homo sapiens (human)
protein tyrosine/serine/threonine phosphatase activityDual specificity protein phosphatase 5Homo sapiens (human)
phosphatase activityDual specificity protein phosphatase 5Homo sapiens (human)
myosin phosphatase activityDual specificity protein phosphatase 5Homo sapiens (human)
MAP kinase tyrosine phosphatase activityDual specificity protein phosphatase 5Homo sapiens (human)
protein tyrosine/threonine phosphatase activityDual specificity protein phosphatase 5Homo sapiens (human)
MAP kinase tyrosine/serine/threonine phosphatase activityDual specificity protein phosphatase 5Homo sapiens (human)
apyrase activityEctonucleoside triphosphate diphosphohydrolase 8Homo sapiens (human)
ATP bindingEctonucleoside triphosphate diphosphohydrolase 8Homo sapiens (human)
metal ion bindingEctonucleoside triphosphate diphosphohydrolase 8Homo sapiens (human)
UDP phosphatase activityEctonucleoside triphosphate diphosphohydrolase 8Homo sapiens (human)
ribonucleoside triphosphate phosphatase activityEctonucleoside triphosphate diphosphohydrolase 8Homo sapiens (human)
GDP phosphatase activityEctonucleoside triphosphate diphosphohydrolase 8Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
chromatin bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
histone deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
protein bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
zinc ion bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent histone deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
histone acetyltransferase bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
histone deacetylase bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
tubulin deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
ubiquitin bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent histone H4K16 deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD+ bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
DNA-binding transcription factor bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent protein demyristoylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent protein depalmitoylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
transcription factor bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
p53 bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
transcription coactivator activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
transcription corepressor activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear receptor bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
enzyme bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone H3K14 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
identical protein bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
HLH domain bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
bHLH transcription factor bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
metal ion bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone H3K9 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone H4K16 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
mitogen-activated protein kinase bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
lysine-acetylated histone bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein-propionyllysine depropionylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA-binding transcription factor bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone H4K12 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone H3K deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone decrotonylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
keratin filament bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
promoter-specific chromatin bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD+ bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
neurotransmitter receptor activityP2Y purinoceptor 11Homo sapiens (human)
signaling receptor activityP2Y purinoceptor 11Homo sapiens (human)
G protein-coupled ATP receptor activityP2Y purinoceptor 11Homo sapiens (human)
lipopolysaccharide bindingP2X purinoceptor 7Homo sapiens (human)
purinergic nucleotide receptor activityP2X purinoceptor 7Homo sapiens (human)
extracellularly ATP-gated monoatomic cation channel activityP2X purinoceptor 7Homo sapiens (human)
signaling receptor bindingP2X purinoceptor 7Homo sapiens (human)
protein bindingP2X purinoceptor 7Homo sapiens (human)
ATP bindingP2X purinoceptor 7Homo sapiens (human)
identical protein bindingP2X purinoceptor 7Homo sapiens (human)
RNA bindingProtein arginine N-methyltransferase 1Homo sapiens (human)
protein bindingProtein arginine N-methyltransferase 1Homo sapiens (human)
methyltransferase activityProtein arginine N-methyltransferase 1Homo sapiens (human)
N-methyltransferase activityProtein arginine N-methyltransferase 1Homo sapiens (human)
protein methyltransferase activityProtein arginine N-methyltransferase 1Homo sapiens (human)
methyl-CpG bindingProtein arginine N-methyltransferase 1Homo sapiens (human)
protein-arginine N-methyltransferase activityProtein arginine N-methyltransferase 1Homo sapiens (human)
enzyme bindingProtein arginine N-methyltransferase 1Homo sapiens (human)
protein-arginine omega-N monomethyltransferase activityProtein arginine N-methyltransferase 1Homo sapiens (human)
protein-arginine omega-N asymmetric methyltransferase activityProtein arginine N-methyltransferase 1Homo sapiens (human)
histone methyltransferase activityProtein arginine N-methyltransferase 1Homo sapiens (human)
identical protein bindingProtein arginine N-methyltransferase 1Homo sapiens (human)
histone H4R3 methyltransferase activityProtein arginine N-methyltransferase 1Homo sapiens (human)
mitogen-activated protein kinase p38 bindingProtein arginine N-methyltransferase 1Homo sapiens (human)
GATOR1 complex bindingProtein arginine N-methyltransferase 1Homo sapiens (human)
S-adenosyl-L-methionine bindingProtein arginine N-methyltransferase 1Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
zinc ion bindingNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
NAD-dependent protein lysine deacetylase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein-malonyllysine demalonylase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein-succinyllysine desuccinylase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein-glutaryllysine deglutarylase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
NAD+ bindingNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (133)

Processvia Protein(s)Taxonomy
nucleoplasmNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
transcription regulator complexNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear bodyNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intermediate filament cytoskeletonNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
chromatinNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nucleusNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase D3Homo sapiens (human)
cytosolSerine/threonine-protein kinase D3Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase D3Homo sapiens (human)
cytosolSerine/threonine-protein kinase D3Homo sapiens (human)
nucleusProtein kinase C gamma typeHomo sapiens (human)
cytosolProtein kinase C gamma typeHomo sapiens (human)
plasma membraneProtein kinase C gamma typeHomo sapiens (human)
cell-cell junctionProtein kinase C gamma typeHomo sapiens (human)
postsynaptic densityProtein kinase C gamma typeHomo sapiens (human)
dendriteProtein kinase C gamma typeHomo sapiens (human)
calyx of HeldProtein kinase C gamma typeHomo sapiens (human)
perinuclear region of cytoplasmProtein kinase C gamma typeHomo sapiens (human)
synaptic membraneProtein kinase C gamma typeHomo sapiens (human)
presynaptic cytosolProtein kinase C gamma typeHomo sapiens (human)
postsynaptic cytosolProtein kinase C gamma typeHomo sapiens (human)
nucleusProtein kinase C beta typeHomo sapiens (human)
nucleoplasmProtein kinase C beta typeHomo sapiens (human)
cytoplasmProtein kinase C beta typeHomo sapiens (human)
centrosomeProtein kinase C beta typeHomo sapiens (human)
cytosolProtein kinase C beta typeHomo sapiens (human)
plasma membraneProtein kinase C beta typeHomo sapiens (human)
brush border membraneProtein kinase C beta typeHomo sapiens (human)
calyx of HeldProtein kinase C beta typeHomo sapiens (human)
extracellular exosomeProtein kinase C beta typeHomo sapiens (human)
presynaptic cytosolProtein kinase C beta typeHomo sapiens (human)
spectrinProtein kinase C beta typeHomo sapiens (human)
collagen-containing extracellular matrixCathepsin BHomo sapiens (human)
extracellular regionCathepsin BHomo sapiens (human)
extracellular spaceCathepsin BHomo sapiens (human)
lysosomeCathepsin BHomo sapiens (human)
external side of plasma membraneCathepsin BHomo sapiens (human)
apical plasma membraneCathepsin BHomo sapiens (human)
endolysosome lumenCathepsin BHomo sapiens (human)
melanosomeCathepsin BHomo sapiens (human)
perinuclear region of cytoplasmCathepsin BHomo sapiens (human)
collagen-containing extracellular matrixCathepsin BHomo sapiens (human)
extracellular exosomeCathepsin BHomo sapiens (human)
peptidase inhibitor complexCathepsin BHomo sapiens (human)
ficolin-1-rich granule lumenCathepsin BHomo sapiens (human)
extracellular spaceCathepsin BHomo sapiens (human)
lysosomeCathepsin BHomo sapiens (human)
ciliary basal bodyProtein kinase C alpha typeHomo sapiens (human)
nucleoplasmProtein kinase C alpha typeHomo sapiens (human)
cytoplasmProtein kinase C alpha typeHomo sapiens (human)
mitochondrionProtein kinase C alpha typeHomo sapiens (human)
endoplasmic reticulumProtein kinase C alpha typeHomo sapiens (human)
cytosolProtein kinase C alpha typeHomo sapiens (human)
plasma membraneProtein kinase C alpha typeHomo sapiens (human)
mitochondrial membraneProtein kinase C alpha typeHomo sapiens (human)
perinuclear region of cytoplasmProtein kinase C alpha typeHomo sapiens (human)
extracellular exosomeProtein kinase C alpha typeHomo sapiens (human)
alphav-beta3 integrin-PKCalpha complexProtein kinase C alpha typeHomo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmProtein kinase C eta typeHomo sapiens (human)
cytosolProtein kinase C eta typeHomo sapiens (human)
plasma membraneProtein kinase C eta typeHomo sapiens (human)
cell-cell junctionProtein kinase C eta typeHomo sapiens (human)
extracellular exosomeProtein kinase C eta typeHomo sapiens (human)
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneDelta-type opioid receptorHomo sapiens (human)
dendrite membraneDelta-type opioid receptorHomo sapiens (human)
presynaptic membraneDelta-type opioid receptorHomo sapiens (human)
axon terminusDelta-type opioid receptorHomo sapiens (human)
spine apparatusDelta-type opioid receptorHomo sapiens (human)
postsynaptic density membraneDelta-type opioid receptorHomo sapiens (human)
neuronal dense core vesicleDelta-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
neuron projectionDelta-type opioid receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
plasma membraneP2Y purinoceptor 2Homo sapiens (human)
plasma membraneP2Y purinoceptor 2Homo sapiens (human)
Golgi membraneProtein kinase C iota typeHomo sapiens (human)
nucleusProtein kinase C iota typeHomo sapiens (human)
nucleoplasmProtein kinase C iota typeHomo sapiens (human)
endosomeProtein kinase C iota typeHomo sapiens (human)
cytosolProtein kinase C iota typeHomo sapiens (human)
plasma membraneProtein kinase C iota typeHomo sapiens (human)
brush borderProtein kinase C iota typeHomo sapiens (human)
bicellular tight junctionProtein kinase C iota typeHomo sapiens (human)
microtubule cytoskeletonProtein kinase C iota typeHomo sapiens (human)
apical plasma membraneProtein kinase C iota typeHomo sapiens (human)
cell leading edgeProtein kinase C iota typeHomo sapiens (human)
Schmidt-Lanterman incisureProtein kinase C iota typeHomo sapiens (human)
intercellular bridgeProtein kinase C iota typeHomo sapiens (human)
extracellular exosomeProtein kinase C iota typeHomo sapiens (human)
tight junctionProtein kinase C iota typeHomo sapiens (human)
Schaffer collateral - CA1 synapseProtein kinase C iota typeHomo sapiens (human)
glutamatergic synapseProtein kinase C iota typeHomo sapiens (human)
PAR polarity complexProtein kinase C iota typeHomo sapiens (human)
plasma membraneP2Y purinoceptor 4Homo sapiens (human)
basolateral plasma membraneP2Y purinoceptor 4Homo sapiens (human)
apical plasma membraneP2Y purinoceptor 4Homo sapiens (human)
presynaptic active zone membraneP2Y purinoceptor 4Homo sapiens (human)
glutamatergic synapseP2Y purinoceptor 4Homo sapiens (human)
plasma membraneP2Y purinoceptor 4Homo sapiens (human)
plasma membraneP2X purinoceptor 3Homo sapiens (human)
axonP2X purinoceptor 3Homo sapiens (human)
Schaffer collateral - CA1 synapseP2X purinoceptor 3Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseP2X purinoceptor 3Homo sapiens (human)
postsynapseP2X purinoceptor 3Homo sapiens (human)
receptor complexP2X purinoceptor 3Homo sapiens (human)
plasma membraneP2X purinoceptor 3Homo sapiens (human)
chromosome, telomeric regionDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nucleusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nucleoplasmDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nucleolusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
cytosolDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
membraneDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
DNA-dependent protein kinase complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
chromatinDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
transcription regulator complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
DNA-dependent protein kinase-DNA ligase 4 complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
small-subunit processomeDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein-containing complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
protein-DNA complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nonhomologous end joining complexDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
nucleusDNA-dependent protein kinase catalytic subunitHomo sapiens (human)
Golgi apparatusProtein kinase C epsilon typeHomo sapiens (human)
nucleusProtein kinase C epsilon typeHomo sapiens (human)
cytoplasmProtein kinase C epsilon typeHomo sapiens (human)
mitochondrionProtein kinase C epsilon typeHomo sapiens (human)
endoplasmic reticulumProtein kinase C epsilon typeHomo sapiens (human)
cytosolProtein kinase C epsilon typeHomo sapiens (human)
plasma membraneProtein kinase C epsilon typeHomo sapiens (human)
intracellular membrane-bounded organelleProtein kinase C epsilon typeHomo sapiens (human)
intermediate filament cytoskeletonProtein kinase C epsilon typeHomo sapiens (human)
synapseProtein kinase C epsilon typeHomo sapiens (human)
perinuclear region of cytoplasmProtein kinase C epsilon typeHomo sapiens (human)
cell peripheryProtein kinase C epsilon typeHomo sapiens (human)
immunological synapseProtein kinase C theta typeHomo sapiens (human)
cytosolProtein kinase C theta typeHomo sapiens (human)
plasma membraneProtein kinase C theta typeHomo sapiens (human)
aggresomeProtein kinase C theta typeHomo sapiens (human)
centriolar satelliteProtein kinase C theta typeHomo sapiens (human)
stress fiberProtein kinase C zeta typeHomo sapiens (human)
nuclear envelopeProtein kinase C zeta typeHomo sapiens (human)
cytoplasmProtein kinase C zeta typeHomo sapiens (human)
endosomeProtein kinase C zeta typeHomo sapiens (human)
microtubule organizing centerProtein kinase C zeta typeHomo sapiens (human)
cytosolProtein kinase C zeta typeHomo sapiens (human)
plasma membraneProtein kinase C zeta typeHomo sapiens (human)
cell-cell junctionProtein kinase C zeta typeHomo sapiens (human)
bicellular tight junctionProtein kinase C zeta typeHomo sapiens (human)
postsynaptic densityProtein kinase C zeta typeHomo sapiens (human)
membraneProtein kinase C zeta typeHomo sapiens (human)
apical plasma membraneProtein kinase C zeta typeHomo sapiens (human)
nuclear matrixProtein kinase C zeta typeHomo sapiens (human)
cell junctionProtein kinase C zeta typeHomo sapiens (human)
cell leading edgeProtein kinase C zeta typeHomo sapiens (human)
vesicleProtein kinase C zeta typeHomo sapiens (human)
myelin sheath abaxonal regionProtein kinase C zeta typeHomo sapiens (human)
axon hillockProtein kinase C zeta typeHomo sapiens (human)
apical cortexProtein kinase C zeta typeHomo sapiens (human)
perinuclear region of cytoplasmProtein kinase C zeta typeHomo sapiens (human)
extracellular exosomeProtein kinase C zeta typeHomo sapiens (human)
tight junctionProtein kinase C zeta typeHomo sapiens (human)
Schaffer collateral - CA1 synapseProtein kinase C zeta typeHomo sapiens (human)
glutamatergic synapseProtein kinase C zeta typeHomo sapiens (human)
PAR polarity complexProtein kinase C zeta typeHomo sapiens (human)
extracellular regionProtein kinase C delta typeHomo sapiens (human)
nucleusProtein kinase C delta typeHomo sapiens (human)
nucleoplasmProtein kinase C delta typeHomo sapiens (human)
cytoplasmProtein kinase C delta typeHomo sapiens (human)
mitochondrionProtein kinase C delta typeHomo sapiens (human)
endoplasmic reticulumProtein kinase C delta typeHomo sapiens (human)
cytosolProtein kinase C delta typeHomo sapiens (human)
plasma membraneProtein kinase C delta typeHomo sapiens (human)
cell-cell junctionProtein kinase C delta typeHomo sapiens (human)
nuclear matrixProtein kinase C delta typeHomo sapiens (human)
azurophil granule lumenProtein kinase C delta typeHomo sapiens (human)
endolysosomeProtein kinase C delta typeHomo sapiens (human)
perinuclear region of cytoplasmProtein kinase C delta typeHomo sapiens (human)
extracellular exosomeProtein kinase C delta typeHomo sapiens (human)
plasma membraneP2Y purinoceptor 6Homo sapiens (human)
basolateral plasma membraneP2Y purinoceptor 6Homo sapiens (human)
apical plasma membraneP2Y purinoceptor 6Homo sapiens (human)
plasma membraneP2Y purinoceptor 6Homo sapiens (human)
autophagosome membraneSerine/threonine-protein kinase D1Homo sapiens (human)
nucleusSerine/threonine-protein kinase D1Homo sapiens (human)
trans-Golgi networkSerine/threonine-protein kinase D1Homo sapiens (human)
cytosolSerine/threonine-protein kinase D1Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase D1Homo sapiens (human)
cell-cell junctionSerine/threonine-protein kinase D1Homo sapiens (human)
cell cortexSerine/threonine-protein kinase D1Homo sapiens (human)
Z discSerine/threonine-protein kinase D1Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase D1Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase D1Homo sapiens (human)
cytosolSerine/threonine-protein kinase D1Homo sapiens (human)
nucleoplasmDual specificity protein phosphatase 5Homo sapiens (human)
cytoplasmDual specificity protein phosphatase 5Homo sapiens (human)
nucleusDual specificity protein phosphatase 5Homo sapiens (human)
plasma membraneEctonucleoside triphosphate diphosphohydrolase 8Homo sapiens (human)
plasma membraneEctonucleoside triphosphate diphosphohydrolase 8Homo sapiens (human)
chromosome, telomeric regionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
chromosomeNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
nucleolusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cytoplasmNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
mitochondrionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
centrosomeNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
centrioleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
spindleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cytosolNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
microtubuleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
plasma membraneNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
growth coneNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
midbodyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
paranodal junctionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
paranode region of axonNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
perikaryonNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
myelin sheathNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
lateral loopNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
Schmidt-Lanterman incisureNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
juxtaparanode region of axonNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
perinuclear region of cytoplasmNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
mitotic spindleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
meiotic spindleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
glial cell projectionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
heterochromatinNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
chromatin silencing complexNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
nucleolusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
ESC/E(Z) complexNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytosolNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
fibrillar centerNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear envelopeNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear inner membraneNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleolusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
mitochondrionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytosolNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
PML bodyNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
eNoSc complexNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
chromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
euchromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
heterochromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
chromatin silencing complexNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
rDNA heterochromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear inner membraneNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
plasma membraneP2Y purinoceptor 11Homo sapiens (human)
plasma membraneP2Y purinoceptor 11Homo sapiens (human)
cytoplasmP2X purinoceptor 7Homo sapiens (human)
mitochondrionP2X purinoceptor 7Homo sapiens (human)
plasma membraneP2X purinoceptor 7Homo sapiens (human)
cell-cell junctionP2X purinoceptor 7Homo sapiens (human)
external side of plasma membraneP2X purinoceptor 7Homo sapiens (human)
membraneP2X purinoceptor 7Homo sapiens (human)
neuromuscular junctionP2X purinoceptor 7Homo sapiens (human)
blebP2X purinoceptor 7Homo sapiens (human)
neuronal cell bodyP2X purinoceptor 7Homo sapiens (human)
presynapseP2X purinoceptor 7Homo sapiens (human)
postsynapseP2X purinoceptor 7Homo sapiens (human)
plasma membraneP2X purinoceptor 7Homo sapiens (human)
lysosomal membraneProtein arginine N-methyltransferase 1Homo sapiens (human)
nucleusProtein arginine N-methyltransferase 1Homo sapiens (human)
nucleoplasmProtein arginine N-methyltransferase 1Homo sapiens (human)
cytoplasmProtein arginine N-methyltransferase 1Homo sapiens (human)
cytosolProtein arginine N-methyltransferase 1Homo sapiens (human)
methylosomeProtein arginine N-methyltransferase 1Homo sapiens (human)
nucleusProtein arginine N-methyltransferase 1Homo sapiens (human)
nucleusNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrionNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrial intermembrane spaceNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrial matrixNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
cytosolNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrial matrixNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (363)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID86726Concentration required to inhibit binding of envelope protein to immobilized heparin in the competition plate assay by 50%2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
Probing the interaction of dengue virus envelope protein with heparin: assessment of glycosaminoglycan-derived inhibitors.
AID378966Antitrypanosomal activity against Trypanosoma brucei brucei MITat 1.2 variant 221 after 72 hrs2006Journal of natural products, Jan, Volume: 69, Issue:1
Isoflavonoids and other compounds from Psorothamnus arborescens with antiprotozoal activities.
AID378968Cytotoxicity against human PC3 cells2006Journal of natural products, Jan, Volume: 69, Issue:1
Isoflavonoids and other compounds from Psorothamnus arborescens with antiprotozoal activities.
AID150321Evaluated for agonist activity against phospholipase C coupled recombinant human P2Y purinoceptor 2 (P2Y2)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID103503Effective concentration of compound necessary to kill 50% of infective larvae of Molinema dessetae after 7 days was determined in vitro; Value ranges from 100-5001987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
New antifilarial agents. 1. Epoxy sulfonamides and ethynesulfonamides.
AID290817Inhibition of Escherichia coli RecA by ADP-linked fluorescent ATPase assay2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Directed molecular screening for RecA ATPase inhibitors.
AID1194531Inhibition of human SIRT5 assessed as reduction in desuccinylase activity using KQTAR(SuK)STGGKA substrate2015Bioorganic & medicinal chemistry letters, Apr-15, Volume: 25, Issue:8
A FRET-based assay for screening SIRT5 specific modulators.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID640598Antitumor activity against mouse LL/2 cells allografted in Lewis mouse assessed as decrease in lung metastasis number at 4 mg/ml, ip administered daily 24 hrs post implantation (Rvb = 11.8 +/- 7.1 number)2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological evaluation of novel indolocarbazoles with anti-angiogenic activity.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1233554Selectivity index, ratio of IC50 against human WI38 cells to IC50 for Trypanosoma brucei brucei Lister 427 bloodstream forms2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID482885Inhibition of Trypanosoma brucei rhodesiense recombinant rhodesain at 100 uM2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID482889Inhibition of human liver cathepsin B2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID369799Biodistribution in perfused BALB/c mouse choroid plexus assessed as tritiated drug level after 2.5 mins in presence of DMSO relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.
AID712586Inhibition of human SIRT5 using H3K9 succinyl peptide substrate2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Inhibitors of the NAD(+)-Dependent Protein Desuccinylase and Demalonylase Sirt5.
AID1064827Inhibition of Trypanosoma brucei PFK-mediated ADP production using ATP/fructose-6-phosphate as substrate by luciferase based luminescence assay2014ACS medicinal chemistry letters, Jan-09, Volume: 5, Issue:1
Identification of ML251, a Potent Inhibitor of T. brucei and T. cruzi Phosphofructokinase.
AID699752Inhibition of SIRT52012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Substrates for efficient fluorometric screening employing the NAD-dependent sirtuin 5 lysine deacylase (KDAC) enzyme.
AID657108Inhibition of human SIRT1 using Fluor-de-Lys as substrate at 50 uM2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Novel acridinedione derivatives: design, synthesis, SIRT1 enzyme and tumor cell growth inhibition studies.
AID764203Cytotoxicity against human WI38 cells by MTT assay2013European journal of medicinal chemistry, Aug, Volume: 66Antiparasitic hybrids of Cinchona alkaloids and bile acids.
AID256356Percent inhibition of agonist-induced calcium mobilization at P2Y purinoceptor 1 recombinantly expressed in human HEK293 cells at 100 uM dose2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency.
AID1233458Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jul-15, Volume: 25, Issue:14
New indole-isoxazolone derivatives: Synthesis, characterisation and in vitro SIRT1 inhibition studies.
AID106635Cytotoxicity in macrophages; ND = Not determined2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Biological evaluation of substituted quinolines.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID39116Concentration required for 50% reduction in B16 tumor cell growth (Human colon) was measured; NA denotes not assayed2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Preliminary structure-antiangiogenic activity relationships of 4-senecioyloxymethyl-6,7-dimethoxycoumarin.
AID1193547Selectivity index, ratio of CC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB9002015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Synthesis of 3-azabicyclo[3.2.2]nonanes and their antiprotozoal activities.
AID540237Phospholipidosis-positive literature compound observed in rat
AID366266Inhibition of human NTPDase 8 expressed in COS7 cells2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Selective nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) inhibitors: nucleotide mimetics derived from uridine-5'-carboxamide.
AID673518Inhibition of Sirt1 expressed in human U2OS cells assessed as acetylation of p53 at 10 uM2012Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15
InCl3-catalysed synthesis of 2-aryl quinazolin-4(3H)-ones and 5-aryl pyrazolo[4,3-d]pyrimidin-7(6H)-ones and their evaluation as potential anticancer agents.
AID369792Biodistribution in perfused wild type FVB Mdr1a/Mdr1b positive mouse choroid plexus assessed as drug accumulation after 2.5 mins2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.
AID215357In vitro anti protozoal activity against Trypanosoma brucei strain S427 was determined2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Biological evaluation of substituted quinolines.
AID1163232Cytotoxicity against human MRC5 SV2 cells assessed as reduction in cell growth after 72 hrs2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID100425Inhibitory concentration against Leishmania donovani axenic amastigotes was determined in vitro; Not determined2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Synthesis and antitubulin activity of N1- and N4-substituted 3,5-dinitro sulfanilamides against African trypanosomes and Leishmania.
AID300660Growth inhibition against Leishmania donovani2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
Synthesis, biological evaluation, and molecular modeling of 3,5-substituted-N1-phenyl-N4,N4-di-n-butylsulfanilamides as antikinetoplastid antimicrotubule agents.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID165262Inhibition of Protein kinase C (PKC)2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Kinase inhibitors: not just for kinases anymore.
AID473009Inhibition of Plasmodium falciparum recombinant falcipain-2 using Cbz-Leu-Arg-AMC as substrate by standard fluorescence assay2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.
AID369773Biodistribution in BALB/c mouse choroid plexus assessed as tritiated drug level at 150 uM perfusion after 10 mins by capillary depletion assay in presence of DMSO2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.
AID84652Inhibitory activity against proliferation of HTLV-1 transformed cell lines (HUT-102) at 10 uM; ND = Not determined2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Biological evaluation of substituted quinolines.
AID736304Antiparasitic activity against Trypanosoma brucei assessed as growth inhibition2013Journal of natural products, Apr-26, Volume: 76, Issue:4
Examination of the mode of action of the almiramide family of natural products against the kinetoplastid parasite Trypanosoma brucei.
AID256355Percent inhibition of agonist-induced calcium mobilization at P2Y purinoceptor 2 recombinantly expressed in human HEK293 cells at 100 uM dose2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency.
AID1163231Antitrypanocidal activity against suramin-sensitive Trypanosoma brucei rhodesiense STIB-900 assessed as reduction in parasite growth after 72 hrs2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID56578Dissociation constant for Dengue virus envelope protein binding by surface plasmon resonance2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
Probing the interaction of dengue virus envelope protein with heparin: assessment of glycosaminoglycan-derived inhibitors.
AID1233456Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jul-15, Volume: 25, Issue:14
New indole-isoxazolone derivatives: Synthesis, characterisation and in vitro SIRT1 inhibition studies.
AID369776Biodistribution in FVB Mdr1a/Mdr1b deficient mouse choroid plexus assessed as tritiated drug level at 150 uM perfusion after 30 mins by capillary depletion assay2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.
AID527462Inhibition of His6x-tagged PRMT1-mediated protein arginine methylation expressed in Escherichia coli BL21 (DE3) using GAR R4 peptide and [14C]-AdoMet by scintillation counting2010Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16
Discovery and mechanistic study of a class of protein arginine methylation inhibitors.
AID312529Antitrypanosomal activity against Trypanosoma brucei brucei TC2212008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
In search of novel agents for therapy of tropical diseases and human immunodeficiency virus.
AID369771Biodistribution in BALB/c mouse pineal gland assessed as tritiated drug level at 5 ml/min perfusion after 30 min2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.
AID311139Cytotoxicity against mouse J774 cells by alamar blue assay2007Journal of natural products, Aug, Volume: 70, Issue:8
Antitrypanosomal activity of triterpenoids and sterols from the leaves of Strychnos spinosa and related compounds.
AID101670Antifilarial activity (percent reduction of live Litomosoides carinii at necropsy relative to controls) was evaluated at dose of 100 mg/kg/day administered perorally1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Synthesis of potential antifilarial agents. 1-(5-Benzoylbenzimidazol-2-yl)-3-alkyl- and -arylureas.
AID455741Inhibition of yeast Hst2 by fluorimetric assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Identification and characterization of novel sirtuin inhibitor scaffolds.
AID369777Biodistribution in wild type FVB Mdr1a/Mdr1b positive mouse pineal gland assessed as tritiated drug level at 150 uM perfusion after 30 mins by capillary depletion assay2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.
AID473012Antiplasmodial activity against Plasmodium falciparum W2 by flow cytometry2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.
AID735756Inhibition of human His6-tagged SIRT2 expressed in Escherichia coli BL21(DE3) assessed as inhibition of ZMAL conversion to ZML after 4 hrs by fluorescence assay2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Discovery of thieno[3,2-d]pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2, and SIRT3.
AID167940Tested for carcinogenic activity on breast after oral administration of the compound; - denotes non carcinogenic activity.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID156323In vitro cytotoxicity against mouse PC3 prostate cancer cell line; Not determined.2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Synthesis and antitubulin activity of N1- and N4-substituted 3,5-dinitro sulfanilamides against African trypanosomes and Leishmania.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID674935Inhibition of human SIRT3 expressed in Escherichia coli assessed as enzyme activity using Z-MAL as substrate at 1 mM after 6 hrs by fluorescence assay2012European journal of medicinal chemistry, Sep, Volume: 55Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2.
AID527461Inhibition of His6x-tagged PRMT1-mediated protein arginine methylation expressed in Escherichia coli BL21 (DE3) using H4(1-20) and [14C]-SAM by scintillation counting2010Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16
Discovery and mechanistic study of a class of protein arginine methylation inhibitors.
AID99863In vitro anti protozoal activity against Leishmania amazonensis strain MHOM/ET/L82/LV9 was determined; ND = Not determined2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Biological evaluation of substituted quinolines.
AID1194534Inhibition of SIRT5 (unknown origin) using (DABCYL)ISGASE(SuK)DIVHSE(EDANS)G peptide substrate incubated for 1 hrs followed by 1 hr incubation with trypsin and nicotinamide by FRET-based assay2015Bioorganic & medicinal chemistry letters, Apr-15, Volume: 25, Issue:8
A FRET-based assay for screening SIRT5 specific modulators.
AID311532Cytotoxicity against african green monkey Vero cells2007Journal of natural products, Oct, Volume: 70, Issue:10
Trypanocidal and antileishmanial dihydrochelerythrine derivatives from Garcinia lucida.
AID369803Protein binding in human plasma assessed as tritiated drug level2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID106584Evaluated for 50% cytotoxic concentration based on reduction of viability of mock-infected cells1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
Potential anti-AIDS naphthalenesulfonic acid derivatives. Synthesis and inhibition of HIV-1 induced cytopathogenesis and HIV-1 and HIV-2 reverse transcriptase activities.
AID150495Antagonist activity against phospholipase C coupled rat P2Y purinoceptor 12 (P2Y12)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID707853Cytotoxicity against human MCF7 cells assessed as growth inhibition at 10 uM after 24 hrs by MTT assay (Rvb = 0.15 %)2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Ethylenediamine diacetate (EDDA) mediated synthesis of aurones under ultrasound: their evaluation as inhibitors of SIRT1.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1215093Activation of rat PXR expressed in human HepG2 cells up to 46 uM after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID158193In vitro anti-protozoal activity against Plasmodium falciparum W2; Not determined2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Biological evaluation of substituted quinolines.
AID1233553Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 bloodstream forms by microtiter plate based assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID199826Inhibitory dose at a concentration of 350 uM cell-free HIV-1 Reverse Transcriptase1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Potential anti-AIDS agents. Synthesis and antiviral activity of naphthalenesulfonic acid derivatives against HIV-1 and HIV-2.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID199661Inhibition of purified HIV-2 reverse transcriptase1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
Potential anti-AIDS naphthalenesulfonic acid derivatives. Synthesis and inhibition of HIV-1 induced cytopathogenesis and HIV-1 and HIV-2 reverse transcriptase activities.
AID1233457Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jul-15, Volume: 25, Issue:14
New indole-isoxazolone derivatives: Synthesis, characterisation and in vitro SIRT1 inhibition studies.
AID256077Relative potency was measured against P2Y purinoceptor 112005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency.
AID213659In vitro anti protozoal activity against Trypanosoma cruzi strain Tulahuen CL2 was determined; ND = Not determined2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Biological evaluation of substituted quinolines.
AID570116Antagonist activity against rat P2X2 receptor expressed in Xenopus laevis oocyte assessed as inhibition of alpha, beta-meATP-induced inward current by two-electrode voltage-clamp electrophysiology2011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor.
AID1215091Activation of human PXR expressed in human HepG2 (DPX-2) cells up to 46 uM after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID552696Antitrypanosomal activity against bloodstream form of Trypanosoma brucei s427 after 72 hrs by MTT assay2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Synthesis and antitrypanosomal evaluation of derivatives of N-benzyl-1,2-dihydroquinolin-6-ols: Effect of core substitutions and salt formation.
AID723620Inhibition of human Sirt5 desuccinylation activity using SKEYFS-succinylLys-QK as substrate at 100 uM after 60 mins by glutamate dehydrpgenase-coupled assay2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Inhibition of the human deacylase Sirtuin 5 by the indole GW5074.
AID215514Minimum effective concentration in vitro against the bloodstream trypomastigote form of Trypanosoma brucei2003Journal of medicinal chemistry, Jan-30, Volume: 46, Issue:3
Synthesis and biological activity of nitro heterocycles analogous to megazol, a trypanocidal lead.
AID355251Inhibition of HIV1 recombinant reverse transcriptase p66/p51 expressed in Escherichia coli1997Journal of natural products, Sep, Volume: 60, Issue:9
In vitro anti-HIV activity of biflavonoids isolated from Rhus succedanea and Garcinia multiflora.
AID1169286Antitrypanosomal activity against Trypanosoma brucei brucei NYSM bloodstream forms incubated for 46 hrs by alamar blue assay2014Journal of natural products, Oct-24, Volume: 77, Issue:10
Antitrypanosomal quinoline alkaloids from the roots of Waltheria indica.
AID657112Cytotoxicity against human HEK293 cells at 10 uM2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Novel acridinedione derivatives: design, synthesis, SIRT1 enzyme and tumor cell growth inhibition studies.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID214974Inhibitory concentration against brucei variant 221 was determined in vitro2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Synthesis and antitubulin activity of N1- and N4-substituted 3,5-dinitro sulfanilamides against African trypanosomes and Leishmania.
AID1064497Antitrypanosomal activity against Trypanosoma brucei brucei GUTat 3.1 after 72 hrs by AlamarBlue assay2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Semisynthesis of salviandulin E analogues and their antitrypanosomal activity.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID32219Minimum inhibitory concentration of the compound, achieving a complete protection of ATH8 cells against the cytopathic effect of HTLV-III / LAV reverse transcriptase1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS).
AID369796Biodistribution in perfused wild type FVB Mdr1a/Mdr1b positive mouse choroid plexus assessed as drug accumulation after 30 mins2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID150170Antagonist activity against recombinant rat P2X purinoceptor 5 (P2X5)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID377052Cytotoxicity against african green monkey Vero cells after 72 hrs by cell-titer assay2005Journal of natural products, Jan, Volume: 68, Issue:1
Antiprotozoal compounds from Psorothamnus polydenius.
AID1215094Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID50771Ability to destroy fluid-phase human complement 1 in the presence of complement 4 with appropriate serial twofold dilutions of the test compound using C1 assay1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Synthetic modulators of the complement system. 1. Synthesis and biological activity of 5,5',5''-[1,3,6-naphthalenetriyltris(sulfonylimino)]-tris[1,3-benzenedisulfonic acid] hexasodium salt.
AID199830Compound tested for % inhibition of cell-free HIV-1 Reverse Transcriptase at a concentration of 2.8 uM1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Potential anti-AIDS agents. Synthesis and antiviral activity of naphthalenesulfonic acid derivatives against HIV-1 and HIV-2.
AID565603Antimicrobial activity against Trypanosoma evansi STIB 806K infected in NMRI mouse assessed as host survival days at 0.25 mg/kg, ip administered 3 to 6 days after infection for 4 consecutive days2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
In vivo investigations of selected diamidine compounds against Trypanosoma evansi using a mouse model.
AID565602Antimicrobial activity against Trypanosoma evansi STIB 806K infected in NMRI mouse assessed as host survival days at 0.5 mg/kg, ip administered 3 to 6 days after infection for 4 consecutive days2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
In vivo investigations of selected diamidine compounds against Trypanosoma evansi using a mouse model.
AID1233552Cytotoxicity against human WI38 cells by MTT assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID311530Antileishmanial activity against Leishmania donovani promastigotes at 1 uM2007Journal of natural products, Oct, Volume: 70, Issue:10
Trypanocidal and antileishmanial dihydrochelerythrine derivatives from Garcinia lucida.
AID369778Biodistribution in FVB Mdr1a/Mdr1b deficient mouse pineal gland assessed as tritiated drug level at 150 uM perfusion after 30 mins by capillary depletion assay2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.
AID369804Protein binding in mouse plasma assessed as tritiated drug level2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.
AID369775Biodistribution in wild type FVB Mdr1a/Mdr1b positive mouse choroid plexus assessed as tritiated drug level at 150 uM perfusion after 30 mins by capillary depletion assay2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.
AID312629Antitrypanosomal activity against Trypanosoma brucei2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Development of potent purine-derived nitrile inhibitors of the trypanosomal protease TbcatB.
AID311528Antileishmanial activity against Leishmania donovani promastigotes at 100 uM2007Journal of natural products, Oct, Volume: 70, Issue:10
Trypanocidal and antileishmanial dihydrochelerythrine derivatives from Garcinia lucida.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID86725Concentration required to inhibit binding of envelope protein to immobilized heparin in the competition plate assay by 100%2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
Probing the interaction of dengue virus envelope protein with heparin: assessment of glycosaminoglycan-derived inhibitors.
AID393027Antiparasitic activity against Trypanosoma brucei rhodesiense2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
New potent imidazoisoquinolinone derivatives as anti-Trypanosoma cruzi agents: biological evaluation and structure-activity relationships.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID712587Inhibition of SIRT5 using ZK(suc)A substrate after 1 hr by homogeneous fluorescence assay2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Inhibitors of the NAD(+)-Dependent Protein Desuccinylase and Demalonylase Sirt5.
AID150145The compound was evaluated for antagonist activity against recombinant rat receptor P2X purinoceptor 2 (P2X2) at 30 uM, expressed in Xenopus oocytes2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID300658Inhibition of porcine tubulin assembly2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
Synthesis, biological evaluation, and molecular modeling of 3,5-substituted-N1-phenyl-N4,N4-di-n-butylsulfanilamides as antikinetoplastid antimicrotubule agents.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID740948Cytotoxicity against african green monkey Vero cells2013Journal of natural products, Mar-22, Volume: 76, Issue:3
8,8-dialkyldihydroberberines with potent antiprotozoal activity.
AID764200Antileishmanial activity against Leishmania mexicana mexicana MHOM/BZ/84/BEL46 promastigotes assessed as parasite LDH activity by three-fold serial dilution method2013European journal of medicinal chemistry, Aug, Volume: 66Antiparasitic hybrids of Cinchona alkaloids and bile acids.
AID311526Antitrypanosomal activity against Trypanosoma brucei brucei MITat 1.2 variant 2212007Journal of natural products, Oct, Volume: 70, Issue:10
Trypanocidal and antileishmanial dihydrochelerythrine derivatives from Garcinia lucida.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID369805Partition coefficient, log D of the compound2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID594418Antitrypanosomal activity against bloodstream form of Trypanosoma brucei brucei2011Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9
Potent antiprotozoal activity of a novel semi-synthetic berberine derivative.
AID412664Selectivity index ratio IC50 for human MRC5 cells to IC50 for Trypanosoma brucei brucei GUTat3.12008Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24
New lycorine-type alkaloid from Lycoris traubii and evaluation of antitrypanosomal and antimalarial activities of lycorine derivatives.
AID150172Antagonist activity against recombinant rat P2X purinoceptor 6 (P2X6 )2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID657111Growth inhibition of human K562 cells2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Novel acridinedione derivatives: design, synthesis, SIRT1 enzyme and tumor cell growth inhibition studies.
AID1233459Inhibition of SIRT1 (unknown origin) using AMC-Arg-His-Lys-Lys(Ac) substrate assessed as deacetylation of substrate by fluorimetric enzyme assay2015Bioorganic & medicinal chemistry letters, Jul-15, Volume: 25, Issue:14
New indole-isoxazolone derivatives: Synthesis, characterisation and in vitro SIRT1 inhibition studies.
AID613125Inhibition of recombinant human SIRT1 lysine deacetylase activity at 50 uM after 60 mins by fluorimetry relative to control2011Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12
Epigenetic profiling of the antitumor natural product psammaplin A and its analogues.
AID103484Antifilarial activity against Molinema dessetae in vivo against female adult worms at a dose of 40 mg/kg subcutaneously once a day for 5 days; Active1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
New antifilarial agents. 1. Epoxy sulfonamides and ethynesulfonamides.
AID764198Selectivity index, ratio of IC50 for human WI38 cells to IC50 for Leishmania mexicana mexicana MHOM/BZ/84/BEL46 promastigotes2013European journal of medicinal chemistry, Aug, Volume: 66Antiparasitic hybrids of Cinchona alkaloids and bile acids.
AID168084Carcinogenic activity on liver after oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID80450Evaluated in vitro for complement activity using guinea pig serum was determined by cap 50 assay1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Synthetic modulators of the complement system. 1. Synthesis and biological activity of 5,5',5''-[1,3,6-naphthalenetriyltris(sulfonylimino)]-tris[1,3-benzenedisulfonic acid] hexasodium salt.
AID276905Inhibition of rat recombinant NTPDase2 expressed in CHO cells2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Polyoxometalates--a new class of potent ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) inhibitors.
AID482888Inhibition of human liver cathepsin B at 100 uM2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID199658Inhibition of purified HIV-1 reverse transcriptase1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
Potential anti-AIDS naphthalenesulfonic acid derivatives. Synthesis and inhibition of HIV-1 induced cytopathogenesis and HIV-1 and HIV-2 reverse transcriptase activities.
AID740950Antileishmanial activity against Leishmania donovani2013Journal of natural products, Mar-22, Volume: 76, Issue:3
8,8-dialkyldihydroberberines with potent antiprotozoal activity.
AID150639The compound was evaluated for antagonist activity against phospholipase C coupled recombinant human P2Y purinoceptor 6 (P2Y6)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID764199Antiplasmodial activity against erythrocytic stage of chloroquine-sensitive Plasmodium falciparum 3D7 assessed as parasite LDH activity by three-fold serial dilution method2013European journal of medicinal chemistry, Aug, Volume: 66Antiparasitic hybrids of Cinchona alkaloids and bile acids.
AID312631Inhibition of human liver cathepsin B2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Development of potent purine-derived nitrile inhibitors of the trypanosomal protease TbcatB.
AID105996Cytotoxicity in MRC-5 cells; ND = Not determined2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Biological evaluation of substituted quinolines.
AID1250597Antiparasitic activity against bloodstream form of Trypanosoma brucei brucei 427 infected in macrophages differentiated from human THP1 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Characterization of 2,4-Diamino-6-oxo-1,6-dihydropyrimidin-5-yl Ureido Based Inhibitors of Trypanosoma brucei FolD and Testing for Antiparasitic Activity.
AID657110Growth inhibition of human MDA-MB-231 cells2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Novel acridinedione derivatives: design, synthesis, SIRT1 enzyme and tumor cell growth inhibition studies.
AID366506Antagonist activity at human P2Y2 receptor expressed in human 1321N1 cells assessed as inhibition of UTP-induced intracellular calcium mobilization by FLUOstar plate reader2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Selective nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) inhibitors: nucleotide mimetics derived from uridine-5'-carboxamide.
AID276906Inhibition of rat recombinant NTPDase3 expressed in CHO cells2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Polyoxometalates--a new class of potent ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) inhibitors.
AID565593Antimicrobial activity against Trypanosoma evansi STIB 806K infected in NMRI mouse assessed as host survival days at 1 mg/kg, ip administered 3 to 6 days after infection for 4 consecutive days2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
In vivo investigations of selected diamidine compounds against Trypanosoma evansi using a mouse model.
AID707855Inhibition of full length recombinant human SIRT1 expressed in Escherichia coli BL21 (DE3) PLysS using Fluor-de-Lys as substrate at 10 uM by fluorimetric assay2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Ethylenediamine diacetate (EDDA) mediated synthesis of aurones under ultrasound: their evaluation as inhibitors of SIRT1.
AID735757Inhibition of human GST-tagged SIRT1 expressed in Escherichia coli BL21(DE3) assessed as inhibition of ZMAL conversion to ZML after 4 hrs by fluorescence assay2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Discovery of thieno[3,2-d]pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2, and SIRT3.
AID657109Inhibition of human SIRT1 using Fluor-de-Lys as substrate2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Novel acridinedione derivatives: design, synthesis, SIRT1 enzyme and tumor cell growth inhibition studies.
AID1605095Inhibition of N-terminal His6-sumo-tagged full length Staphylococcus aureus ClpP expressed in Escherichia coli BL2 (DE3) at 10 uM pre-incubated for 10 mins before Suc-LY-AMC addition and measured after 1 hr by fluorescence based assay relative to control2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
Discovery of Novel Peptidomimetic Boronate ClpP Inhibitors with Noncanonical Enzyme Mechanism as Potent Virulence Blockers
AID757410Selectivity index, ratio of ED50 for human HL60 cells to ED50 for Trypanosoma brucei brucei2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Inhibition of rhodesain as a novel therapeutic modality for human African trypanosomiasis.
AID150173Antagonist activity against recombinant human P2X purinoceptor 7 (P2X7)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID1233560Selectivity index, ratio of IC50 against human WI38 cells to IC50 for Plasmodium falciparum 3D72015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID158190In vitro anti-protozoal activity against Plasmodium falciparum Ghana strain; Not determined2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Biological evaluation of substituted quinolines.
AID300657Inhibition of Leishmania tarentolae tubulin assembly2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
Synthesis, biological evaluation, and molecular modeling of 3,5-substituted-N1-phenyl-N4,N4-di-n-butylsulfanilamides as antikinetoplastid antimicrotubule agents.
AID300661Growth inhibition against Trypanosoma brucei brucei2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
Synthesis, biological evaluation, and molecular modeling of 3,5-substituted-N1-phenyl-N4,N4-di-n-butylsulfanilamides as antikinetoplastid antimicrotubule agents.
AID712590Inhibition of recombinant SIRT2 using ZMAL substrate after 4 hrs by homogeneous fluorescence assay2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Inhibitors of the NAD(+)-Dependent Protein Desuccinylase and Demalonylase Sirt5.
AID369795Biodistribution in perfused wild type FVB Mdr1a/Mdr1b positive mouse choroid plexus assessed as tritiated drug level after 30 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.
AID150627The compound was evaluated for antagonist activity against phospholipase C coupled recombinant human P2Y purinoceptor 4 (P2Y4)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID378965Antileishmanial activity against Leishmania donovani MHOM/SD/62/IS-CL2D axenic amastigotes after 3 days2006Journal of natural products, Jan, Volume: 69, Issue:1
Isoflavonoids and other compounds from Psorothamnus arborescens with antiprotozoal activities.
AID712588Inhibition of recombinant SIRT3 using ZMAL substrate after 4 hrs by homogeneous fluorescence assay2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Inhibitors of the NAD(+)-Dependent Protein Desuccinylase and Demalonylase Sirt5.
AID1163248Trypanocidal activity against suramin-sensitive Trypanosoma brucei brucei Squib427 infected in Swiss mouse assessed as reduction in parasitemia at 10 mg/kg first dose through orally and next four dosed administered intraperitoneally for 4 days2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID1193543Cytotoxicity against rat L6 cells after 72 hrs by alamar blue assay2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Synthesis of 3-azabicyclo[3.2.2]nonanes and their antiprotozoal activities.
AID311529Antileishmanial activity against Leishmania donovani promastigotes at 10 uM2007Journal of natural products, Oct, Volume: 70, Issue:10
Trypanocidal and antileishmanial dihydrochelerythrine derivatives from Garcinia lucida.
AID254595Inhibitory concentration against P2Y purinoceptor 11 expressed in 1321N1 astrocytoma cells; n=62005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID256357Percent inhibition of agonist-induced calcium mobilization at P2Y purinoceptor 11 recombinantly expressed in human HEK293 cells at 100 uM dose2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency.
AID81705Inhibitory percentage against HCT116 cell lines at a concentration of 30 ug/mL; ND denotes no data2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Preliminary structure-antiangiogenic activity relationships of 4-senecioyloxymethyl-6,7-dimethoxycoumarin.
AID53307Inhibitory activity against DNA-DNA dependent protein kinase (DNA-PK)2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Kinase inhibitors: not just for kinases anymore.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID723626Inhibition of human Sirt5 deacetylation activity using FKRGVL-acetylLys-EYGVKV as substrate at 100 uM after 60 mins by glutamate dehydrogenase-coupled assay2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Inhibition of the human deacylase Sirtuin 5 by the indole GW5074.
AID103500Antifilarial activity against Molinema dessetae in vivo in Proechimys oris the natural host at a dose of 40 mg/kg subcutaneously once a day for 5 days. Value is expressed as number of infected P. oris.1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
New antifilarial agents. 1. Epoxy sulfonamides and ethynesulfonamides.
AID152481The compound was evaluated for antagonist activity against recombinant rat P2X purinoceptor 1 (P2X1) at 1 uM, expressed in Xenopus oocytes2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID274293Antiprotozoal activity against Trypanosoma brucei rhodesiense STIB9002006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
Antiprotozoal activities of new bis-chlorophenyl derivatives of bicyclic octanes and aza-nonanes.
AID640594Toxicity in Lewis mouse allografted with mouse LL/2 cells assessed as change in body weight at 4 mg/ml, ip administered daily 24 hrs post implantation measured on day 18 (Rvb = 22.7 +/- 0.2 g)2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological evaluation of novel indolocarbazoles with anti-angiogenic activity.
AID712589Inhibition of recombinant SIRT1 using ZMAL substrate after 4 hrs by homogeneous fluorescence assay2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Inhibitors of the NAD(+)-Dependent Protein Desuccinylase and Demalonylase Sirt5.
AID537630Inhibition of Schistosoma mansoni recombinant NAD+ glycohydrolase expressed in Pichia pastoris at up to 100 uM by continuous fluorometric method2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Identification by high-throughput screening of inhibitors of Schistosoma mansoni NAD(+) catabolizing enzyme.
AID369794Biodistribution in perfused FVB Mdr1a/Mdr1b deficient mouse choroid plexus assessed as drug accumulation after 2.5 mins2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.
AID588172Antitrypanosomal activity against bloodstream-form Trypanosoma brucei brucei 427 after 72 hrs2011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
Design, synthesis, and structure-activity relationship of Trypanosoma brucei leucyl-tRNA synthetase inhibitors as antitrypanosomal agents.
AID1163245Trypanocidal activity against suramin-sensitive Trypanosoma brucei brucei Squib427 infected in Swiss mouse assessed as mean survival time at 10 mg/kg first dose through orally and next four dosed administered intraperitoneally for 4 days (Rvb = 7.2 days)2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID39288Inhibitory percentage against B16 cell lines at a concentration of 30 ug/mL; ND denotes no data2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Preliminary structure-antiangiogenic activity relationships of 4-senecioyloxymethyl-6,7-dimethoxycoumarin.
AID565604Antimicrobial activity against Trypanosoma evansi STIB 806K infected in NMRI mouse assessed as complete cure from microbial infection at 0.25 mg/kg, ip administered 3 to 6 days after infection for 4 consecutive days2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
In vivo investigations of selected diamidine compounds against Trypanosoma evansi using a mouse model.
AID1215095Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay relative to SR128132011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID199827Compound tested for % inhibition of cell-free HIV-1 Reverse Transcriptase at a concentration of 14 uM.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Potential anti-AIDS agents. Synthesis and antiviral activity of naphthalenesulfonic acid derivatives against HIV-1 and HIV-2.
AID274294Selectivity index, IC50 for L6 cells/ IC50 for Trypanosoma brucei rhodesience2006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
Antiprotozoal activities of new bis-chlorophenyl derivatives of bicyclic octanes and aza-nonanes.
AID199845Compound tested for % inhibition of giant cell formation at a concentration of 70 uM1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Potential anti-AIDS agents. Synthesis and antiviral activity of naphthalenesulfonic acid derivatives against HIV-1 and HIV-2.
AID1143363Antitrypanosomal activity against Trypanosoma brucei brucei 427 after 72 hrs by alamar blue assay2014European journal of medicinal chemistry, Jun-23, Volume: 81Novel pyrrolobenzoxaboroles: design, synthesis, and biological evaluation against Trypanosoma brucei.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1194535Inhibition of SIRT5 (unknown origin) using (DABCYL)ISGASE(SuK)DIVHSE(EDANS)G peptide substrate incubated for 1 hrs followed by 1 hr incubation with trypsin and nicotinamide by HPLC-based assay2015Bioorganic & medicinal chemistry letters, Apr-15, Volume: 25, Issue:8
A FRET-based assay for screening SIRT5 specific modulators.
AID167927Carcinogenic activity on all sites after oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID32220Selectivity index expressed as ratio of compound concentration required to reduce the growth of normal uninfected ATH8 cells by 50% to the compound concentration (MIC)1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS).
AID215324Effective concentration in vitro against the bloodstream trypomastigote form of Trypanosoma brucei2003Journal of medicinal chemistry, Jan-30, Volume: 46, Issue:3
Synthesis and biological activity of nitro heterocycles analogous to megazol, a trypanocidal lead.
AID707854Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition at 10 uM after 24 hrs by MTT assay (Rvb = 0.23 %)2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Ethylenediamine diacetate (EDDA) mediated synthesis of aurones under ultrasound: their evaluation as inhibitors of SIRT1.
AID369802Protein binding in artificial plasma assessed as tritiated drug level2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.
AID103506Effective concentration of compound necessary to kill 90% of infective larvae of Molinema dessetae after 7 days was determined in vitro; Value ranges from 100-5001987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
New antifilarial agents. 1. Epoxy sulfonamides and ethynesulfonamides.
AID56457Association rate constant for Dengue virus envelope protein binding by surface plasmon resonance2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
Probing the interaction of dengue virus envelope protein with heparin: assessment of glycosaminoglycan-derived inhibitors.
AID1064495Selectivity index, ratio of IC50 for human MRC5 cells to IC50 for Trypanosoma brucei brucei GUTat 3.12014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Semisynthesis of salviandulin E analogues and their antitrypanosomal activity.
AID377050Antileishmanial activity against Leishmania donovani MHOM/SD/62/1S-CL2D axenic amastigotes after 3 days by tetrazolium dye method2005Journal of natural products, Jan, Volume: 68, Issue:1
Antiprotozoal compounds from Psorothamnus polydenius.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID412485Cytotoxicity against human MRC5 cells after 7 days by MTT assay2008Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24
New lycorine-type alkaloid from Lycoris traubii and evaluation of antitrypanosomal and antimalarial activities of lycorine derivatives.
AID1194530Inhibition of human recombinant SIRT5 isoform 1 (34 to 302 amino acids) expressed in Escherichia coli BL21 (DE3) codon plus RIL cells assessed as reduction in deacetylase activity using acetylated chicken histone substrate and [3H]-NAD+2015Bioorganic & medicinal chemistry letters, Apr-15, Volume: 25, Issue:8
A FRET-based assay for screening SIRT5 specific modulators.
AID366500Inhibition of rat NTPDase 22008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Selective nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) inhibitors: nucleotide mimetics derived from uridine-5'-carboxamide.
AID366502Inhibition of rat NTPDase 32008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Selective nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) inhibitors: nucleotide mimetics derived from uridine-5'-carboxamide.
AID1193546Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 bloodstream forms after 72 hrs by alamar blue assay2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Synthesis of 3-azabicyclo[3.2.2]nonanes and their antiprotozoal activities.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID674937Inhibition of human SIRT2 assessed as enzyme activity using Fluor-de-Lys as substrate at 1 mM by fluorometry2012European journal of medicinal chemistry, Sep, Volume: 55Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2.
AID369800Biodistribution in perfused BALB/c mouse choroid plexus assessed as tritiated drug level after 2.5 mins in presence of phenylarsine oxide relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.
AID76199Evaluated in vivo after intraperitoneal administration by guinea pig assay1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Synthetic modulators of the complement system. 1. Synthesis and biological activity of 5,5',5''-[1,3,6-naphthalenetriyltris(sulfonylimino)]-tris[1,3-benzenedisulfonic acid] hexasodium salt.
AID1194532Inhibition of SIRT5 (unknown origin) at 30 uM using (DABCYL)ISGASE(SuK)DIVHSE(EDANS)G peptide substrate incubated for 1 hrs followed by 1 hr incubation with trypsin and nicotinamide by FRET-based assay2015Bioorganic & medicinal chemistry letters, Apr-15, Volume: 25, Issue:8
A FRET-based assay for screening SIRT5 specific modulators.
AID455742Inhibition of human full length SIRT1 expressed in DE3 cells by fluorimetric assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Identification and characterization of novel sirtuin inhibitor scaffolds.
AID369780Biodistribution in FVB Mdr1a/Mdr1b deficient mouse pituitary gland assessed as tritiated drug level at 150 uM perfusion after 30 mins by capillary depletion assay2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.
AID300662Toxicity against monkey Vero cells2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
Synthesis, biological evaluation, and molecular modeling of 3,5-substituted-N1-phenyl-N4,N4-di-n-butylsulfanilamides as antikinetoplastid antimicrotubule agents.
AID438024Inhibition of Dengue virus sEnvelope glycoprotein binding to immobilized heparin2009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
The medicinal chemistry of dengue fever.
AID552695Cytotoxicity against rat L6 cells after 70 hrs by alamar blue assay2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Synthesis and antitrypanosomal evaluation of derivatives of N-benzyl-1,2-dihydroquinolin-6-ols: Effect of core substitutions and salt formation.
AID1194533Inhibition of SIRT1 (unknown origin) at 30 uM using (DABCYL)ISGASE(AcK)DIVHSE(EDANS)G peptide substrate incubated for 1 hr followed by 1 hr incubation with trypsin and nicotinamide by FRET-based assay2015Bioorganic & medicinal chemistry letters, Apr-15, Volume: 25, Issue:8
A FRET-based assay for screening SIRT5 specific modulators.
AID167951Carcinogenic activity on ear duct after oral administration of the compound; - denotes non carcinogenic activity.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID280502Inhibition of Aspergillus nidulans recombinant GST-RmtA expressed in BL21 cells2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Small molecule inhibitors of histone arginine methyltransferases: homology modeling, molecular docking, binding mode analysis, and biological evaluations.
AID276908Stability at pH 7.6 at 10 uM2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Polyoxometalates--a new class of potent ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) inhibitors.
AID369798Biodistribution in perfused FVB Mdr1a/Mdr1b deficient mouse choroid plexus assessed as drug accumulation after 30 mins2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID369793Biodistribution in perfused FVB Mdr1a/Mdr1b deficient mouse choroid plexus assessed as tritiated drug level after 2.5 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.
AID1163252Trypanocidal activity against suramin-sensitive Trypanosoma brucei brucei Squib427 infected in Swiss mouse assessed as survivors on day 14 post infection at 10 mg/kg first dose through orally and next four dosed administered intraperitoneally for 4 days2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID473011Inhibition of Trypanosoma brucei rhodesiense recombinant rhodesain by standard fluorescence assay2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.
AID764202Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 bloodstream form assessed as parasite LDH activity by three-fold serial dilution method2013European journal of medicinal chemistry, Aug, Volume: 66Antiparasitic hybrids of Cinchona alkaloids and bile acids.
AID150151Antagonist activity against recombinant human P2X purinoceptor 3 (P2X3 )2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID290818Inhibition of RecA-mediated DNA strand exchange reaction assessed as abrogation of nicked circular dsDNA formation at 100 uM2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Directed molecular screening for RecA ATPase inhibitors.
AID369769Biodistribution in perfused wild type FVB Mdr1a/Mdr1b positive mouse choroid plexus assessed as tritiated drug level after 2.5 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.
AID369770Biodistribution in BALB/c mouse 4th ventricle choroid plexus assessed as tritiated drug level at 5 ml/min perfusion after 30 min2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.
AID369806Biodistribution in perfused BALB/c mouse choroid plexus assessed as drug accumulation after 2.5 mins in presence of DMSO2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.
AID369779Biodistribution in wild type FVB Mdr1a/Mdr1b positive mouse pituitary gland assessed as tritiated drug level at 150 uM perfusion after 30 mins by capillary depletion assay2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.
AID552075Antitrypanosomal activity against Trypanosoma brucei brucei S427 after 48 hrs by alamar blue assay2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
NF kappa B inhibitors and antitrypanosomal metabolites from endophytic fungus Penicillium sp. isolated from Limonium tubiflorum.
AID757412Antitrypanosomal activity against blood stream form of Trypanosoma brucei brucei2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Inhibition of rhodesain as a novel therapeutic modality for human African trypanosomiasis.
AID276904Inhibition of rat recombinant NTPDase1 expressed in CHO cells2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Polyoxometalates--a new class of potent ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) inhibitors.
AID740951Antimalarial activity against erythrocyte stage Plasmodium falciparum 3D72013Journal of natural products, Mar-22, Volume: 76, Issue:3
8,8-dialkyldihydroberberines with potent antiprotozoal activity.
AID482887Antitrypanosomal activity against Trypanosoma brucei brucei2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID104295Evaluated for 50% antiviral effective concentration based on inhibition of HIV-1 (HTLV-IIIB) induced cytopathogenicity in MT-4 cells1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
Potential anti-AIDS naphthalenesulfonic acid derivatives. Synthesis and inhibition of HIV-1 induced cytopathogenesis and HIV-1 and HIV-2 reverse transcriptase activities.
AID311138Antitrypanosomal activity against Trypanosoma brucei brucei bloodstream trypomastigotes by alamar blue assay2007Journal of natural products, Aug, Volume: 70, Issue:8
Antitrypanosomal activity of triterpenoids and sterols from the leaves of Strychnos spinosa and related compounds.
AID377051Antitrypanosomal activity against blood stream-form of Trypanosoma brucei brucei MITat1.2 after 72 hrs by MTT assay2005Journal of natural products, Jan, Volume: 68, Issue:1
Antiprotozoal compounds from Psorothamnus polydenius.
AID764201Selectivity index, ratio of IC50 for human WI38 cells to IC50 for Trypanosoma brucei brucei Lister 427 bloodstream form2013European journal of medicinal chemistry, Aug, Volume: 66Antiparasitic hybrids of Cinchona alkaloids and bile acids.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID274295Antiprotozoal activity against chloroquine-, pyrimethamine-resistant Plasmodium falciparum K12006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
Antiprotozoal activities of new bis-chlorophenyl derivatives of bicyclic octanes and aza-nonanes.
AID377053Cytotoxicity against mouse J774A1 cells after 72 hrs by cell-titer assay2005Journal of natural products, Jan, Volume: 68, Issue:1
Antiprotozoal compounds from Psorothamnus polydenius.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID81697Concentration required for 50% reduction in HCT116 tumor cell growth (Human colon) was measured; NA denotes not assayed2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Preliminary structure-antiangiogenic activity relationships of 4-senecioyloxymethyl-6,7-dimethoxycoumarin.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID369797Biodistribution in perfused FVB Mdr1a/Mdr1b deficient mouse choroid plexus assessed as tritiated drug level after 30 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.
AID150472Evaluated for antagonist activity against phospholipase C coupled P2Y purinoceptor 1 (P2Y1) of turkey erythrocytes2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID482886Inhibition of Trypanosoma brucei rhodesiense recombinant rhodesain2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID366504Antagonist activity at human P2Y4 receptor expressed in human 1321N1 cells assessed as inhibition of UTP-induced intracellular calcium mobilization at 100 uM by FLUOstar plate reader2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Selective nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) inhibitors: nucleotide mimetics derived from uridine-5'-carboxamide.
AID106611Cytotoxicity against HIV-1 in MT-4 cells was evaluated by using a clinical strain (HE)1993Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14
Structure-activity relationship studies with symmetric naphthalenesulfonic acid derivatives. Synthesis and influence of spacer and naphthalenesulfonic acid moiety on anti-HIV-1 activity.
AID723627Inhibition of human Sirt5 deacetylation activity using FKRGVL-acetylLys-EYGVKV as substrate after 60 mins by glutamate dehydrogenase-coupled assay2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Inhibition of the human deacylase Sirtuin 5 by the indole GW5074.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID311531Antileishmanial activity against Leishmania donovani promastigotes in RAW cells assessed as reduction in infection2007Journal of natural products, Oct, Volume: 70, Issue:10
Trypanocidal and antileishmanial dihydrochelerythrine derivatives from Garcinia lucida.
AID674938Inhibition of human SIRT3 expressed in Escherichia coli assessed as enzyme activity using Z-MAL as substrate at 100 uM after 6 hrs by fluorescence assay2012European journal of medicinal chemistry, Sep, Volume: 55Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2.
AID378967Cytotoxicity against african green monkey Vero cells2006Journal of natural products, Jan, Volume: 69, Issue:1
Isoflavonoids and other compounds from Psorothamnus arborescens with antiprotozoal activities.
AID473010Inhibition of Plasmodium falciparum recombinant falcipain-3 by standard fluorescence assay2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.
AID199835Compound tested for % inhibition of cell-free HIV-1 Reverse Transcriptase at a concentration of 350 uM1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Potential anti-AIDS agents. Synthesis and antiviral activity of naphthalenesulfonic acid derivatives against HIV-1 and HIV-2.
AID254593Inhibitory concentration against P2Y purinoceptor 11 expressed in 1321N1 astrocytoma cells; n=32005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency.
AID1143367Trypanocidal activity against bloodstream stage of Trypanosoma brucei brucei infected in acute BALB/c mouse assessed as animal survival rate at 20 mg/kg, ip bid administered for 5 days initiated 24 hrs post infection2014European journal of medicinal chemistry, Jun-23, Volume: 81Novel pyrrolobenzoxaboroles: design, synthesis, and biological evaluation against Trypanosoma brucei.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID274300Cytotoxicity against L6 cells2006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
Antiprotozoal activities of new bis-chlorophenyl derivatives of bicyclic octanes and aza-nonanes.
AID674936Inhibition of human SIRT1 assessed as enzyme activity using Fluor-de-Lys as substrate at 1 mM by fluorometry2012European journal of medicinal chemistry, Sep, Volume: 55Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2.
AID1233720Antiparasite activity against Trypanosoma brucei 427 assessed as growth inhibition incubated for 48 hrs by PrestoBlue based fluorescence assay2015Journal of medicinal chemistry, Jul-23, Volume: 58, Issue:14
Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery.
AID84798Antiproliferative activity against human umbilical vein endothelial cells (HUVECs) using MTT assay2001Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20
Synthesis and biological evaluation of novel bisindolylmaleimides that inhibit vascular endothelial cell proliferation.
AID366510Antagonist activity at human P2Y6 receptor expressed in human 1321N1 cells assessed as inhibition of UDP-induced intracellular calcium mobilization by NOVOstar plate reader2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Selective nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) inhibitors: nucleotide mimetics derived from uridine-5'-carboxamide.
AID366499Inhibition of rat NTPDase 12008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Selective nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) inhibitors: nucleotide mimetics derived from uridine-5'-carboxamide.
AID50770Inhibition of the complement alternative pathway by Mercaptan-treated human erythrocytes lyse in autologous serum via the alternative pathway activated by cobra venom factor in the presence of appropriate serial twofold dilutions of the test compound1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Synthetic modulators of the complement system. 1. Synthesis and biological activity of 5,5',5''-[1,3,6-naphthalenetriyltris(sulfonylimino)]-tris[1,3-benzenedisulfonic acid] hexasodium salt.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID99713The ability to inhibit late component of human complement (C3-C9) using C-late assay1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Synthetic modulators of the complement system. 1. Synthesis and biological activity of 5,5',5''-[1,3,6-naphthalenetriyltris(sulfonylimino)]-tris[1,3-benzenedisulfonic acid] hexasodium salt.
AID472449Inhibition of human recombinant C-terminal FLAG-tagged autotaxin expressed in baculovirus-infected Sf9 cells assessed as FS-3 hydrolysis at 10 uM relative to control2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors.
AID91777In vitro cytotoxicity against mouse J774 macrophages; Not determined.2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Synthesis and antitubulin activity of N1- and N4-substituted 3,5-dinitro sulfanilamides against African trypanosomes and Leishmania.
AID640590Antiproliferative activity against human HUVEC after 48 to 72 hrs by MTT assay2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological evaluation of novel indolocarbazoles with anti-angiogenic activity.
AID56456Dissociation rate constant for Dengue virus envelope protein binding by surface plasmon resonance2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
Probing the interaction of dengue virus envelope protein with heparin: assessment of glycosaminoglycan-derived inhibitors.
AID106951Antiviral activity against HIV-1 in MT-4 cells was evaluated by using a clinical strain (HE)1993Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14
Structure-activity relationship studies with symmetric naphthalenesulfonic acid derivatives. Synthesis and influence of spacer and naphthalenesulfonic acid moiety on anti-HIV-1 activity.
AID740949Antitrypanosomal activity against Trypanosoma brucei brucei blood-stream forms2013Journal of natural products, Mar-22, Volume: 76, Issue:3
8,8-dialkyldihydroberberines with potent antiprotozoal activity.
AID100892In vitro anti protozoal activity against Leishmania infantum strain MHOM-ET-67/L82 was determined; ND = Not determined2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Biological evaluation of substituted quinolines.
AID764197Selectivity index, ratio of IC50 for human WI38 cells to IC50 for erythrocytic stage of chloroquine-sensitive Plasmodium falciparum 3D72013European journal of medicinal chemistry, Aug, Volume: 66Antiparasitic hybrids of Cinchona alkaloids and bile acids.
AID311527Antileishmanial activity against Leishmania donovani axenic amastigotes2007Journal of natural products, Oct, Volume: 70, Issue:10
Trypanocidal and antileishmanial dihydrochelerythrine derivatives from Garcinia lucida.
AID150155The compound was evaluated for antagonist activity against recombinant rat P2X purinoceptor 3 (P2X2) at 10 uM, expressed in Xenopus oocytes2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID280501Inhibition of human recombinant GST-PRMT1 expressed in BL21 cells2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Small molecule inhibitors of histone arginine methyltransferases: homology modeling, molecular docking, binding mode analysis, and biological evaluations.
AID218679Inhibition of beta-lactamase from Escherichia coli2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Kinase inhibitors: not just for kinases anymore.
AID707852Inhibition of full length recombinant human SIRT1 expressed in Escherichia coli BL21 (DE3) PLysS using Fluor-de-Lys as substrate by fluorimetric assay2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Ethylenediamine diacetate (EDDA) mediated synthesis of aurones under ultrasound: their evaluation as inhibitors of SIRT1.
AID565601Antimicrobial activity against Trypanosoma evansi STIB 806K infected in NMRI mouse assessed as complete cure from microbial infection at 1 mg/kg, ip administered 3 to 6 days after infection for 4 consecutive days2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
In vivo investigations of selected diamidine compounds against Trypanosoma evansi using a mouse model.
AID168110Carcinogenic activity on other sites after oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID412484Antitrypanosomal activity against Trypanosoma brucei brucei GUTat3.1 after 72 hrs by alamar blue assay2008Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24
New lycorine-type alkaloid from Lycoris traubii and evaluation of antitrypanosomal and antimalarial activities of lycorine derivatives.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID103493Antifilarial activity against Molinema dessetae in vivo against male adult worms at a dose of 40 mg/kg subcutaneously once a day for 5 days; Active1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
New antifilarial agents. 1. Epoxy sulfonamides and ethynesulfonamides.
AID640596Antitumor activity against mouse LL/2 cells allografted in Lewis mouse assessed as change in tumor weight at 4 mg/ml, ip administered daily 24 hrs post implantation (Rvb = 7.1 +/- 1.1 g)2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological evaluation of novel indolocarbazoles with anti-angiogenic activity.
AID1163230Antitrypanocidal activity against suramin-sensitive Trypanosoma brucei brucei Squib427 assessed as reduction in parasite growth after 72 hrs2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID1233559Antiplasmodial activity against Plasmodium falciparum 3D7 assessed as reduction in parasite viability by parasite lactate dehydrogenase assay2015European journal of medicinal chemistry, Jul-15, Volume: 100Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities.
AID643372Antitrypanosomal activity against bloodstream form of Trypanosoma brucei rhodesiense EATRO3 after 72 hrs by alamar blue assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Diamine and aminoalcohol derivatives active against Trypanosoma brucei.
AID369772Biodistribution in BALB/c mouse pituitary gland assessed as tritiated drug level at 5 ml/min perfusion after 30 min2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.
AID1215092Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 up to 46 uM after 24 hrs by luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID369801Biodistribution in perfused BALB/c mouse choroid plexus assessed as drug accumulation after 2.5 mins in presence of phenylarsine oxide2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.
AID101834Antifilarial activity against infections of Litomosoides carinii in the Jird by oral route(dose (mg/kg) is given in parentheses)1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
Synthesis and antifilarial activity of N-[4-[[4-alkoxy-3-[(dialkylamino)methyl]phenyl]amino]- 2-pyrimidinyl]-N'-phenylguanidines.
AID1064496Cytotoxicity against human MRC5 cells2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Semisynthesis of salviandulin E analogues and their antitrypanosomal activity.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID150490The compound was evaluated for antagonist activity against phospholipase C coupled human P2Y purinoceptor 11 (P2Y11)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID482884Inhibition of Trypanosoma brucei rhodesiense rhodesain after 12 hrs by fluorescence spectroscopy-based on-bead assay2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID397122Inhibition of HIV1 RT
AID150165Antagonist activity against recombinant rat P2X purinoceptor 4 (P2X4) at 3 uM, expressed in Xenopus oocytes2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID552697Antitrypanosomal activity against bloodstream form of Trypanosoma brucei rhodesiense STIB900 after 70 hrs by alamar blue assay2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Synthesis and antitrypanosomal evaluation of derivatives of N-benzyl-1,2-dihydroquinolin-6-ols: Effect of core substitutions and salt formation.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347157Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346305Human P2Y13 receptor (P2Y receptors)2003Molecular pharmacology, Jul, Volume: 64, Issue:1
Pharmacological characterization of the human P2Y13 receptor.
AID1346559Rat P2X1 (P2X receptors)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID1346309Human P2Y1 receptor (P2Y receptors)2002Molecular pharmacology, Nov, Volume: 62, Issue:5
Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist.
AID1346990Rat P2X3 (P2X receptors)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID1346621Human P2X3 (P2X receptors)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID1346426Human P2Y6 receptor (P2Y receptors)2016Neuropharmacology, 05, Volume: 104Pharmacology and structure of P2Y receptors.
AID1347028Human P2Y2 receptor (P2Y receptors)1997British journal of pharmacology, May, Volume: 121, Issue:2
An examination of deoxyadenosine 5'(alpha-thio)triphosphate as a ligand to define P2Y receptors and its selectivity as a low potency partial agonist of the P2Y1 receptor.
AID1346638Rat P2X2 (P2X receptors)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID1346335Human P2Y11 receptor (P2Y receptors)1999British journal of pharmacology, Nov, Volume: 128, Issue:6
Pharmacological characterization of the human P2Y11 receptor.
AID1346574Rat P2X5 (P2X receptors)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID1347028Human P2Y2 receptor (P2Y receptors)1999British journal of pharmacology, Jun, Volume: 127, Issue:3
Human P2Y2 receptor polymorphism: identification and pharmacological characterization of two allelic variants.
AID1802735p-NPP Assay from Article 10.1186/s12858-015-0048-3: \\Identification of inhibitors that target dual-specificity phosphatase 5 provide new insights into the binding requirements for the two phosphate pockets.\\2015BMC biochemistry, Aug-19, Volume: 16Identification of inhibitors that target dual-specificity phosphatase 5 provide new insights into the binding requirements for the two phosphate pockets.
AID1800407Quatitative Inhibition Analysis Assay from Article 10.1021/bi4011286: \\Discovery of inhibitors of Bacillus anthracis primase DnaG.\\2013Biochemistry, Oct-01, Volume: 52, Issue:39
Discovery of inhibitors of Bacillus anthracis primase DnaG.
AID1802584In Vitro PTP1B Inhibition Assay from Article 10.1016/j.bioorg.2017.01.007: \\Synthesis, biological evaluation and in silico studies of 5-(3-methoxybenzylidene)thiazolidine-2,4-dione analogues as PTP1B inhibitors.\\2017Bioorganic chemistry, 04, Volume: 71Synthesis, biological evaluation and in silico studies of 5-(3-methoxybenzylidene)thiazolidine-2,4-dione analogues as PTP1B inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,920)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990586 (20.07)18.7374
1990's1112 (38.08)18.2507
2000's743 (25.45)29.6817
2010's397 (13.60)24.3611
2020's82 (2.81)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 85.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index85.50 (24.57)
Research Supply Index8.04 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index156.25 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (85.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials92 (3.04%)5.53%
Reviews154 (5.09%)6.00%
Case Studies72 (2.38%)4.05%
Observational0 (0.00%)0.25%
Other2,705 (89.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (20)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Three-Arm, Prospective, Randomized, Double Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of 2 Doses of Suramin vs. Placebo in Male Children With ASD Receiving Standard Treatment [NCT06058962]Phase 252 participants (Actual)Interventional2019-06-01Completed
Randomized Phase II Study of Suramin and Docetaxel Versus Docetaxel in Non-Small Cell Lung Cancer After Failure of First-Line Chemotherapy [NCT01671332]Phase 280 participants (Actual)Interventional2012-06-30Completed
A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma [NCT00001266]Phase 270 participants Interventional1990-10-31Completed
Combination of Non-Cytotoxic Suramin With Docetaxel and Carboplatin in Chemo-Naive Non-small Cell Lung Cancer (NSCLC): A Randomized Single-Blind Placebo-Controlled Phase II Study [NCT01038752]Phase 214 participants (Actual)Interventional2010-08-31Terminated
A PHASE II PILOT STUDY OF SURAMIN IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA AND PATIENTS WITH CASTLEMAN'S DISEASE [NCT00002652]Phase 20 participants Interventional1995-05-31Completed
A Phase I Study of Intravesicular Suramin in Recurrent Superficial Bladder Cancer [NCT00006476]Phase 115 participants (Anticipated)Interventional2000-10-31Completed
A Phase I/II Study of Carboplatin / Paclitaxel / Suramin Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) [NCT00006929]Phase 282 participants (Anticipated)Interventional2000-09-30Completed
A Pilot Study of Low Dose Suramin as Modulator of Docetaxel and Gemcitabine in Patients With Previously Treated Non-Small Cell Lung Cancer (NSCLC) [NCT00066768]Phase 124 participants (Actual)Interventional2003-07-31Completed
Phase I/II Trial Of Low Dose Suramin (CI-1003, NSC#34936) And 5-Fluorouracil In Patients With Metastatic Renal Cell Carcinoma (RCC) [NCT00083109]Phase 1/Phase 236 participants (Actual)Interventional2004-03-31Completed
A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Study to Evaluate the Tolerance and Pharmacokinetics of Suramin Sodium in Healthy Chinese Adults [NCT03804749]Phase 136 participants (Anticipated)Interventional2018-12-19Recruiting
A PHASE III STUDY OF THREE DIFFERENT DOSES OF SURAMIN (NSC #34936) ADMINISTERED WITH A FIXED DOSING SCHEDULE IN PATIENTS WITH ADVANCED PROSTATE CANCER [NCT00002723]Phase 3390 participants (Actual)Interventional1996-01-31Completed
Phase II Study of Suramin and Concurrent Radiation Therapy in Newly Diagnosed Glioblastoma Multiforme [NCT00004073]Phase 254 participants (Anticipated)Interventional1999-12-31Completed
A Phase I/II Study of Suramin in Combination With Paclitaxel in Advanced (Stage IIIB or IV) Metastatic Breast Cancer [NCT00054028]Phase 1/Phase 231 participants (Actual)Interventional2002-12-31Completed
A Prospective, Double-Blind, Placebo-controlled Study of Suramin in Subjects With Furosemide-Resistant Acute Kidney Injury (AKI): Efficacy in Preventing Dialysis Dependent AKI [NCT04496596]Phase 268 participants (Actual)Interventional2020-11-13Active, not recruiting
The UCSD Suramin Autism Treatment-1 (SAT1) Trial [NCT02508259]Phase 1/Phase 210 participants (Actual)Interventional2015-05-31Completed
A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder [NCT00001381]Phase 118 participants Interventional1994-03-31Completed
A Phase I Trial of Suramin With Sequential Doxorubicin in Patients With Advanced Solid Tumors [NCT00003038]Phase 10 participants Interventional1997-10-31Completed
PHASE III TRIAL OF ORCHIECTOMY/LHRH ANALOG + FLUTAMIDE + SURAMIN + HYDROCORTISONE VS ORCHIECTOMY/LHRH ANALOG + FLUTAMIDE IN PATIENTS WITH METASTATIC PROSTATE CANCER [NCT00002881]Phase 30 participants Interventional1996-10-31Completed
ANALYSIS OF THE EFFICACY OF SURAMIN IN RECURRENT MALIGNANT PRIMARY BRAIN TUMORS [NCT00002639]Phase 20 participants Interventional1995-07-31Completed
Evaluation of Suramin in Advanced Adrenal Cortical Carcinoma, Phase II [NCT00002921]Phase 213 participants (Actual)Interventional1997-03-31Terminated(stopped due to Permanently Closed Due to Lack of Accrual)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00054028 (3) [back to overview]Percentage of Patients That Achieved Target Suramin Concentrations in Plasma
NCT00054028 (3) [back to overview]Response as Measured by RECIST Criteria
NCT00054028 (3) [back to overview]Objective Response Rate (Complete Response and Partial Response) as Measured by RECIST Criteria (Phase II)
NCT01671332 (5) [back to overview]Evaluation of Peripheral Blood Lymphocytes for DNA Damage-induced Checkpoint Control.
NCT01671332 (5) [back to overview]Number of Participants With Toxicity/Adverse Events From Treatment
NCT01671332 (5) [back to overview]Overall Survival
NCT01671332 (5) [back to overview]Progression-free Survival in Months
NCT01671332 (5) [back to overview]Response Rate Per RECIST 1.1 Criteria
NCT02508259 (6) [back to overview]Aberrant Behavior Checklist (ABC)
NCT02508259 (6) [back to overview]Autism Diagnostic Observation Schedule, 2nd Edition (ADOS2)
NCT02508259 (6) [back to overview]Autism Treatment Evaluation Checklist (ATEC)
NCT02508259 (6) [back to overview]Expressive Language
NCT02508259 (6) [back to overview]Repetitive Behavior Questionnaire
NCT02508259 (6) [back to overview]The Clinical Global Impression - Improvement Scale (CGI-I)

Percentage of Patients That Achieved Target Suramin Concentrations in Plasma

Target suramin concentration was considered achieved, if at least 5 of 6 patients achieved the target plasma concentration of 10-50 µM over the duration of 8-48 hours when paclitaxel levels are therapeutic. (NCT00054028)
Timeframe: Up to 5 years

Interventionpercent of patients (Number)
Suramin and Paclitaxel88

[back to top]

Response as Measured by RECIST Criteria

Evaluation of secondary endpoints will be primarily descriptive. Descriptive data will be computed and compared using analysis of variance and non-parametric rank equivalents for continuous data and chi-square or Fisher's exact test for discrete data. Response rates will include 95% confidence limits. (NCT00054028)
Timeframe: Up to 5 years

Interventionpercentage of patients (Number)
Treatment (Suramin and Paclitaxel)23

[back to top]

Objective Response Rate (Complete Response and Partial Response) as Measured by RECIST Criteria (Phase II)

Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v 1.0) for target lesion s and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR+PR. (NCT00054028)
Timeframe: Up to 8 weeks

Interventionpatients (Number)
Complete Response (CR)Partial Response (PR)
Suramin and Paclitaxel05

[back to top]

Evaluation of Peripheral Blood Lymphocytes for DNA Damage-induced Checkpoint Control.

The investigators hypothesize that suramin in combination with docetaxel improves response rates and survival by increasing the cancer cell population in the M phase of the cell cycle. The G2-M checkpoint control score, defined as (%M-phase arrested cells after cisplatin+suramin)/(%M-phase arrested cells after cisplatin), is an indicator of the effect of suramin on cell accumulation in the M-phase. G2-M checkpoint control was evaluated as a predictor of PFS and OS in participant receiving suramin by linear correlation. (NCT01671332)
Timeframe: Baseline

InterventionG2-M checkpoint control score (Mean)
Docetaxel0.91
Docetaxel Plus Suramin1.30

[back to top]

Number of Participants With Toxicity/Adverse Events From Treatment

The investigators will compare the toxicity profiles of the two arms of therapy to determine if the docetaxel + suramin has a more favorable toxicity profile than docetaxel alone. This count includes only adverse events considered definitely, probably, or possibly due to treatment. (NCT01671332)
Timeframe: Up to 2 years

InterventionParticipants (Count of Participants)
Docetaxel35
Docetaxel Plus Suramin31

[back to top]

Overall Survival

Compare overall survival of participants in both treatment arms. (NCT01671332)
Timeframe: Up to 50 months

Interventionmonths (Median)
Docetaxel5.3
Docetaxel Plus Suramin4.1

[back to top]

Progression-free Survival in Months

Compare progression-free survival (PFS) in participants with advanced NSCLC treated with docetaxel with or without suramin after failure of first-line chemotherapy. PFS is defined as the duration of time from the time of randomization to time of disease progression or death, whichever occurs first. (NCT01671332)
Timeframe: Up to 1 year

Interventionmonths (Median)
Docetaxel2.8
Docetaxel Plus Suramin1.6

[back to top]

Response Rate Per RECIST 1.1 Criteria

"Response rate per RECIST 1.1, as follows:~Complete response (CR): Disappearance of all extranodal target lesions. All pathological lymph nodes must have decreased to <10 mm in short axis Partial response (PR): At least 30% decrease in the sum of longest diameters (SLD) of target lesions, taking as reference the baseline sum diameters Progressive disease (PD): SLD increased by at least 20% from the smallest value on study (including baseline, if that is smallest). The SLD must also demonstrate an absolute increase of at least 5 mm. (Two lesions increasing from 2mm to 3mm, for example, does not qualify).~Stable disease (SD): Neither sufficient shrinkage to qualify for PR not sufficient increase to qualify for PD" (NCT01671332)
Timeframe: Up to 1 year

,
Interventionparticipants (Number)
Partial ResponseStable DiseaseProgressive DiseaseNot Assessed
Docetaxel117175
Docetaxel Plus Suramin311251

[back to top]

Aberrant Behavior Checklist (ABC)

The full ABC is a 58-item parent rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. Stereotypy is reported, and scores range from 0 to 21, with higher scores indicating worse behavior. A negative difference corresponds to decreased symptoms after treatment. A positive difference corresponds to increased symptoms after treatment. (NCT02508259)
Timeframe: 6 weeks compared to baseline

Interventionunits on a scale (Mean)
Suramin-4.0
Saline (Placebo)1.0

[back to top]

Autism Diagnostic Observation Schedule, 2nd Edition (ADOS2)

ADOS2 comparison scores are units on a scale of 0-10. A score of 7-10 was required for enrollment. A score of 7-10 is diagnostic for autism spectrum disorder (ASD). The higher the score, the more severe the core symptoms of autism spectrum disorder. Scores of 6 and below are considered off the ASD spectrum. (NCT02508259)
Timeframe: 6 weeks compared to baseline

Interventionunits on a scale (Mean)
Suramin-1.6
Saline (Placebo)-0.4

[back to top]

Autism Treatment Evaluation Checklist (ATEC)

The reported value is the Language sub-score of the ATEC, and the range for the language sub-score is 0-20. The higher the score, the worse the disability. Outcomes were measured at 6 weeks after treatment compared to baseline. A negative difference corresponds to a decrease in language disability, i.e an improvement in speech and language. A positive difference reflects an increase in language disability, i.e. a decrease in speech and language. (NCT02508259)
Timeframe: 6 weeks

Interventionunits on a scale (Mean)
Suramin-2.0
Saline (Placebo)-0.2

[back to top]

Expressive Language

Expressive One Word Picture Vocabulary Test (EOWPVT) scores are normalized for age. Typical language development produces a mean score of 100 with a standard deviation of 15. Outcomes for EOWPVT were expressed as the mean of the child-specific difference before and 6-weeks after treatment. For example, if the 6-week standard EOWPVT score was 59.6 and the baseline score was 63.8, the difference is -4.2 (= 59.6 - 63.8). A decrease in score at 6 weeks would corresponds to a decrease in language performance, while an increase, a positive difference, would reflect an increase. (NCT02508259)
Timeframe: 6 weeks compared to baseline

Interventionunits on a scale (Mean)
Suramin-4.2
Saline (Placebo)2.0

[back to top]

Repetitive Behavior Questionnaire

Total repetitive behavior was assessed using the Repetitive behavior questionnaire (RBQ), which has a scale from 0-87. Higher scores correspond to more severe repetitive behavior. Outcomes were analyzed as the difference in the score 6 weeks after treatment compared to baseline. A negative difference corresponds to improved behavior compared to baseline. A positive difference corresponds to worse behavior. (NCT02508259)
Timeframe: 6 weeks compared to baseline

Interventionunits on a scale (Mean)
Suramin-3.2
Saline (Placebo)-0.8

[back to top]

The Clinical Global Impression - Improvement Scale (CGI-I)

The CGI-I is scale that ranges from 1-7, reflecting the change in core autism behaviors after treatment. 1 is much improved, 4 is unchanged, and 7 is much worse. (NCT02508259)
Timeframe: Overall ASD symptoms at 6 weeks

Interventionunits on a scale (Mean)
Suramin-1.8
Saline (Placebo)0.0

[back to top]